Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424400000 - PREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORM

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424490000 Coated (e.g., microcapsules) 865
424499000 Contains proteins or derivative or polysaccharides or derivative 200
424501000 Contains solid synthetic resin 125
424502000 Contains waxes, higher fatty acids, higher fatty alcohols 14
424500000 Contains natural gums and resins 2
20100239684GRANULAR JELLY BEVERAGE FOR MEDICATION AND PROCESS FOR PRODUCING THE SAME - Provided is a granular jelly beverage for medication used for taking the crude drug(s) and/or herbal medicine(s), which granular jelly beverage for medication comprises (a) 0.1 to 15.0% by mass of a bitterness masking ingredient comprising a plant fat and oil and/or animal fat and oil; (b) 5.0 to 20.0% by mass of a bitterness masking auxiliary ingredient comprising a sugar alcohol; (c) 0.1 to 5.0% by mass of an aggregation-inhibiting gelling ingredient; (d) 0.1 to 5.0% by mass of at least one taste adjusting ingredient selected from the group consisting of acids, derivatives thereof and salts thereof; and (e) a balance of water.09-23-2010
20080220081Water-Dispersible Xanthan Gum Containing Composition - One aspect of the present invention relates to a readily water-dispersible particulate composition comprising by weight of dry matter at least 10% of xanthan gum and not more than 60% of starch, said composition being characterised in that the xanthan gum present in the composition can be dispersed completely within 2 minutes in distilled water of 25° C. at a concentration of 0.7% based on the dry weight of xanthan. The particulate xanthan gum compositions of the present invention exhibit unique viscosity enhancing properties that are dependent on the electrolyte levels of the aqueous environment in which they are applied. The favourable properties of the xanthan compositions according to the invention can be realised without resorting to chemical modification of the xanthan gum. The xanthan compositions according to the present invention can be applied advantageously in e.g. food products and oil drilling fluids.09-11-2008
Entries
DocumentTitleDate
20110142940Analgesic Apatitic Calcium-Phosphate Cement - The present invention concerns a composition useful as bone substitute comprising one or more calcium-phosphate compounds in association with an analgesic. It also refers to a preparation process of said composition, a preparation process of a drug-combined device comprising said composition, the drug combined device thus obtained, a kit comprising said composition and the use of said composition for the preparation of a drug-combined device useful for filling a bony defect caused in the iliac crest by collection of auto-graft bone, as a scaffold for tissue engineering and to produce a dental or bony implant.06-16-2011
20110200680WATER INSOLUBLE POLYMER: STARCH-BASED FILM COATINGS FOR COLON TARGETING - A controlled release delivery dosage form for controlled release of an active ingredient, includes an active ingredient coated in a polymeric mixture of: at least a water insoluble polymer and a starch composition including at least one component selected from the group consisting of a starch having an amylose content of between 20 and 45%, a modified starch having an amylose content of between 50 and 80% and a legume starch. The present invention also relates to the use and method for making the same.08-18-2011
20110200678MANUFACTURING METHOD AND APPARATUS OF ULTRAFINE PARTICLES HAVING UNIFORM PARTICLE SIZE DISTRIBUTION - The present invention relates to a novel technology for forming fine particles with a size of 0.02˜3 microns from a solid that can be dissolved in a liquid solvent and is not decomposed by heat. The particle preparation technology according to the present invention may be applicable to the fields of food, cosmetics, biopolymer, polymer compositions, and pharmaceuticals.08-18-2011
20080248121MULTIPLE EMULSION CONTAINING A TENSIONING AGENT - The present invention relates to a W/O/W multiple emulsion containing an inner aqueous phase, an oily phase and an outer aqueous phase, the emulsion containing at least one tensioning agent present at least in the inner aqueous phase of the emulsion. The invention also relates to compositions containing the emulsion and to the cosmetic use of these compositions and emulsions for, e.g., smoothing out wrinkles and fine lines and/or for restoring tautness to the skin.10-09-2008
20090123549Pharmaceutical Compositions - A composition comprising a pharmaceutically acceptable group (2, 4, 12, 13 or 14) metal compound for the treatment of a dermatological condition involving an abnormal decrease in the cell-to-cell adhesion between epithelial cells in the epidermal barrier.05-14-2009
20090123551GASTROINTESTINAL DELIVERY SYSTEMS - Provided herein are compositions suitable for the delivery of therapeutic agents to the gastrointestinal tract. Also provided herein are methods for treating, preventing or alleviating disorders of the gastrointestinal tract, for example, those involving the esophagus, by orally administering compositions described herein.05-14-2009
20090123550CORTICOSTEROID COMPOSITIONS - Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.05-14-2009
20090123548Device for administering aromatherapy - A device for administering aromatherapy to a subject and the method of using the device are disclosed. The device comprises an aromatherapy composition housed within a container. The container has at least one opening or aperture through which the subject may breathe in or inhale the aromatic and volatile components of the aromatherapy composition through the mouth and/or nose. The aromatherapy composition comprises a particulate component comprising one or more irregularly- or regularly-shaped particles, granules, beads or the like. In addition, the aromatherapy composition has a volatile component comprising an amount of an essential oil-containing composition. The volatile component is that portion of the essential oil-containing composition that is retained by the particulate component after contacting the particulate component with the essential oil-containing composition and removal of the portion that is not retained by the particulate component.05-14-2009
20090196929Silica Wetcake Treatment Method - New methods of treating silica wetcake during precipitated silica materials manufacturing are provided. Such methods permit a significant increase in high solids content processing while simultaneously reducing high viscosity of the resultant particles for transport facilitation. The resultant precipitated silica wetcake is treated with a borate-containing dispersant to impart the necessary low viscosity characteristics thereto. Such a dispersant accords not only such a viscosity result, but will not char or otherwise discolor the silica particles during evaporation of the liquids within the wetcake itself. Furthermore, such a dispersant, if left on the surfaces of such particles, will not deleteriously affect the abrasivity, fluoride compatibility, or other dentifrice properties of the precipitated silica materials themselves. Also encompassed within this invention are the resultant precipitated silica particles exhibiting borate residues and dentifrices including such materials.08-06-2009
20110182994METHODS AND SYSTEMS FOR PRODUCTION OF NANOPARTICLES - Methods and systems for preparing nanoparticles. A source of a carrier fluid is connected to an inlet of a flow conduit, such as an intravenous solution administration tube with injection ports, such that the carrier fluid flows through the conduit. A substance (e.g., a drug solution or other substance solution) is introduced into the conduit at a first location causing substance nanoparticles to form within and continue to flow thought he conduit. A stabilizer is introduced into the conduit at a second location to cause a stabilizing effect on the nanoparticles. In some embodiments, the stabilizer may limit or deter agglomeration or growth of the nanoparticles, thereby limiting the size of the nanaparticles produced.07-28-2011
20100062071Particle Formulations and Uses Thereof - Aqueous dispersions of chemically and physically stable particles for use in delivery of active pharmaceutical ingredients and processes for their production and use to enhance a biological response to an active pharmaceutical ingredient and prophylactically or therapeutically treat a subject are provided. Vaccines, wherein the active pharmaceutical ingredient is a solution of subunit vaccine antigen mixed with a colloidal dispersion of electrically charged particles and use of such vaccines in immunization are also provided.03-11-2010
20100062069PROCESS FOR PREPARING PARTICLES CONTAINING AN ANTIVIRAL - A process for preparing a particle comprising a co-precipitate surrounding a neutral hydrophilic carrier, said process comprising spraying an organic solution on a neutral hydrophilic carrier, said solution comprising at least one triazine or pyrimidine active ingredient having HIV inhibiting properties, one surface active agent, and one hydrophilic polymer, wherein the spraying of whole of the solution occurs in at least two separate steps, each of these steps followed by a grinding step of the product obtained at the end of the preceding step.03-11-2010
20080260840Suspension formulations of insulinotropic peptides and uses thereof - A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.10-23-2008
20080260839Pulmonary Formulation - The use of microparticles of silicon and particularly resorbable and/or photoluminescent silicon in the preparation of a medicament for nasal or pulmonary delivery. Aerosol formulations and their preparation are also described and claimed. These formulations may be used for example as carriers for pharmaceutical compounds as well as having diagnostic applications.10-23-2008
20080260838GLUCAGON-LIKE PEPTIDE 1 (GLP-1) PHARMACEUTICAL FORMULATIONS - A composition is disclosed comprising glucagon-like peptide 1 (GLP-1) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions. In particularly, the composition has utility as a pharmaceutical formulation for pulmonary delivery.10-23-2008
20100055192MICRONIZED PARTICLES OF LOW-DOSAGE STRENGTH ACTIVE AGENTS FOR POWDER FORMULATIONS FOR INHALATION - Micronized particles of a low-dosage strength active ingredient, to be used in dry powder formulations for inhalation, with particular properties can easily and homogenously disperse in a dry powder formulation to be administered by means of a dry powder inhaler device.03-04-2010
20100055191POWDER COMPOSITION, METHOD FOR PRODUCING THE SAME, AND FOOD COMPOSITION, COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - A powder composition of a functional oil material is obtained by drying an emulsion composition comprising at least one functional oil component and (i) at least one water-soluble encapsulating agent selected from saccharide containing at least two sugar units including a fructose unit or (ii) at least one water-soluble encapsulating agent selected from saccharides containing at least one galactose unit and one fructose unit. Food compositions, cosmetic compositions and pharmaceutical compositions are provided which contain the powder composition described above.03-04-2010
20100055189Nanoparticles for immunotherapy - Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics. Surface chemistries and chemical formulations for the nanoparticles are described.03-04-2010
20110189298DOUBLE EMULSION AND METHOD TO PRODUCE SUCH - The invention is directed to a method to produce a water-in-oil-in-water (w/o/w) emulsion, comprising: a. preparing a water-in-oil (w/o) emulsion; b. atomizing said w/o emulsion in the presence of a carrier material comprising at least a water soluble matrix material and at least one emulsifier, to form agglomerates; c. dispersing said agglomerates in an aqueous liquid, such as water or an aqueous solution. Also provided is a new instant powder (obtained after step b) that can be used to prepare the w/o/w emulsion. The emulsion of the invention is advantageously suited for the encapsulation of active components.08-04-2011
20090098206Particulate Metal Oxide - A particulate metal oxide having a median volume particle diameter in the range from 24 to 42 nm, a photogreying index in the range from 0.05 to 3 and/or and a yellowing index of less than 6. The dispersion can be used in a sunscreen product which is transparent, exhibits effective UV protection, reduced photoactivity, and reduced yellowing in combination with organic UV absorbers.04-16-2009
20100129455NANOPARTICLE-DISPERSED FINE GLASS BEADS HAVING A CAVITY THEREIN, AND METHOD OF PRODUCING THE SAME - The present invention provides fine silicon-containing glass beads each having one or more cavities therein and containing nanoparticles in a glass phase of each of the silicon-containing glass beads, and a method of producing such glass beads, and also provides silicon-containing glass beads containing nanoparticles, which may be identical to or different from the nanoparticles in the glass phase, and a functional material such as pharmaceutical molecules (e.g., materials having fluorescent properties, magnetic properties, drug effects, etc.), and a method of producing such glass beads.05-27-2010
20100015237NSAID Delivery from Polyarylates - This invention provides biodegradable, sustained-release pharmaceutical compositions of non-steroidal, anti-inflammatory drugs (NSAIDs) formulated with biocompatible, biodegradable tyrosine-derived polyarylates. The compositionsare particularly suitable for localized delivery of NSAIDs for various disease states. For example, implantation of the compositions at the site of surgery leads to relatively high local concentrations of the NSAID to reduce or alleviate post-surgical pain. Long term zero order release of certain NSAIDs can also be provided by with certain polymer formulations.01-21-2010
20100008997COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS - Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)). Additional aspects include therapeutic compositions, and combination treatment methods comprising administration of electrokinetically generated fluid in combination with at least one additional therapeutic agent.01-14-2010
20100086605MATERIAL, ITEM AND PRODUCTS COMPRISING A COMPOSITION HAVING ANTI-MICROBIAL PROPERTIES - A coating product composition has the general formula AO04-08-2010
20100080849PELLETS CONTAINING A PHARMACEUTICAL SUBSTANCE, METHOD FOR THE PRODUCTION THEREOF AND USE OF THE SAME - The invention relates to pellets containing a pharmaceutical substance with a breaking strength of more than 0.001 newton, method of production thereof and pharmaceutical preparations based on said pellets.04-01-2010
20110195125Nanoparticles For Drug Delivery To The Central Nervous System - The present disclosure relates to compositions and methods for producing nanoparticles to provide relatively more rapid delivery of such particles across the blood-brain barrier. The nanoparticles may be formed from bis-quaternary pyridinium-aldoxime salts that may also be of a specific polymorphic structure and which may be formed in either hydrophobic or hydrophilic type liquid media. In addition, the nanoparticle for transport across the blood-brain barrier may comprise a polymeric resin encapsulating a bis-quaternary pyridinium-2-aldoxime salt of the formula: 08-11-2011
20090191273Metal Oxide Dispersion - A dispersion contains particles of metal oxide having a median volume particle diameter in the range from 24 to 42 nm which are dispersed in a medium which includes a mixture of at least one polar material having an interfacial tension of less than 30 mNm07-30-2009
20090191272Use of vegetable fine grain sized fibres for preparing a nutritional composition for reducing mycotoxin bioavailability - The invention relates to using substantially insoluble vegetable fibres embodied in the form of microparticles at least 90% in weight of which has a size less than 700 μm as ingredients for preparing a nutritional composition for reducing a mycotoxin bioavailability in a human being or an animal during ingestion of a food contaminated by said mycotoxins.07-30-2009
20100034886Polyglutamic Acids Functionalised by Histidine Derivatives and Hydrophobic Groups and the Uses Thereof, in Particular for Therapeutic Purposes - The invention relates to novel biodegradable materials based on modified polyamino acids and suitable, in particular, for vectoring active substance(s) (AS). Said invention also relates to novel pharmaceutical, cosmetic, dietary or plant protective compositions which are based on said polyamino acids.02-11-2010
20100047353HAIR CARE COMPOSITION - A hair care composition which comprises a plurality of cross-linked polymer particles, said polymer being the polymerization product of at least two monomer units selected from the group consisting of monoalkenyl aromatic compounds, alkyl esters derived from a saturated alcohol and acrylic or methacrylic acid, and vinyl esters of an aliphatic carboxylic acid is useful for controlling sebum on hair without providing undue whiteness to the hair.02-25-2010
20100119608Synthesis of pH-sensitive, Acid-Stable Metal-Binding Nanoparticles - Among natural mechanisms of cell deaths, disease or toxicity, one of the most common method is through overloading of certain biological metals such as calcium, iron and zinc. We propose to utilize this natural mechanism of cell death against cancer by utilizing the well known phenomenon of enhanced permeation and retention effect (EPR effect) and metal-binding nanoparticle moieties that can self-degrade under certain biological conditions such as pH. More specifically, we show that one can form nanoparticles that consist of polymerized citric acid and various different types of metals including, but not limited to, iron, calcium, zinc, silver and magnesium, displaying acid-stability and self-degradation leading to constituent metal release when pH rises closer to the neutral pH of 7 or higher. We also show that these nanoparticles with different metal compositions have distinct cytotoxicity against various different types of cancer cell lines, including B16F10 melanoma, H460 human lung cancer, T98G kidney cancer, Ramos leukemic cancer, etc. in vitro. We also show evidence of in vivo anti-cancer activity of our nanoparticles containing various different metals using mouse model studies.05-13-2010
20100119609METHODS, COMPOSITIONS, AND FORMULATIONS FOR THE TREATMENT OF THYROID EYE DISEASE - Compositions, formulations, methods, and systems for treating thyroid eye disease and related conditions (e.g., Grave's Ophthalmopathy). The methods described herein include administering, to a patient in need, systemic or local beta adrenergic agonists (e.g., as an extended release crystalline microparticle suspension). The methods can further include administering a compound for reducing beta adrenergic receptor desensitization (e.g., a corticosteroid) prior to administering or coadministered with the beta adrenergic agonist. The methods can also include locally administering to the eye an immunosuppressant agent (e.g., rapamycin) prior to administering a beta adrenergic agonist. The compositions described herein include ophthalmic pharmaceutical formulations of beta adrenergic agonists in the form of extended release crystalline microparticle suspensions or mixtures of the crystalline microparticle suspensions with beta adrenergic agonist solutions. The compositions also include ophthalmic formulations of a compound for reducing beta adrenergic receptor desensitization in the form of extended release crystalline microparticle suspensions.05-13-2010
20100074959LIPID GROWTH FACTOR FORMULATIONS - The present invention is directed to novel formulations and methods for the improved delivery and administration of hydrophobic therapeutic compounds that are substantially insoluble and/or susceptible to precipitation in aqueous solution at physiological pH, including, e.g., growth and differentiation factor-5 and related proteins. Many therapeutic compounds are hydrophobic at physiological pH levels.03-25-2010
20100074958METHODS AND COMPOSITIONS FOR TARGETING FENESTRATED VASCULATURE - Targeting of a fenestrated vasculature at a body site by micro or nanoparticles can be increased by using particles that have a radius substantially equal to a critical radius of a normal vasculature at the body site. The particles can be used for treating or monitoring a physiological condition responsible for the fenestrated vasculature. A method of improving an ability of micro or nanoparticles to target fenestrated blood vessels in a body site by selecting particles from a population of the micro or nanoparticles, where the selected particles have a radius that permits enhanced delivery into the fenestrated blood vessels.03-25-2010
20090104270Film delivery system for tetrahydrolipstatin - The present invention includes a pharmaceutical-based film system which includes various small-scale forms of pharmaceutically active agents, including tetrahydrolipstatin, in a film base. Such forms include nanoparticles, microparticles, and combinations thereof. Methods of producing such film and providing a dosage of the pharmaceutical in a film are also provided.04-23-2009
20100034887Bursting Pellets - In the present invention, a new pharmaceutical formulation of bursting pellets comprising in the core a high dose of a low potency active substance which is poorly soluble in water is described. Release of the active substance from the core takes place within minutes.02-11-2010
20130034609SMART POLYMERS FUNCTIONALIZED HOLLOW SILICA VESICLES - The present invention provides a porous hollow silica micro- or nanoparticle with a polymer grafted thereon, wherein the polymer is selected from poly(methacrylic acid) and copolymers thereof. The polymer may be covalently linked to the silica particle via a bridging group. Provided is also a method of covalently coupling a poly(methacrylic acid) to a silica surface of a hollow silica particle. The method comprises contacting a silica surface of a hollow silica particle that carries amino functional or halogen functional groups with a poly(methacrylic acid) or a copolymer or a respective monomer thereof. The method further comprises allowing the carboxyl group of the monomer or the poly(methacrylic acid) and an amino functional group or a halogen functional group on the silica surface to undergo a coupling reaction, thereby covalently coupling the polymer to the silica surface.02-07-2013
20130034608Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents - The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a α-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours.02-07-2013
20090098209PHARMACEUTICAL COMPOSITIONS CONTAINING WATER-SOLUBLE DERIVATIVES OF PROPOFOL AND METHODS OF ADMINISTERING SAME VIA PULMONARY ADMINISTRATION - The present invention is directed to methods of delivering propofol derivative compounds via pulmonary administration to a mammal in order to induce or maintain anesthetized, sedated and sub-hypnotic states.04-16-2009
20090252804MEDICAL DEVICES WITH AN ANTIBACTERIAL POLYURETHANEUREA COATING - The present invention relates to a medical device which has at least one coating which is obtained starting from an aqueous dispersion, the aqueous dispersion comprising at least one nonionically stabilized polyurethaneurea and at least one silver-containing constituent.10-08-2009
20090324723Method of prophylaxis of infection - A method for prophylaxis of infection of the respiratory tract of a subject by pathogenic airborne bacteria the method comprising administering to the subject by inhalation binding proteins directed against the bacteria. the pathogenic bacteria is a bacteria which survives inside phagocytes and the binding proteins are directed against said bacteria which survives inside phagocytes. The binding proteins comprise antibodies or antibody fragments directed against said bacteria which survives inside phagocytes. The binding proteins are selected from the group consisting of polyclonal antibodies, monoclonal antibodies, F(ab) fragments, F(ab′)12-31-2009
20130039986Silk-Based Ionomeric Compositions - Disclosed herein are pH-dependent silk fibroin-based ionomeric compositions and colloids, and methods of making the same. The state of the silk fibroin ionomeric compositions is reversible and can transform from a gel-like colloid to a more fluid-like solution, or vice versa, upon an environmental stimulus, e.g., pH. Thus, the silk-based ionomeric compositions and colloids can be applied in various industries, ranging from electronic applications to biomedical applications, such as sensors, gel diodes, absorbent materials, drug delivery systems, tissue implants and contrast agents.02-14-2013
20100098765Powder Makeup Compositions And Methods - An anhydrous powder composition wherein the ratio of platelet to non-platelet particulates is greater than about 5 to 1 respectively, which is preferably talc-free, oil-free, paraben-free, and fragrance-free; and a method for preparing the powder composition of the invention.04-22-2010
20100098766USE OF AN AQUEOUS MICRO-EMULSION FOR THE PREPARATION OF A FORMULATION FOR THE TREATMENT OF ADIPOSE DISEASES - Use of a micro-emulsion comprising at least one surfactant having a HLB value between 5 and 15, at least one lipophilic substance, and water for the preparation of a formulation for the treatment of adipose tissue disease and/or condition with improved bioavailability and good release behaviour of active substances.04-22-2010
20100112070Composition and dosage form comprising a particle formulation and suspending vehicle - A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.05-06-2010
20100112068Compositions and methods for biological remodeling with frozen particle compositions - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.05-06-2010
20130209563COMBINATION IMMEDIATE/DELAYED RELEASE DELIVERY SYSTEM FOR SHORT HALF-LIFE PHARMACEUTICALS INCLUDING REMOGLIFLOZIN - A combination immediate/delayed release delivery system for compounds which have short half-life's, such as the antidiabetic remogliflozin etabonate, is provided which provides a dosage form that has two distinct phases of release, a formulation that promotes immediate release of the compound upon ingestion and another formulation which delays the release of the compound so that a dosing regimen of remogliflozin etabonate, once daily, may be achieved while providing effective control of plasma glucose and minimizing the nighttime exposure of this compound. The delivery system includes, but is not limited to, a combination of enteric coating of an immediate release formulation such that a delay in release is provided. Methods for forming the so-described immediate/delayed release delivery system and using such delivery system for treating diabetes are also provided.08-15-2013
20090155368Pharmaceutical compositions - The present invention relates to crosslinked polyamine particles and/or pharmaceutical compositions comprising, at least in part, crosslinked polyamine particles and aggregates of such particles (including cured aggregates of crosslinked polyamine particles). The compositions may be in the form of tablets comprising, for example, particles larger than 500 μm, and used for treating patients, for example, patients with hyperphosphatemia.06-18-2009
20100104651Pharmaceutical Compositions Containing Diacerein - A once-daily controlled-release formulation of diacerein for treating inflammatory or autoimmune diseases or their complications, with reduced adverse side effects and methods of treating such diseases are disclosed.04-29-2010
20100104650CHARGED MESOPOROUS SILICA NANOPARTICLE-BASED DRUG DELIVERY SYSTEM FOR CONTROLLED RELEASE AND ENHANCED BIOAVAILABILITY - A charged mesoporous silica nanoparticle (MSN)-based drug delivery system for controlled release and enhanced bioavailability is disclosed. The system comprises a positively charged MSN, which has a silica matrix and an array of pores and/or nanochannels in the matrix. The entire substance of the matrix, all the surfaces and the pores and/or nanochannels comprise a plurality of silanol (Si—OH) and quaternary ammonium functional groups. The bioavailability of a negatively charged bioactive compound can be increased by loading it into the pores and/or nanochannels. The silanol (Si—OH) functional groups on the surfaces lining the walls of the pores and/or nanochannels are free to deprotonate in a fluid having pH above the pI of the positively charged MSN and lead to a sustained release of the negatively charged drug from the pores and/or nanochannels, and thereby enhance the bioavailability of the drug.04-29-2010
20100104649Lercanidipine Hydrochloride Polymorphs and an Improved Process for Preparation of 1,1,N-Trimethyl-N-(3,3-Diphenylpropyl)-2-Aminoethyl Acetoacetate - Disclosed herein is an improved, commercially viable and industrially advantageous process for the preparation of substantially pure Lercanidipine intermediate, 1,1,N-trimethyl-N-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate. The intermediate is useful for preparing Lercanidipine, or a pharmaceutically acceptable salt thereof, in high yield and purity. The present invention further provides a novel crystalline form of Lercanidipine hydrochloride and a process for its preparation. The present invention also provides a process for the preparation of amorphous form of Lercanidipine hydrochloride.04-29-2010
20100104644Compositions and Methods for Treating or Preventing Ophthalmic Disease - Methods are disclosed for treating or preventing ophthalmic conditions related to a toxic visual cycle product. Compounds and compositions useful in these methods, either alone or in combination with other therapeutic agents, are also described, along with methods of screening for new agents useful in said the therapeutic and prophylactic methods of the invention.04-29-2010
20100104646NANOPARTICLE COMPOSITION FOR PREVENTION OF HAIR LOSS AND PROMOTION OF HAIR GROWTH - A nanoparticle composition is provided for preventing hair loss and promoting hair growth. It is based on herbal materials and thus has no harmful side effects on the body. When applied to the scalp, the nanoparticle composition deeply infiltrates into the dermis to promote blood circulation therein and provide nutrients thereto. Accordingly, the nanoparticle composition stimulates and activates hair follicles to thus promote the metabolism of hairs. Also, the nanoparticle composition exerts antioxidant activity on the scalp to thus inhibit depilation and aid in hair regrowth.04-29-2010
20100104645METHODS FOR THE PREPARATION OF TARGETING AGENT FUNCTIONALIZED DIBLOCK COPOLYMERS FOR USE IN FABRICATION OF THERAPEUTIC TARGETED NANOPARTICLES - This application provides methods of making nanoparticles using pre-functionalized poly(ethylene glycol) (also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. These diblock copolymers comprise a poly(ethylene glycol) block bearing a targeting agent at its terminus and a second biocompatible and biodegradable hydrophobic polymer block (e.g. a poly(ester)). The poly(ethylene glycol) is hetero-bifunctional with a targeting moiety (agent) covalently bound to its α terminus and a polymerization initiating functional group (e.g., a hydroxyl group) present on its ω terminus. Ring opening polymerization yields the desired poly(ester)-poly(ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This “polymerization from” approach typically employs precursors of the targeting agent wherein the reactivity of functional groups of the targeting agent is masked using protecting groups. Also described is a “coupling to” that utilized the poly(ethylene glycol)-targeting agent conjugate where the targeting agent remains in its native un-protected form. This method uses “orthogonal” chemistry that exhibit no cross reactivity towards functional groups typically found within targeting agents of interest. Nanoparticles produced according to the disclosed methods as well as their use in the treatment of various diseases are also provided.04-29-2010
20100104647HOLLOW MICROPARTICLES - The invention provides a process for making hollow microparticles. The process comprises providing a dispersion having a continuous aqueous phase and a discontinuous organic phase and polymerising a monomer in the dispersion to form hollow polymeric microparticles. The continuous aqueous phase of the dispersion comprises a stabiliser and the discontinuous organic phase of the dispersion comprises the monomer and an organic liquid. The monomer has two or more polymerisable groups per molecule. Prior to the step of polymerising the monomer, the discontinuous organic phase does not contain a polymer.04-29-2010
20100104648TREATMENT OF INFLAMMATORY AND/OR BACTERIAL CONDITIONS WITH PARTICLES OF MICROSTRUCTURE - The present invention refers to a method for treatment of an inflammatory and/or bacterial condition, wherein particles of microstructure comprising titanium, titanium alloy, at least one titanium oxide or a combination thereof, and having a surface with at least a substantial part consisting of at least one type of titanium oxide, are brought into contact with at least one infected site in a human or animal body by insertion, injection or implantation, which at least one infected site exhibits the inflammatory and/or bacterial condition. Moreover, the present invention refers to an injectable suspension comprising the particles according to the invention and a fluid vehicle for use as a medicament. Finally, the present invention also defines use of the particles of microstructure according to the invention for the manufacture of a medicament in the form of an injectable suspension. Examples of conditions being treated with the injectable suspension according to the present invention are periodontitis, periimplantitis, and osteitis.04-29-2010
20100040694LOW-MOLECULAR WEIGHT, WATER-SOLUBLE CHITOSAN NANOPARTICLE FOR GENE DELIVERY WITH FOLIC ACID CONJUGAED THERETO AS TARGET LIGAND AND PREPARATION METHOD THEREOF - Disclosed are low-molecular weight, water-soluble chitosan nanoparticles with folic acid conjugated thereto as a target ligand and a preparation method thereof. The nanoparticles can be simply prepared since the strong reactivity of the chitosan allows folic acid to be readily introduced thereinto. Also, the folic acid-conjugated, low-molecular weight, water-soluble chitosan nanoparticles can be useful as gene carriers because they are of low or zero-toxicity, have sizes suitable for use as gene carriers, can readily form complexes with DNA, allow high gene expression rates, and are excellent in targeting tumor cells which are rich in folic acid receptors.02-18-2010
20090246283Repeat Sequence Protein Polymer Nanoparticles Optionally Containing Active Agents and Their Preparation - A nanocomposite of a repeat sequence protein polymer, such as a copolymer of silk and elastin, is produced by Supercritical Antisolvent Precipitation with Enhanced Mass Transfer (SAS-EM). The nanocomposite may include an active agent, such as a protein or hormone, that is releasably bound to the repeat sequence protein polymer.10-01-2009
20100092568DRUG MICROPARTICLES - Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them.04-15-2010
20100092564Composition of and Method for Preparing Orally Disintegrating Tablets - An improved orally dissolving tablet (ODT) and method of manufacture is provided. The improved ODT disclosed herein are prepared by direct compression of a mixture of pharmaceutical excipients including at least one water-insoluble hydrophobic inorganic salt in combination with at least one water-insoluble inorganic salt with less hydrophobicity compared to the water-insoluble hydrophobic inorganic salt component. These components may be formed into granules, and may include other commonly used excipients. In an illustrative embodiment, the granules are formed into tablets by direct compression, optionally using a lubricant. The fast disintegrating tablets prepared using these components exhibit desirable performance properties such as sufficient hardness, low friability, quick disintegration time and good mouth-feel when compared to conventional ODT. A further advantage is that the improved ODT may be manufactured using commonly available manufacturing equipment for granulation, blending and tableting.04-15-2010
20110311633Combination of a Silicon Containing Component and a Hormone - The invention relates to the use of a silicon-containing material to reduce the amount of hormone required in a method of hormone treatment to achieve a desired response, particularly in hormone replacement therapy (HRT) and especially in the maintenance of post-menopausal bone health and the management or treatment of osteoporosis, and to pharmaceutical compositions for use in such a method.12-22-2011
20130089614Magnetic Nanoparticles and Uses Thereof - Magnetic nanoparticles are provided that have a superparamagnetic core and a nanoporous silica shell surrounding the core. The shell is functionalized with amine or S-nitrosothiol groups both inside and outside the nanopores. A process to provide such nanoparticles involves hydrolyzing tetraethoxysilane (TEOS) in a microemulsion of a superparamagnetic nanoparticle to form a superparamagnetic nanoparticle encapsulated by an incompletely hydrolyzed nanoporous silica shell, and hydrolyzing an amine-containing compound or a thiol-containing compound in situ in the presence of the incompletely hydrolyzed nanoporous silica shell before hydrolysis and densification of the silica shell is complete to functionalize the nanoporous silica shell with amine or thiol groups both inside and outside the nanopores and to maintain nanoporosity of the shell. Such magnetic nanoparticles are useful as carriers for chemical or biological species, particularly for magnetic resonance imaging, optical imaging, targeted drug delivery, cell delivery and magnetic separation applications.04-11-2013
20100136121MEDICAMENTS - There is described a bimodal pharmaceutical composition comprising effective amounts of a first active ingredient which substantially comprises a coarse fraction and a second active ingredient which substantially comprise a fine fraction characterized in that the coarse fraction possesses a greater mass median aerodynamic diameter than the fine fraction. There is also described a method of delivering a therapeutically effective amount of a substantially fine active ingredient to the lung of a patient by co-administration with a substantially coarse active ingredient.06-03-2010
20090246282RECOMBINANT GELATIN PARTICLES FOR CELL ADHESION - The present invention relates to cell carrier particles prepared from recombinantly produced gelatins comprising at least two outer lysine residues which are separated by at least 25 percent of the total number of amino acids in the recombinant gelatin polypeptide. The invention is also directed at applications in which such cell carriers are used, for example as injectable cell carrier, for tissue augentation or cosmetic surgery or as microcarrier in in vitro cell cultivation.10-01-2009
20090317476COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LEUKOTRIENE RECEPTOR ANTAGONIST FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a leukotriene receptor antagonist for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.12-24-2009
20090311331Pellet Formulation Comprising Colloidal Silicon Dioxide - The present invention provides a pellet formulation comprising colloidal silicon dioxide (CSD) and one or both of a surfactant and a plasticiser. A process for the production of 5 said formulation is also provided.12-17-2009
20090304799NANOEMULSION INFLUENZA VACCINE - The present invention relates to methods for inducing an immune response to influenza in a subject comprising administering a nanoemulsion vaccine composition comprising an influenza immunogen or protein.12-10-2009
20090304796Nanoparticle suitable for delivery of a biomolecule into or out of a membrane enclosed cell or cell organelle - A nano sized particle for in vitro or ex vivo biomolecule delivery to cell cultures through heat induced endosomal release comprising a superparamagnetic core coated in a heat sensitive coating, comprising membrane disruptive components and binding sites for attachment of biomolecules and markers to be delivered is provided. A method is provided for introducing the release effect of a plurality of said biomolecule and endosomal disrupture molecules by applying an alternating field to a cell culture harbouring the particle described by the invention.12-10-2009
20090117193Compositions Comprising an Active Agent - The present invention provides a highly dispersible formulation comprising an active agent and a dipeptide or tripeptide comprising at least two leucyl residues. The composition of the invention possesses superior aerosol properties and is thus preferred for aerosolized administration to the lung. Also provided are a method for (i) increasing the dispersibility of an active-agent containing formulation for administration to the lung, and (ii) delivery of the composition to the lungs of a subject.05-07-2009
20090041849DISSOLUTION AIDS FOR ORAL PEPTIDE DELIVERY COMPRISING A BIGUANIDE - A pharmaceutical composition comprising a mixture of: (c) an active macromolecular principle; (d) an aromatic alcohol absorption enhancer chosen from propyl gallate, butylated hydroxy toluene (BHT), butylated hydroxy anisole (BHA) and analogues and derivatives thereof, or mixtures thereof; and (d) a biguanide or a pharmaceutically acceptable salt thereof, capable of increasing the solubility of the aromatic alcohol absorption enhancer in an aqueous medium, wherein the aromatic alcohol absorption enhancer is present in an amount by weight greater than or equal to that of the active principle.02-12-2009
20090041848SKIN ANTI-AGING AGENT FOR EXTERNAL USE - It is an object of the present invention to provide a skin anti-aging agent for external use which comprises highly safe protein nanoparticles having high transparency due to the small particle size and high permeability into skin. The present invention provides a skin anti-aging agent for external use, which comprises protein nanoparticles containing an active ingredient.02-12-2009
20090041847METHOD OF QUENCHING ELECTRONIC EXCITATION OF CHROMOPHORE-CONTAINING ORGANIC MOLECULES IN PHOTOACTIVE COMPOSITIONS - The photostabilizing electronic excited state energy—particularly singlet state energy from a UV-absorbing molecule has been found to be readily transferred to (accepted by) α-cyanodiphenylacrylate compounds of formulas (I) and (V) having an alkoxy radical preferably in the four (para) position (hereinafter methoxycrylenes) on one or both of the phenyl rings:02-12-2009
20100055190Sterol-Containing Compositions - The invention relates to a powder formulation containing sterol in the form of a super-cooled melt from sterols and sterol esters, provided that the sterol ester content is at least 30 wt % in relation to the content of the powder. The introduced sterol ester is a fatty acid ester having a chain length of 2 to 24, preferably 8 to 12 carbon atoms. As the sterol preparations are wettable and melt easily without the use of complex equipment, they can easily be incorporated into food, and produce, in particular, good organoleptic and sensory properties, in particular, in drinks.03-04-2010
20090092671Cerium Oxide Nanoparticles for Treatment and Prevention of Alzheimer's Disease, Parkinson's Disease, and Disorders Associated with Free Radical Production and/or Mitochondrial Dysfunction - Cerium oxide nanoparticles (CeONP) can be used to treat or prevent neurodegenerative diseases, including for example Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, AIDS-related dementia, ALS, progressive supranuclear palsy, and encephalitis, as well as mitochondrial diseases and diseases associated with mitochondrial damage. In particular, CeONP having an average size of about 2 nm to about 100 nm can be administered in an amount sufficient to block production of hydroxyl or superoxide radicals, block free radical production by Aβ04-09-2009
20130059008DRYING METHODS FOR TUNING MICROPARTICLE PROPERTIES - Described herein are drying methods for tuning one or more properties of a microparticle. In one aspect, the release profile of a microparticle comprising a bioactive agent therein can be affected by the disclosed drying methods.03-07-2013
20110059178Tissue Engineered Meniscus Repair Composition - A meniscus repair composition for application to a meniscus defect site to promote growth of new tissue at the meniscus defect site is provided. The composition comprises: from about 10 to about 50 percent by weight of allograft meniscus particles having an average particle size of from about 10 μm to about 500 μm; a carrier selected from the group consisting of sodium hyaluronate, gelatin, collagen, polyethylene glycol, glycerin, carboxymethylcellulose, dextrose, blood derivatives, aqueous solutions thereof, and mixtures thereof; and a curing agent. The curing agent may be the carrier where the carrier is cross-linkable. When introduced to a defect site in a meniscus and cured, the composition will not flow away from the defect site, and the composition is non-adhering to the defect site after it is cured.03-10-2011
20100086608Methods and Devices for Detecting Binding Events via Zeta-Potential and Pharmacologically Active Compounds and Delivery Systems Identified Thereby - Methods, devices and arrays for measuring a change in zeta-potential of a surface indicative of a binding event are provided. Pharmacologically active compounds and delivery systems for active pharmaceutical ingredients determined to be pharmacologically active or optimized for pharmacological activity or determined to be useful for delivery of the active pharmaceutical ingredient to a target via measurement of a change in zeta-potential of the compound, ingredient or delivery system are also provided.04-08-2010
20110014294STIMULATION OF OCULAR RETROBULBAR BLOOD FLOW USING OCULAR IRRITANTS - Disclosed are uses of an ocular irritant such as saponin in stimulating the retrobulbar blood flow of an eye. Disclosed are also methods of treatment including administration of a pharmaceutical composition including an ocular irritant to an eye, for example as a mist, in order to stimulate the retrobulbar blood flow. In some embodiments, the stimulation of the retrobulbar blood flow has a beneficial effect.01-20-2011
20110014293CLEAVAGE KIT, AND GENE THERAPY BY USING THE SAME AND NUCLEIC ACID CLEAVAGE DETECTION APPARATUS - A nucleic acid cleavage kit is used to cleave a target nucleic acid. The nucleic acid cleavage kit includes a carrier, an oligonucleotide, and a nucleic acid cleavage agent. The oligonucleotide recognizes at least partial sequence of the target nucleic acid. Then, the nucleic acid cleavage agent cleaves the target nucleic acid. A nucleic acid cleavage detection apparatus including the nucleic acid cleaving kit and a gene therapy by administering the nucleic acid cleavage kit are also disclosed.01-20-2011
20110014292 METHOD OF PROPHYLAXIS AND AGENTS FOR USE THEREIN - The present invention relates generally to a method of prophylactically or therapeutically treating antigen-induced airway tissue inflammation and agents for use therein. More particularly, the present invention provides a method of prophylactically or therapeutically treating allergic airway inflammation and agents for use therein via the administration of the method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by antigen-induced airway tissue inflammation.01-20-2011
20110014291Novel Polymorphs of Bosentan - Disclosed herein are novel polymorphic forms of bosentan, processes for preparation, pharmaceutical compositions, and method of treating thereof.01-20-2011
20090297611COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A TYROSINE KINASE INHIBITOR, DELTA OPIOID RECEPTOR ANTAGONIST, NEUROKININ RECEPTOR ANTAGONIST, OR VCAM INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.12-03-2009
20090214658Inorganic sorbent copolymer - A medicinal preparation useful for treating viral diseases and for prophylaxis of various diseases—including zoonotic diseases—along with methods of using the same, is described. The preparation comprises a fine crystalline antimony silicate-based sorbent of the compositional formula xA08-27-2009
20090285900COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A BETA-AGONIST BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a β2-agonist bronchodilator for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.11-19-2009
20090269410Inhibition of Neovascularization by Cerium Oxide Nanoparticles - The present invention provides methods for reducing, reversing or inhibiting neovascularization in a tissue of a mammalian subject having a pathological condition involving neovascularization by administration in vivo of nanoceria particles (cerium oxide nanoparticles) to the subject. The method of the invention is useful, for example, for reducing, treating, reversing or inhibiting neovascularization in ocular tissue such as the retina, macula or cornea; in skin; in synovial tissue; in intestinal tissue; or in bone. In addition, the method of the invention is useful for reducing or inhibiting neovascularization in a neoplasm (tumors), which can be benign or malignant and, where malignant, can be a metastatic neoplasm. As such, the invention provides compositions, which contain nanoceria particles and are useful for reducing, treating, reversing or inhibiting angiogenesis in a mammalian subject.10-29-2009
20090269409PHARMACEUTICAL COMPOSITIONS COMPRISING ESZOPICLONE - Pharmaceutical compositions comprising eszopiclone, including its pharmaceutically acceptable salts, hydrates, clathrates, solvates, polymorphs, and mixtures thereof. The invention also relates to processes for preparing the compositions and their methods of use.10-29-2009
20090269408Aqueous formulations of imidoalkanepercarboxylic acids - Liquid formulations of imidoalkanepercarboxylic acids, in the form of aqueous dispersions comprising, in percentages by weight relative to the total weight of the composition: A) from ≧7% to 40% and preferably from 10% to 20% of imidoalka-nepercarhoxylic acids having the general formula (I), the said imidoalkanepercarboxylic acids being in the β form and having a dissolution time, determined via the test of the rate of dissolution at a temperature of 40° C. or 18° C., of not more than 5 minutes when determined at 40° C. or 15 minutes when determined at 18° C., for an amount of dissolved acid equal to 99% of the theoretical amount; B) from 0.001% to 0.9% of a nonionic surfactant; the said dispersions having a viscosity of not more than 2000 mPa·sec at 25° C. by applying a shear rate of 20 s10-29-2009
20130064894NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF - The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.03-14-2013
20090035378NANOSTRUCTURED BIOACTIVE MATERIALS PREPARED BY DUAL NOZZLE SPRAY DRYING TECHNIQUES - Nano-particles of calcium and phosphorous compounds are made in a highly pure generally amorphous state by spray drying a weak acid solution of said compound and evaporating the liquid from the atomized spray in a heated column followed by collection of the precipitated particles. Hydroxyapatite (HA) particles formed by such apparatus and methods are examples of particle manufacture useful in bone and dental therapies. Dual nozzle spraying techniques are utilized for generally insoluble compounds.02-05-2009
20090258073MAGNETIC CARRIER AND MEDICAL PREPARATION FOR CONTROLLABLE DELIVERY AND RELEASE OF ACTIVE SUBSTANCES, METHODS OF THEIR PRODUCTION AND METHODS OF TREATMENT USING THEREOF - The present invention relates to magnetic carriers and medical preparations for controllable delivery and release of active substances. The carrier for active substances comprises material A, which is magnetically or electrically sensible, and material B capable of controlling the retention/release rate of the said active substance from the said carrier, the said retention/release rate being temperature dependent; wherein the material B is in thermal contact with material A, and wherein the material A has magnetocaloric or electrocaloric effect sufficient to substantially vary the said retention/release rate of the active substance from the carrier. The invention further provides methods for controllable delivery and release of active substances in a predetermined place and at a predetermined time, and methods of treatment using these carriers. Methods of production of magnetic carriers are also proposed.10-15-2009
20110020454NOVEL DOSAGE AND FORMULATION - The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 200 micrograms aclidinium bromide.01-27-2011
20090238882Carbon-substituted diketopiperazine delivery systems - Compositions useful in the delivery of active agents are provided. These delivery compositions include (a) an active agent; and (b) a carrier of at least one mono-C-substituted or di-C-substituted diketopiperazine. Methods for preparing these compositions and administering these compositions are also provided.09-24-2009
20090238881IONOPHORE ANTIBIOTIC FORMULATIONS - The invention relates to an ionophore antibiotic composition capable of diluting with water to a substantially stable dispersed form in all water than present, said composition comprising or including:—at least one ionophore antibiotic (preferably monensin) of a mean particle size of less than 20 microns,—and at least one dispersing agent. A method of preparing the ionophore antibiotic composition is also disclosed.09-24-2009
20090238880PHOSPHOLIPID-BASED PHARMACEUTICAL FORMULATIONS AND METHODS FOR PRODUCING AND USING SAME - Pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, pharmaceutically acceptable salts thereof, or prodrugs thereof. In specific embodiments, the pharmaceutically active compounds are ansamycins and the overall formulation is substantially devoid of medium and long chain triglycerides.09-24-2009
20090238877Agent For Improving Fine Wrinkles - An agent for improving fine wrinkles contains an oil based preparation for external use for skins, the oil based preparation containing: (i) 50% by mass to 95% by mass of an oil constituent, which contains 10% by mass to 100% by mass of a solid or semisolid oil constituent, and (ii) 5% by mass to 50% by mass of particles, the oil based preparation having occlusion characteristics of at least 50%. A beauty culture method for improving fine wrinkles comprises applying the oil based preparation for external use for skins onto a skin.09-24-2009
20090238876BISPHOSPHONATES FOR TREATING ENDOMETRIOSIS - A novel method of treating endometriosis is disclosed. The method comprises administering to a female subject in need thereof a therapeutically effective amount of particles comprising an agent capable of inhibiting phagocytic cells of the female subject.09-24-2009
20110045083USE LARCH WOOD FOR TREATING INFLAMMATION - The application of raw wood material from a tree of the genus 02-24-2011
20110045082AGGLOMERATES BY CRYSTALLISATION - The present invention describes novel agglomerates in crystalline form of β-lactum compounds, Furthermore, a process for the preparation of said agglomerates, wherein a solution or suspension of at least one β-lactum compound in a solvent is mixed with one or more anti-solvents has been described.02-24-2011
20090232895PROCEDURE AND DEVICES FOR THE CONTROLLED OBTAINING OF DRY SALINE AEROSOLS WITH THERAPEUTIC EFFECT - The patent refers to a procedure and devices for the generation of dry aerosols, continuously, by mechanic self-erosion, by average stirring in air or air-oxygen feed, of some crystals with special structure obtained by controlled crystallization processes. There can be also used other salts known to have physiological effects or mixtures of saline crystals with capacities close to the micro-particle generation. The devices can be for human or veterinary individual use, in intensive therapies or for producing aerosols with therapeutic or preventive effect in public rooms.09-17-2009
20090232894Process for Stabilizing an Adjuvant Containing Vaccine Composition - The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an influenza vaccine composition, particularly an adjuvanted influenza vaccine composition in dry form.09-17-2009
20090232893miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION - The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-143, using miR-143 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.09-17-2009
20090232892Cellooligosaccharide-Containing Composition - Disclosed is a cellooligosaccharide composition comprising, as the main ingredient, at least one cellooligosaccharide selected from the group consisting of cellobiose, cellotriose, cellotetraose, cellopentaose and cellohexaose, which is in the powdery form having an average L/D value of 3.0 or lower, a bulk density of 0.80 g/mL or lower and an angle of repose of 60° or lower.09-17-2009
20090304797Process for the Preparation of Micronized Valsartan - The present invention relates to process for preparing micronized Valsartan with particle size distribution of d12-10-2009
20090047354 PROCESS FOR THE PREPARATION OF 5-(2-(4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL) ETHYL)-6-CHLORO-1, 3-DIHYDRO-2H-INDOL-2-ONE HYDROCHLORIDE (ZIPRASIDONE HYDROCHLORIDE) AND ITS INTERMEDIATE - The present invention relates to improved processes for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one and its hydrochloride, which is known as Ziprasidone hydrochloride of Formula (I) and 5-(2-Chloro acetyl)-6-chloro oxindole of Formula (IV), which is an intermediate for the preparation of 5-(2-chloro ethyl)-6-chloro oxindole of Formula (V). Ziprasidone hydrochloride of Formula (I) of the present invention is depicted by the following structure.02-19-2009
20090047353CHANGING TH1/TH2 BALANCE IN SPLIT INFLUENZA VACCINES WITH ADJUVANTS - The invention seeks to avoid components in split vaccines that could cause an excessive Th2 response. Thus the invention provides an immunogenic composition comprising a split influenza virus antigen and a Th1 adjuvant, wherein the antigen is preferably prepared from a virus grown in cell culture (e.g., it is free from egg proteins).02-19-2009
20090047352Colourant Compositions and Their Use - A fibre colourant and an ink composition are provided which comprise monodisperse particles capable of forming a colloidal crystal that diffracts light having a wavelength in a range that corresponds to the wavelength of visible light. The use of such compositions in colouring substrates is also provided.02-19-2009
20090047351Processes For Making Lactose Utilizing Pre-Classification Techniques And Pharmaceutical Formulations Formed Therefrom - A process for forming lactose suitable for use in a pharmaceutical formulation comprises providing a plurality of lactose particles containing no more than 10% w/w of lactose particles having a volume average particle size of about 70 microns or less; milling the plurality of lactose particles to yield a plurality of milled lactose particles with an average particle size, (D50), ranging from about 50 microns to about 100 microns; and classifying the plurality of milled lactose particles into at least two fractions comprising a fine fraction and a coarse fraction wherein the fine fraction has an average particle size, (D50), ranging from about 3 microns to about 50 microns, and the coarse fraction has an average particle size, (D50), ranging from about 40 microns to about 250 microns.02-19-2009
20090258072LARGE ULTRAVIOLET ATTENUATING PIGMENTS - Large particle sunscreen powders useful as ingredients in cosmetic compositions and in dispersions for incorporation into cosmetic compositions comprise a UV shielding agent in a matrix material. The macroparticle powders can be used in a wide range of cosmetic formulations, including sunscreens, eyeshadow, mascara, foundation, blusher, toner, lipstick and other compositions requiring ultraviolet protection.10-15-2009
20090285898COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH AN ANTICHOLINERGIC BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an anticholinergic bronchodilator for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.11-19-2009
20100040693SILICA CAPSULES HAVING NANO-HOLES OR NANO-PORES ON THEIR SURFACES AND METHOD FOR PREPARING THE SAME - The present invention relates to silica capsules having nano-holes or nano-pores on the surface thereof, and preparation methods thereof. More specifically, relates to silica capsules having holes with a size ranging from a few nanometers (nm) to a few hundreds of nanometers (nm), on the surface thereof, multifunctional silica capsules containing magnetic nanoparticles and optical nanoparticles, and preparation methods thereof. According to the present invention, the silica capsules having holes on the surface thereof can be prepared by making an emulsion system using two fluids having different surface tensions, and selectively evaporating only one fluid of the two fluids during a process of forming a silica layer. In addition, the multifunctional silica capsules containing magnetic nanoparticles and optical nanoparticles can be prepared by loading various multifunctional nanoparticles into the two fluids.02-18-2010
20120114757PARTICLES COMPRISING DROSPIRENONE ENCAPSULATED IN A POLYMER - The present invention relates to particles comprising Drospirenone encapsulated in a polymer selected from the group consisting of glycolic acid polymer, lactic acid polymer, poly caprolactones, poly anhydrides and any copolymer of these, e.g., poly(lactic acid-co-glycolic acid) polymer and any combination of these. Furthermore, the present invention also relates to compositions comprising such particles. The present invention also relates to the use of such particles or compositions as contraceptives and for treatment of diseases, disorders and symptoms associated with deficient endogenous levels of estrogen in women.05-10-2012
20090011031Delivery of oral drugs - Disclosed is a system for delivery of a drug comprising a multiple unit dosing device comprising a chousing and an actuator, said device containing multiple doses of multiparticulates comprising drug particles, said device upon actuation delivering a unit dose of said multiparticulates, said drug particles having a mean diameter of greater than 10 μm to about 1 mm such that an effective dose of said drug cannot be delivered into the lower lung of a human patient. Also disclosed are novel methods, devices and dosage forms for delivering a drug.01-08-2009
20090011029COLORLESS AND TRANSPARENT ANTIBIOTIC MATERIAL INCLUDING SILVER, AND A METHOD FOR THE PREPARATION OF IT - Disclosed herein is a colorless and transparent antibiotic material including silver and a method of preparing the same. Specifically, the current invention pertains to a method of preparing a colorless and transparent antibiotic material including silver (Ag), which includes a) reacting a salt including a silver ion (Ag+) with a salt including a sulfate anion, to prepare a silver (Ag)-sulfate complex; and b) diluting the silver (Ag)-sulfate complex prepared in a) with water, and to an antibiotic material prepared using the method. Further, the current invention pertains to an antibiotic material including silver, which is harmless to the human body and exhibits disinfecting and antibiotic activities, and as well, is colorless and transparent and does not easily form colored oxides, unlike conventional silver-based antibiotic materials, and to a method of preparing such an antibiotic material. Thus, the colorless and transparent antibiotic material of this invention can be widely applied to manufacture industrial goods, such as nonwoven fabrics, packaging materials, etc., living goods, such as clothes, bedclothes, etc., and fiber goods.01-08-2009
20080268059IMMOBILIZING PARTICLES ONTO SURFACES - A method for immobilizing micro-particles, nano-particles or combinations thereof onto a surface is disclosed. The method includes distributing the micro-particles, nano-particles or combinations thereof onto the surface. The surface and the particles are exposed to thermal treatment, vapor treatment or combinations thereof, thereby adhering at least some of the micro-particles, nano-particles or combinations thereof to the surface. Materials including such immobilized micro-particles, nano-particles or combinations thereof are also disclosed herein.10-30-2008
20080206342Compositions and Methods For Increasing the Bioavailability of Pulmonarily Administered Insulin - A pharmaceutical composition suitable for pulmonary delivery includes insulin and EDTA. The presence of EDTA is effective to increase the relative pulmonary bioavailability of the insulin compared to the relative pulmonary bioavailability exhibited by a composition having the same components but absent the EDTA. The composition is in dry powder form. A method of treating or ameliorating diabetes or a related condition in a mammal includes administering by inhalation a pharmacologically effective amount of the composition. A method of improving the pulmonary bioavailability of an insulin composition includes adding EDTA to an insulin composition suitable for pulmonary delivery, wherein the composition is in dry powder form.08-28-2008
20110033544INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH IMPROVED PHARMACOKINETCS - Methods are provided for the engineering of inhalable dry powder pharmaceutical formulations with desired pharmacokinetic profiles and parameters. Compositions with improved pharmacokinetics are disclosed.02-10-2011
20110117199FOAMY BIOMATERIAL FOR BIOLOGICAL TISSUE REPAIR - A kit for producing a foamed biocompatible material includes a container configured to sustain a high pressure, and a tissue-repair composition placed in the container. The composition contains a biocompatible material, a liquid carrier, and a gas. The container has an internal pressure of greater than 1 atm and less than 250 atm, and includes a valve and a nuzzle for releasing from the nuzzle a foam formed of the composition upon opening the valve. Methods of producing and applying the biocompatible material are also disclosed.05-19-2011
20100172994Nanoparticles for Protection of Cells from Oxidative Stress - The present invention concerns metal oxide semiconductor nanoparticles with free radical scavenging activity, compositions comprising such nanoparticles, methods for their use, and methods for their production. In one aspect, the invention concerns a method for enhancing the survival or viability of transplanted cells, comprising administering an effective amount of metal oxide semiconductor nanoparticles to a target anatomical site of a subject before, during, or after administration of transplant cells to the subject. Preferably, the metal oxide nanoparticle is a cerium oxide (ceria) nanoparticle.07-08-2010
20110091556Antimicrobial compositions and methods of use - The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present invention relates to methods and compositions for decreasing the infectivity of pathogenic organisms in foodstuffs. In particular, decreased pathogenic organism infectivity, morbidity, and mortality is accomplished by contacting the pathogenic organism with an oil-in-water nanoemulsion comprising an oil, an organic solvent, and a surfactant dispersed in an aqueous phase.04-21-2011
20080274198USE OF MULTILAYERED PIGMENTS IN THE FOOD AND PHARMACEUTICALS SECTOR - The present invention relates to the use of multilayered pigments based on platelet-shaped substrates for colouring food and pharmaceutical products.11-06-2008
20090324727NANOEMULSION - The present invention relates to a nanoemulsion comprising at least one aqueous component and a carrier, wherein the carrier comprises at least one lipophilic component, at least one surfactant and at least one alcohol, characterised in that at least one alcohol has at least three carbon atoms. The present invention further relates to a composition comprising said nanoemulsion and an active agent. In particular, the composition is present as a gel and the active agent is 5-aminolevulinic acid, a derivative, precursor and/or metabolite thereof. The invention further relates to the preparation of said nanoemulsion and/or composition and to their use for the treatment of dermatological diseases, virus-associated diseases as well as diseases associated with cell proliferation, in particular, tumor diseases and/or psoriasis. The present invention is further directed to the use of said nanoemulsion in cosmetics.12-31-2009
20110142945Hydrophobic Active Agent Compositions and Related Methods - Compositions and methods for providing hydrophobic active agents in a bioavailable form are disclosed and described. In one aspect of the invention, pharmaceutical composition containing a testosterone ester is provided. The composition includes a testosterone ester in both dissolved form and as undissolved particles and the dissolved form comprises at least 35 wt % of the testosterone ester present in the composition. The composition further includes a solubilizer and a stabilizer.06-16-2011
20110142944ANDROGRAPHIS EXTRACT FORMULATIONS - A pharmaceutical formulation containing 50-90% by weight a powdered extract of Andrographis paniculata and 5-50% by weight a powdered blocking agent. The formulation may further contain a pore-forming agent, a filler, a lubricant, or a glidant. Also described are a method for preparing this pharmaceutical formulation and a method for treating inflammatory disease, immunological disease, or respiratory disease with it.06-16-2011
20110142942USE OF pH SENSITIVE COMPOUNDS IN TASTE MASKING OF DRUG SUBSTANCES WITHIN ORAL THIN FILM STRIPS - The present invention relates to an edible film dosage form that includes a film-forming polymer and a coated active composition capable of taste-masking an active contained therein. An edible film that includes an edible, water-soluble film forming polymer and an active with at least two coating layers is also disclosed.06-16-2011
20100215753Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose - A solid dosage form is provided which includes an active agent and silicified microcrystalline cellulose, the dosage form formed by a) combining a wetted active agent with dry silicified microcrystalline cellulose in a dryer to form agglomerated particles; and b) incorporating the agglomerated particles into the solid dosage form. In certain preferred embodiments, step b comprises combining said silicified microcrystalline cellulose, said active agent, and colloidal silicon dioxide in a dryer. Preferably, the dryer is a spray dryer, and, in certain embodiments, the active agent may be an herbal extract.08-26-2010
20100203144Immobilized Metallic Nanoparticles as Unique Materials for Therapeutic and Biosensor Applications - The present invention relates to compositions and methods by which surface modification techniques can be used to modify wide range polymeric or metal substrates using metal nanoparticles.08-12-2010
20100003330ANTIMICROBIAL NANOEMULSION COMPOSITIONS AND METHODS - The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present invention relates to methods and compositions for decreasing the infectivity of pathogenic organisms in foodstuffs.01-07-2010
20080206343Hepatocytes and Chondrocytes from Adherent Placental StemCells; And CD34+ ,CD45- Placental Stem Cell-Enriched Cell Populations - Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD3408-28-2008
20100008995Processes for preparing pharmaceutical compositions - A process for the production of a composition comprising a water-insoluble triptan which comprises the steps of: a) providing a mixture comprising: i) a water-insoluble triptan, ii) a water soluble carrier, and iii) a solvent for each of the triptan and the carrier, and b) spray-drying the mixture to remove the or each solvent and obtain a substantially solvent-free nano-dispersion of the triptan in the carrier.01-14-2010
20100008994ELECTROSPUN STRUCTURES AND METHODS FOR FORMING AND USING SAME - The present invention relates to structures that contain one or more fiber and/or nanofiber structures where such structures can be formed on a wide variety of structures or surfaces (e.g., asperities, flat surfaces, angled surface, hierarchical structures, etc.). In one embodiment, the present invention relates to a process for forming one or more fibers, nanofibers or structures made therefrom on a wide variety of structures or surfaces (e.g., asperities, flat surfaces, angled surface, hierarchical structures, etc.). In another embodiment, the present invention relates to a process for forming one or more fibers, nanofibers or structures made therefrom on a wide variety of structures or surfaces (e.g., asperities, flat surfaces, angled surface, hierarchical structures, etc.) where such fibers and/or structures are designed to sequester, carry and/or encapsulate one or more substances. In still another embodiment, the present invention relates to structures that contain one or more fiber and/or nanofiber structures on asperities where the nanofiber and/or fiber structures are designed to sequester, carry and/or encapsulate one or more substances.01-14-2010
20100172997GOLD, SILVER, AND COPPER NANOPARTICLES STABILIZED IN BIOCOMPATIBLE AQUEOUS MEDIA - The present invention includes metal nanoparticles composition and methods of making and using the same by converting a metal (I) to a metal (0) and forming one or more metal nanoparticles from the metal (0). The one or more metal nanoparticles are stabilized with one or more biocompatible stabilizers to prevent agglomeration and make them amenable for biomedical applications.07-08-2010
20100266695MULTIVALENT CLUSTERING TARGETING STRATEGY FOR DRUG CARRIERS - The present invention provides clustered ligand vehicles for the delivery of a nucleic acid therapeutic agent to a target expressing a receptor. The invention further provides methods for treating a disease state by targeting a nucleic acid therapeutic agent to a target expressing a receptor using clustered ligand vehicles.10-21-2010
20100266694Chitosan/Carbon Nanotube Composite Scaffolds for Drug Delivery - A novel composite for internal application within wounds, incisions, and the like, for the prevention of biofilm growth therein is provided. Such a composite includes an antibiotic introduced within a sponge-like chitosan delivery product with electrically conductive nanomaterials present. Such a delivery product is also lyophilized subsequent to nanomaterial introduction but prior to antibiotic inclusion. The inventive lyophilized composite permits delivery of needed antibiotics internally within a patient with the simultaneous exposure to a sufficiently strong electrical current to permit a synergistic effect of increased antibiotic efficacy. In such a manner, relatively low amounts of antibiotic may be utilized to reduce the propensity of biofilm formation and/or growth within a wound or incision, or on the surface of an implant. Additionally, the lyophilized chitosan/nanomaterial composite allows for a maximum amount of antibiotic to be introduced with maximum elution therefrom as well. Lastly, the chitosan degrades over time within the subject's body, thereby avoiding any further invasive removal procedures. The method of such a manner of delivering improved antibiotic efficacy for biofilm prevention is encompassed within this invention as well.10-21-2010
20080206341Lipid Nanoparticles as Vehicles for Nucleic Acids, Process for Their Preparation and Use - The invention relates to solid lipid nanoparticles composed of lipid material and containing, as bioactive molecule, a nucleic acid, preferably an antisense oligonucleotide, preferably modified by chemical methods to achieve a greater resistance to endo- and exo-nucleases, and to the process for preparation of the nanoparticles. In the present invention, the efficiency of the delivery system represented by nanoparticles containing synthetic or natural polynucleotides allows the use of such system for transfection. The particles are especially effective in the treatment of diseases of the posterior segment of the eye (such as diabetic retinopathy, macular degeneration, etc.) and in angiogenesis.08-28-2008
20110123623RHAMNOLIPID MECHANISM - A topical composition for treating a patient having rhamnolipid as an active ingredient. The rhamnolipid is absorbed by the skin of a human or animal, absorbed by the blood stream, and distributed through the human or animal body.05-26-2011
20080241254PHARMACEUTICAL COMPOSITION COMPRISING ATOVAQUONE PARTICLES - The present invention relates to atovaquone particles having d10-02-2008
20100255104PHARMACEUTICAL FORMULATION OF TAXANE - A pharmaceutical formulation of taxane to be administered to mammals, preferably humans, including two compositions which are combined prior to their administration, forming a transparent solution free from precipitates and essentially free from foam, wherein said compositions comprise a solid composition of taxane and a solubilizing composition of said solid taxane composition comprising a tensoactive and an antifoam agent. A kit for such a formulation of injectable taxane includes a prefilled syringe. Also there is a pharmaceutical taxane perfusion solution.10-07-2010
20090061005Paliperidone Polymorphs - Described herein are novel polymorphic forms of paliperidone, processes for preparing the novel forms and use thereof. Also provided are processes for the preparation of novel polymorphic forms of paliperidone and the use thereof in the preparation of pharmaceutical compositions.03-05-2009
20080260841Micronized wood preservative formulations - The present invention provides wood preservative compositions comprising micronized particles. In one embodiment, the composition comprises dispersions of micronized metal or metal compounds. In another embodiment, the wood preservative composition comprises an inorganic component comprising a metal or metal compound and organic biocide. When the composition comprises an inorganic component and an organic biocide, the inorganic component or the organic biocide or both are present as micronized particles. When compositions of the present invention are used for preservation of wood, there is minimal leaching of the metal and biocide from the wood.10-23-2008
20090068275Process for the Manufacture of Powders of Inhalable Medicaments - The invention relates to an improved process for the production of powders of an inhalable medicament by crystallization from a supersaturated fluid containing said medicament, the method comprising passing along a tubular reactor 03-12-2009
20100266699Pharmaceutical Suspensions and Related Methods - A pharmaceutical suspension having a therapeutically effective amount of phenylephrine and a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent having an average particle size of between about 10 and about 100 microns, an effective amount of non-reducing sweetener; an effective amount of water; and an effective amount of a suspending system; wherein the pharmaceutical suspension has a pH of from about 4 to about 6 and is substantially free of a reducing sugar and related methods.10-21-2010
20090196932PHARMACEUTICAL COMPOSITIONS OF ATORVASTATIN - A dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof, as well as a dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing such compositions, and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's disease using a therapeutically effective amount of the pharmaceutical composition.08-06-2009
20100062067COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT - A composition comprising lipid and surfactant, characterised in that the lipid and surfactant are in the form of macromolecular assemblies of less than 100 nm in diameter. The surfactant can have a HLB number of less than 20, or be an ether or ester surfactant, or be ionic.03-11-2010
20100255105EXTENDED RELEASE PHARMACEUTICAL COMPOSITION COMPRISING METOPROLOL SUCCINATE - An extended release pharmaceutical composition comprising metoprolol succinate and at least two pharmaceutically acceptable excipients, wherein the first pharmaceutically acceptable excipient is an extended release agent; the second pharmaceutically acceptable excipient is selected from a binder, a diluent and mixtures thereof; and metoprolol succinate is in a crystalline form having a D50 ranging from 5 to 16 microns and a D90 below 50 microns.10-07-2010
20100040691PHARMACEUTICAL COMPOSITIONS COMPRISING METHOTREXATE - The present invention relates to pharmaceutical compositions and their uses in therapy. In particular, the invention relates to compositions comprising methotrexate, preferably wherein the compositions are for administration via the inhaled or intranasal route.02-18-2010
20110300220SOLID CALCIUM LACTATE IN SUBSTANTIALLY SPHERICAL FORM - Solid calcium lactate in the form of substantially spherical particles, characterised in that the spherical particles have a particle size distribution such that most of the particles are between 280 and 550 microns in size and the calcium lactate can be rapidly dissolved in water.12-08-2011
20110300219NANOSTRUCTURES FOR DRUG DELIVERY - The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a plurality of particles comprising a platinum(IV) therapeutically active precursor.12-08-2011
20110300218NOVEL SOLID STATE FORMS OF RANOLAZINE SALTS - Provided herein are solid state forms of ranolazine salts. Also provided is a stable amorphous form of ranolazine hydrochloride having a water content of less than about 0.5% by weight. Further provided are amorphous co-precipitates of ranolazine or a pharmaceutically acceptable salt thereof with povidone. Processes for the preparation of ranolazine forms, pharmaceutical compositions, and methods of treating thereof are also included. The solid state forms of ranolazine salts are useful for preparing ranolazine in high purity.12-08-2011
20100136116NOVEL HYDRATED FORM OF ERLOTINIB FREE BASE AND A PROCESS FOR PREPARATION OF ERLOTINIB HYDROCHLORIDE POLYMORPH FORM A SUBSTANTIALLY FREE OF POLYMORPH FORM B - The present invention provides a novel and stable hydrated form of erlotinib free base, and a process for its preparation thereof. The present invention also provides a process for preparation of erlotinib hydrochloride crystalline polymorph A substantially free of polymorph B. The present invention further relates to erlotinib hydrochloride crystalline particles having mean particle size (D06-03-2010
20090081298SUSTAINED RELEASE OF APO A-I MIMETIC PEPTIDES AND METHODS OF TREATMENT - A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.03-26-2009
20110123624FORMULATIONS COMPRISING AMINOSTEROLS - This invention relates to stable aminosterol phosphate compositions. The aminosterol phosphate compositions permit administration without associated tissue damage and achieve a sustained release effect.05-26-2011
20090011030BREAKTHROUGH PAIN MANAGEMENT - The present invention is directed to a powdered formulation comprising an analgesic, preferably fentanyl, for use in pulmonary inhalation administration for the rapid analgesic titration of pain, in particular breakthrough pain. Upon administration, the powdered formulation is able to provide a narrower titration range in patients suffering from pain, as well as effective analgesic amounts of fentanyl in a shorter time and at lower dose levels of administered fentanyl when compared to fentanyl administered by an oral transmucosal route.01-08-2009
20090280184PHARMACEUTICAL COMPOSITION, METHOD OF PREPARATION AND METHODS OF TREATING ACHES/PAINS - Provided are methods and compositions useful for treating/aches and/or pains. The compositions comprise an herbal therapeutic agent and an analgesic agent, wherein the composition is effective when delivered to the mucosal membrane.11-12-2009
20100143481METHOD OF PREPARING SOLID DOSAGE FORMS OF MULTI-PHASIC PHARMACEUTICAL COMPOSITIONS - Pharmaceutical formulations comprising a multi-phasic pharmaceutical composition, and an adsorbent carrier, where the pharmaceutical formulation is a solid dosage form. Methods for preparing such pharmaceutical compositions are described.06-10-2010
20110111038PROCESS FOR PRODUCING A STABLE CONCENTRATED DIETARY SUPPLEMENT AND SUPPLEMENT PRODUCED THEREBY - A stable concentrated dietary supplement containing fucoxanthin as the main active component. The dietary supplement is made by a process including grinding crude freeze-dried flakes of wakame seaweed (05-12-2011
20100003331SUSTAINED RELEASE DOSAGE FORMS OF ZIPRASIDONE - A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier.01-07-2010
20090311330LIQUID ORAL COMPOSITIONS - A suspension which is suitable for oral administration, comprising simvastatin, at least one suspending agent, and at least one preservative, wherein at least 90 wt % of the particles of simvastatin are less than 100 μm in diameter. The present invention also includes uses of the suspension and methods of making the suspension.12-17-2009
20090208580Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles - The present invention relates to compositions comprising functionalized dendrimer-stabilized nanoparticles (DSNPs), functionalized dendrimer-encapsulated nanoparticles (DENPs) (e.g., metal DENPs), and methods of generating and using the same.08-20-2009
20110293723SYNTHETIC NANOCARRIER COMBINATION VACCINES - Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.12-01-2011
20090324725PEG-MODIFIED HYDROXYAPATITE, PHARMACEUTICAL USING THE SAME AS BASE MATERIAL AND PRODUCTION PROCESS THEREOF - The present invention provides a PEG-modified HAP having a high degree of safety and novel functions by modifying the surface of hydroxyapatite particles with a polyethylene glycol derivative, applications thereof, and a production process of the same. The PEG-modified HAP of the present invention is a substance in which hydroxyapatite having a particle diameter of 50 μm to 10 nm is bonded to a polyethylene glycol derivative having a carboxyl group as a terminal functional group through —O(CO) bonds, and the carbon content thereof is 10 to 0.1%. In addition, the present invention is a substance composed of this substance and a pharmaceutical active ingredient or pharmaceutical additive, in which the weight ratio of the pharmaceutical active ingredient is 1 to 30%, and the substance is obtained by treating hydroxyapatite having a particle diameter of 50 μm to 10 nm and an active ester of polyethylene glycol derivative having a carboxyl group as a terminal functional group in an anhydrous organic solvent.12-31-2009
20090017123DERMAL REGENERATION ENHANCER - An object of the present invention is to provide a novel dermal regeneration enhancer. In accordance with the present invention, there is provided a dermal regeneration enhancer as a novel pharmaceutical use of lyotropic liquid crystal which has been utilized as a basic material for pharmaceutical preparations for external application and for cosmetics, and the dermal regeneration enhancer of the present invention achieves an excellent suppressive effect to aging of the skin, generation of spots, etc.01-15-2009
20090104271Use of microparticles combined with submicron oil-in-water emulsions - Compositions are provided which include biodegradable microparticles with entrapped or adsorbed antigens, in combination with submicron oil-in-water emulsions. Also provided are methods of immunization which comprise administering to a vertebrate subject (a) a submicron oil-in-water emulsion, and (b) a therapeutically effective amount of a selected antigen entrapped in a microparticle.04-23-2009
20090017122Drug Forms Having Controlled Bioavailability - The present application relates to novel drug formulations of vardenafil which dissolve rapidly in the mouth and have controlled bioavailability, and to processes for their preparation.01-15-2009
20080286364EXTERNAL DERMATOLOGIC PREPARATION - An object of the present invention is to provide an external dermatologic preparation which comprises nanoparticles consisting of proteins that can exhibit desirable effects via regulation of particle diameters. The present invention provides an external dermatologic preparation which comprises protein nanoparticles containing an active ingredient and having an average particle size of 200 to 500 nm.11-20-2008
20110003000Transvaginal Delivery of Drugs - Drug delivery compositions which are suitable for transvaginal administration for the treatment of diseases and disorders of the urogenital tract are described. The drug delivery compositions are administered directly to the vagina using a convenient transvaginal application that deposits a very small volume of drug at the desired site for delivery. This method of administration reduces the systemic levels of the drugs and decreases the side effects which are associated with systemic administration. In the preferred embodiment, the compositions are in the form of a gel. The formulation is administered in volumes of less than or equal to 1 milliliter. In the preferred embodiment, the composition contains an antimuscarinc drug, such as oxybutynin.01-06-2011
20080299206Ophthalmic preparations - The present invention provides ophthalmic formulations containing cyclosporine, methods for preparing the formulation, and methods for using the formulation.12-04-2008
20090297610Composition and system to promote wound healing - An externally applied non-absorbent composition applied to a wound to promote the healing of skin. The composition contains a plurality of granulated minerals to provide a protective cover and to mask the wound. The composition, together with similar compositions, may be assembled as a system and layered above the wound to better bar undesired particles from contaminating the wound and to camouflage the wound site. The compositions of the system may each be applied via a dispensing brush which retains the composition in a reservoir and dispenses the composition to the skin through the brush bristles, preventing contamination of the composition from the wound.12-03-2009
20100291220ANTIBIOTIC FORMULATION AND METHOD OF TREATMENT - A formulation comprised of particles which may be in groups and are comprised of a biocompatible polymer and an antimicrobial drug for controlled release of the drug is disclosed. The particles may be in an aqueous solution comprising thrombin and be dispersed in a gel. The formulation is administered to an area such as an open wound having an orthopedic implant therein and provides a therapeutically effective level of drug to the patient over therapeutically effective period of time.11-18-2010
20090162446ABSORBENT ARTICLE HAVING A STABLE SKIN CARE COMPOSITION - The present invention relates to an absorbent article having a stable skin care composition disposed on its skin-contacting surface. The skin care composition is readily transferable to the skin via normal contact, wearer motion, and/or body heat. Importantly, the skin care composition contains at least one skin care ingredient imparting visible skin benefits to the skin upon transfer to the skin and at least one theological agent for stabilizing the composition such that agglomeration, stratification and/or settling of the composition are minimized. The present invention also relates to a process for making the absorbent articles having a stable skin care composition disposed thereon.06-25-2009
20100034890COMBINATIONS OF FORMOTEROL AND FLUTICASONE PROPIONATE FOR ASTHMA - A pharmaceutical composition comprising (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or said salt and (B) fluticasone propionate, suitable for use in the treatment of inflammatory or obstructive airways diseases.02-11-2010
20100034889EFFERVESCENT TABLETS/GRANULES - This invention provides an effervescent solid form that dissolves in cold water quickly enough to not disappoint consumers yet not so quickly that the visual interest generated during the effervescent reaction is lost. This performance is achieved by forming effervescent particles that are dense enough to retard dissolution and small enough to not take too long to dissolve. The aim of this invention is to provide a beverage in solid effervescent form that takes between about 30 and about 120 seconds to dissolve in warm water. The granules may carry functional additives such as flavors, vitamins, minerals, sweeteners, colors and drugs. The granules may also be compounded of materials intended to provide relief from skin or topical discomfort, as in the form of a wash or bath additive. The granules may also be formulated to provide cleaning agents, such as ceramic cleaners and denture cleaners.02-11-2010
20100034885FORMULATIONS CONTAINING GLIMEPIRIDE AND/OR ITS SALTS - The invention relates, in general, to new formulations and dosage units containing glimepiride of defined particle size and/or salts thereof that are useful for the therapeutic treatment (including prophylactic treatment) of mammals, including humans, without the need for micronizing any excipients together with the glimepiride that advantageously saves time, energy and resources and a process for making the same. In particular, the invention can be useful for the treatment of diabetes.02-11-2010
20100266696Organic Compounds - A process of preparing a particulate and substantially crystalline drug substance. The process involves suspending a substantially crystalline drug substance in an anti-solvent to give a suspension, homogenising the suspension at elevated pressure to give drug particles that have a mean particle size of less than about 10 μm, and drying the drug particles to remove any residual anti-solvent.10-21-2010
20110217381PHARMACEUTICAL COMPOSITIONS - The present invention provides a substantially solvent-free nano-dispersion of an active in a carrier, wherein the carrier comprises an enteric carrier soluble at intestinal pH, but insoluble at stomach pH, and wherein the enteric carrier comprises at least 50% by weight of the nano-dispersion; and processes for the preparation of a substantially solvent-free nano-dispersion of an active in a carrier.09-08-2011
20110217382Methods and Compositions for Treating Pain Comprising a Statin - Methods and compositions are provided for reducing, treating or preventing pain and/or inflammation in a patient in need of such treatment, the methods and compositions comprising administering a therapeutically effective amount of a statin or pharmaceutically acceptable salt thereof to a target tissue site beneath the skin.09-08-2011
20110217380PROTEINS THAT STIMULATE THE SECRETION OF SATIETY HORMONES - The invention is in the field of weight management, in particular in the field of weight management by influencing the mechanisms of body-weight regulation. Intact pea protein and intact wheat protein were found to be effective in reducing appetite or inducing or increasing satiety when brought into contact with their receptors in the duodenum. Since it is known that intact proteins hydrolyse in the gastrointestinal tract, intact pea protein and intact wheat protein will not exhibit their satiating effect when ingested in a conventional oral preparation. Therefore, special care should be taken to deliver the intact proteins to the duodenum in order for them to arrive there intact. One object of the invention may therefore be achieved by incorporating the intact protein in an enteric delivery vehicle.09-08-2011
20090291143Combination of Azelastine and Steroids - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.11-26-2009
20090162440SODIUM ALGINATE MICROSPHERE VASCULAR EMBOLUS CONTAINING WATER-SOLUBLE DRUG AND PREPARATION AND APPLICATION THEREOF - The present disclosure relates to a kind of sodium alginate microsphere vascular embolus that contains water-soluble drug and preparation and application thereof. The embolus preparation falls into dry microsphere type and wet one that are made of degradable materials. The drug carrier can be sodium alginate, human serum albumin, chitosan or sodium hyalurate, solidifying and forming microsphere together with calcium ion solution under presence of static charge. The microsphere can have a diameter in the range of 20-1000 μm and can be divided into a wide variety of sizes in case of need. The present disclosure adopts raw materials that are good at mechanical strength, bio-compatibility, bio-degradability and stability. In vitro experiments, animal trials and clinical observations reveal that this embolus is a good targeting medication for embolism treatment and immunochemotherapy, which is safe, effective for the treatment of solid tumors including primary liver cancer, lung cancer, renal tumors, bladder cancer, uterine cancer, ovary cancer, colon carcinoma and rectal cancer.06-25-2009
20090098208PHARMACEUTICAL COMPOSITIONS BASED ON POROUS ZEOLITES AS RELEASE MEANS OF PHARMACOLOGICALLY ACTIVE MOLECULES AND RELATIVE USE - The present invention relates to pharmaceutical compositions for the oral administration of pharmacologically active molecules, comprising a release means consisting of porous zeolite in powder form, incorporating pharmacologically active molecules inside the pores and/or on its surface, the relative use for the preparation of drugs for oral administration, in particular for the treatment of inflammatory pathologies at an intestinal level and the preparation process of these compositions.04-16-2009
20100112071POLYPEPTIDES AND POLYNUCLEOTIDES FOR ENHANCING IMMUNE REACTIVITY TO HER-2 PROTEIN - Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also provided are pharmaceutical compositions comprising such immunogenic compositions. Methods for stimulating an immune response to HER-2 protein are provided. Methods for treating breast cancer, ovarian cancer, prostate cancer, colon cancer and lung cancer are provided.05-06-2010
20100112069Flowable Carrier Matrix - A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site.05-06-2010
20100143480TRICALCIUM PHOSPHATE COARSE PARTICLE COMPOSITIONS AND METHODS FOR MAKING THE SAME - Methods for preparing a tricalcium phosphate coarse particle composition are provided. Aspects of the methods include converting an initial tricalcium phosphate particulate composition to hydroxyapatite, sintering the resultant hydroxyapatite to produce a second tricalcium phosphate composition and then mechanically manipulating the second tricalcium phosphate composition to produce a tricalcium phosphate coarse particle composition. The subject methods and compositions produced thereby find use in a variety of applications.06-10-2010
20110262544OPHTHALMIC ADMINISTRATION OF A COMPOSITION INCLUDING BRIMONIDINE AS A MIST - Disclosed are methods of treatment including administration of a pharmaceutical composition including brimonidine to an eye as a mist, the composition devoid of a penetration enhancer.10-27-2011
20090148531RATE-CONTROLLED PARTICLES - Rate-controlled particles, comprising compounds of the formula06-11-2009
20100266700USE OF ADSORBENT CARBON MICROSPHERES FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME - Adsorbent carbon microspheres are administered to treat irritable bowel syndrome or symptoms associated with irritable bowel syndrome.10-21-2010
20080279948Treatment of Asthma and Copd Using Triple-Combination Therapy - A medicament comprising, separately or together (A) a compound of formula I11-13-2008
20100278921SOLID ORAL FORMULATION OF ABT-263 - An orally deliverable pharmaceutical composition comprises (a) a pharmaceutically acceptable acid addition salt of ABT-263 in solid particulate form, and (b) a plurality of pharmaceutically acceptable excipients including at least a solid diluent and a solid disintegrant; wherein the salt is formed from more than one equivalent of acid per equivalent of ABT-263. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.11-04-2010
20080206344ENDOCYTOTIC PARTICLES - Endocytosis of an active agent into a cell having surface receptors can be enhanced by using particles that have a radius no less than an endocytotic threshold determined based on a surface density of the receptors, a surface density of the moieties and interaction parameters that include at least one of a receptor-moiety spring constant and a non-specific interaction strength.08-28-2008
20100266698USE OF INSULIN FOR THE TREATMENT OF CARTILAGINOUS DISORDERS - The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilaginous disorders, including arthritis, comprising the administration of insulin and/or insulin variants. Optionally, the administration may be in combination with a cartilage agent (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, anti-inflammatory factor), in an extended- or sustained-release form. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilaginous disorders comprising the administration of insulin and/or insulin in combination with standard surgical techniques. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilaginous disorders comprising the administration of chondrocytes previously treated with an effective amount of insulin and/or insulin variant.10-21-2010
20100266697MIXED LIGAND SURFACE-MODIFIED NANOPARTICLES - A composition comprises surface-modified nanoparticles of at least one amphoteric metal oxide or oxyhydroxide. The nanoparticles bear, on at least a portion of their surfaces, a surface modification comprising (i) at least one surface modifier selected from lactate, thiolactate, and mixtures thereof, and (ii) at least one surface modifier selected from halide, nitrate, acetate, carbonate, formate, propionate, sulfate, bromate, perchlorate, tribromoacetate, trichloroacetate, trifluoroacetate, carboxylate comprising from one to about four alkyleneoxy moieties, chlorate, and mixtures thereof.10-21-2010
20090311326Pulmonary Insulin Crystals - The present invention provides methods and compositions for treating diabetes by administering insulin or an insulin analog via a pulmonary route, wherein the insulin or insulin analog is in crystalline form with a diameter below 10 microns when recovered from a solution having a pH between 7.0 and 9.5. The insulin or insulin analog may be in the form of a dry. The present invention provides methods and compositions for treating diabetes by administering acylated insulin or an acylated insulin analog via a pulmonary route. The insulin or insulin analog may be in the form of a dry powder or a solution. 12-17-2009
20100086604ABSORBANT SUPERHYDROPHOBIC MATERIALS, AND METHODS OF PREPARATION AND USE THEREOF - The present invention relates to coated, absorbent, freestanding assemblies comprising inorganic nanowires, articles of manufacture comprising the same, processes of producing the same and methods of use thereof. The assemblies of this invention are useful in various applications, including removal of organics or hydrophobic materials, and waterproofing applications.04-08-2010
20100086607Self-Assembled Biodegradable Nanoparticles for Medical and Biological Applications - A method for forming a biodegradable composition that self-assembles into nanoparticles is provided. The method includes reacting N,N′-Disuccinimidyl carbonate with hydroxyl end-groups of poly(lactide-co-fumarate) to form a composition comprising succinimide-terminated poly(lactide-co-fumarate).04-08-2010
20110165251LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS - The present invention relates to liquid dosage compositions of stable nanoparticulate active agents. The liquid dosage compositions of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the active agent.07-07-2011
20110027372MULTIPARTICULATES COMPRISING LOW-SOLUBILITY DRUGS AND CARRIERS THAT RESULT IN RAPID DRUG RELEASE - Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed.02-03-2011
20100291222ANTIOXIDANT NANOSPHERE COMPRISING [1,2]-DITHIOLANE MOIETIES - The present invention is directed to multiple a-lipoic acid-containing hydrophobic compounds (mALAs) capable of acting as scavengers of free radicals, metals and reactive oxygen species (ROS). Methods of synthesizing novel antioxidant mALAs, spontaneous emulsification or nanoprecipitaion thereof to produce antioxidant nanospheres and their use in preventing or treating diseases or conditions caused by oxidative stress and other free radical mediated conditions are also described. Another aspect of this invention is the use of these antioxidant nanospheres for the preparation of antioxidant particulate delivery system of therapeutic agents.11-18-2010
20110123627HIGH DENSITY COMPOSITIONS CONTAINING POSACONAZOLE AND FORMULATIONS COMPRISING THE SAME - The present application provides novel compositions comprising posaconazole and a polymer wherein the composition has a glass transition temperature (Tg) of less than about 1100 C. The application also describes compositions comprising posaconazole and a polymer having a bulk density of greater than about 0.4 mg/mL. The application also describes compositions comprising posaconazole and a polymer which provide an exposure (AUCtf) of at least about 10,000 ng·hr/mL when administered to a patient in a fasted state. The application also describes a novel process for preparing these compositions. The preff erred polymer is HPMCAS. Preferably the composition is an extruded material.05-26-2011
20100068284Stable Fixed Dose Topical Formulation - The present invention relates to stable fixed dose topical formulations comprising an antiacne agent and an antibiotic, which exhibit storage stability at a temperature of about 40° C. and relative humidity of about 75% for a period of at least 3 months. Particularly, the present invention relates to stable fixed dose topical formulations comprising therapeutically effective amounts of (a) adapalene-containing microspheres and (b) clindamycin, a process for their preparation thereof and their use for the treatment of acne.03-18-2010
20100068282Preparation of pharmaceutical compositions - A process for the production of a composition comprising a water-insoluble paracetamol or NSAID which comprises the steps of: a) providing a mixture comprising: i) a water-insoluble paracetamol or NSAID, ii) a water soluble carrier, and iii) a solvent for each of the paracetamol or NSAID and the carrier, and b) spray-drying the mixture to remove the or each solvent and obtain a substantially solvent-free nano-dispersion of the paracetamol or NSAID in the carrier.03-18-2010
20090087491METHOD FOR PREPARING PARTICLES FROM AN EMULSION IN SUPERCRITICAL OR LIQUID CO2 - The present invention relates to a method for preparing particles, notably particles encapsulating an active substance. It also relates to particles obtainable by this process, dispersion thereof, and their use as a vehicle for pharmaceutical, cosmetic, diagnostic, veterinary, phytosanitary active substances or processed foodstuff.04-02-2009
20100086601Modified Calcium Phosphate Nanoparticle Formation - The present disclosure relates to non-aggregating nanoparticles and their associated methods of preparation. The nanoparticles may have a surface and a size range of 1 nm to 999 nm, along with a zeta potential of −50 to 50 millivolts. A polycation and/or polyanion may be disposed on the nanoparticle surface. In addition, an active ingredient may be encapsulated within the nanoparticles or associated with the polycation or polyanion on the nanoparticle surface.04-08-2010
20100086609Methods and Compositions for Delivering Peptides - Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, from the peptide or protein. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting for example in a rapid increase in blood agent concentration. The formulations include microparticles formed of (i) the active agent, which may be charged or neutral, and (ii) a transport enhancer that masks the charge of the agent and/or that forms hydrogen bonds with the target biological membrane in order to facilitate transport. In one embodiment, insulin is administered via the pulmonary delivery of microparticles comprising fumaryl diketopiperazine and insulin in its biologically active form. This method of delivering insulin results in a rapid increase in blood insulin concentration that is comparable to the increase resulting from intravenous delivery.04-08-2010
20090196931THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS - Methods are provided for inhibiting or treating stenosis or restenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective amount of a therapeutic agent via a catheter. Also provided is a catheter adapted for administering a therapeutically effective amount of a therapeutic agent to a mammalian host for inhibiting or treating stenosis or restenosis.08-06-2009
20100068287Process for Preparation of a Stable Dispersion of Solid Amorphous Submicron Particles in an Aqueous Medium - The invention relates to a process for the preparation of a stable dispersion of particles, particularly sub-micron particles in an aqueous medium and to a stable dispersion of particles in a liquid medium. The sub-micron dispersion provided exhibit reduced or substantially no particle growth during storage and reduced crystallisation rate of the substantially water insoluble active compound.03-18-2010
20100080850POLYPEPTIDE LIGANDS FOR TARGETING CARTILAGE AND METHODS OF USE THEREOF - Ligands that specifically bind to articular cartilage tissues are disclosed, including uses for targeting therapeutics towards articular cartilage tissue and new materials for articular cartilage. The ligands are effective in vivo to target therapeutic materials to articular cartilage.04-01-2010
20090169630Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications - Methods and compositions for the controlled and sustained release of peroxides or oxygen to aqueous environments (e.g. a patient's body or circulatory system, or for other applications) or non-aqueous environments, include a material coating or encapsulating hydrogen peroxide, inorganic peroxides or peroxide adducts. In the case of peroxide adducts, and particularly in one type of embodiment, the peroxide adducts should be able to permeate the material, but water, hydrogen peroxide and inorganic peroxides should be able to permeate the material. The methods and compositions that allow the release of oxygen, H07-02-2009
20090263488PRESSURISED METERED DOSE INHALERS CONTAINING SOLUTIONS OF BETA-2 AGONISTS - The present invention relates to a pharmaceutical formulation for use in the administration of 2(1H)-quinolinone derivatives long-acting β10-22-2009
20090263487Bubble drink provided by bubbling engineering progress - A bubble drink as a health food, which is produced by imparting a catalytic function for gas escaping to an adsorptive fine food powder to allow the fine food powder to be dispersed in a colloidal solution reverse vessel, and reacting the dispersion with a gas-saturated solution to generate foam (a bubbling engineering process), whereby the food is converted into foam having a three-state composite structure of gas, liquid and solid states suitable to be ingested within a digestive system.10-22-2009
20090263485Targeted hollow gold nanostructures and methods of use - Provided are novel nanostructures comprising hollow nanospheres and nanotubes for use as chemical sensors and molecular specific photothermal coupling agents. The nanostructures can be used in laser-induced phototherapy for treatment of cancer and other disorders. The nanostructures can also be used as a sensor that detects molecules. The nanostructures are of particular use in the fields of clinical diagnosis, clinical therapy, clinical treatment, and clinical evaluation of various diseases and disorders, manufacture of compositions for use in the treatment of various diseases and disorders, for use in molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof. The hollow gold nanospheres have a unique combination of spherical shape, small size, and strong, tunable, and narrow surface plasmon resonance absorption covering the entire visible to near IR region.10-22-2009
20090263486NANOPARTICLE-STABILIZED CAPSULE FORMULATION FOR TREATMENT OF INFLAMMATION - A formulation for the delivery of an anti-inflammatory agent to a subject is described. In one particular application of the invention, the formulation comprises oil-based or aqueous droplets comprising indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1-H-indole-3-acetic acid) or celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl) pyrazol-1-yl] benzenesulfonamide) stabilised by nanoparticles, particularly silica nanoparticles.10-22-2009
20100098767CONVECTION ENHANCED DELIVERY APPARATUS, METHOD, AND APPLICATION - An embodiment of the invention is directed to a microfabrπcated, silicon-based, Convection Enhanced Delivery (CED) device The device comprises a silicon shank portion, at least one individual parylene channel disposed along at least a part of an entire length of the shank, wherein the channel has one or more dimensioned fluid exit ports disposed at one or more respective locations of the channel and a fluid (drug) input opening The fluid input opening may be configured or adapted to be connected to a fluid reservoir and/or a pump and/or a meter and/or a valve or other suitable control device(s) or apparatus that supplies and/or delivers fluid (e g, a drug) to the microfabricated device The device may have multiple channels disposed side by side or in different surfaces of the device04-22-2010
20100226990Method of Producing Porous Microparticles - A method of preparing porous microparticles comprises the steps of combining one or more organic compounds with a volatile system, and drying the system thus formed to provide substantially pure porous microparticles of the organic compound or composite porous microparticles of combinations of organic compounds. Organic compounds used in the method may be one or more of a bioactive, a pharmaceutically acceptable excipient, a pharmaceutically acceptable adjuvant or combinations thereof. The invention also relates to porous microparticles produced by such a method, and pharmaceutical compositions comprising such porous microparticles.09-09-2010
20090162441PULMONARY DELIVERY IN TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM - A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm06-25-2009
20110200679METHOD FOR MANUFACTURING SUSTAINED RELEASE MICROSPHERE BY SOLVENT FLOW EVAPORATION METHOD - The present invention relates to a method for preparing a sustained-release microsphere which can control the long-term release of a drug. More particularly, as the preparation of a microsphere in which a drug is loaded in a carrier comprising a biodegradable polymer, the present invention relates to a method for preparing a sustained-release microsphere wherein a solvent intra-exchange evaporation method by means of co-solvent is used for suppressing the initial burst release of physiologically active substance, to release the physiologically active substance in the body continuously and uniformly.08-18-2011
20090098207Technology for the Preparation of Microparticles - Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.04-16-2009
20110171312MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE - Modified therapeutic peptide compositions comprising conjugates of therapeutic peptides covalently coupled to one or more hydrophilic polymers. Optionally, the therapeutic peptide is also covalently coupled to one or more moieties having one to ten carbon atoms. Methods of making and use are also provided. The conjugates, when administered by any of a number of administration routes, exhibit characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer and/or one or moiety having one to ten carbon atoms.07-14-2011
20080311208Pharmaceutical Formulations Useful in the Treatment of Insomnia - There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.12-18-2008
20110268804TARGETING OF ANTIGEN PRESENTING CELLS WITH IMMUNONANOTHERAPEUTICS - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface. The nanocarriers are capable of targeting antigen presenting cells when administered to a subject. The invention provides pharmaceutical compositions comprising nanocarriers. The present invention provides methods of designing, manufacturing, and using nanocarriers and pharmaceutical compositions thereof.11-03-2011
20080311209TOPICAL COMPOSITIONS COMPRISING NANOPARTICLES OF AN ISOFLAVONE - The present invention is directed to topical compositions, comprising isoflavone nanoparticle compositions. The isoflavone nanoparticle compositions contain isoflavone in the form of nanoparticles and preferably a carrier. In the topical compositions recrystallization of the isoflavone to bigger particles is avoided.12-18-2008
20080311212CRYSTALLINE ISOXAZOLE DERIVATIVE AND PHARMACEUTICAL PREPARATION THEREOF - Crystalline 3-[(1S)-1-(2-fluorobiphenyl-4-yl)ethyl]-5-{[amino(morpholin-4-yl)methylene]amino}-isoxazole that exhibits the following angle of diffraction (2θ) and relative intensity in a powder X-ray diffraction pattern, is very easy to handle and stable in a process of its formulation into a pharmaceutical preparation.12-18-2008
20080311207Micelles and Nanoemulsions for Preventive and Reactive Treatment of Atherosclerosis - The subject invention is directed to microemulsion-based (ME) nanoparticles and methods of using same. The ME nanoparticles of the subject invention encompass self-assemblies of oil in water emulsions in the presence of at least two emulsifiers. One of the emulsifiers is a salt of a fatty acid, and the combined concentration of the at least two emulsifiers is sufficiently large to produce micelles, wherein the oil droplets are the hydrophobic core of the micelles. The subject invention also contemplates methods of modifying lipids, high density lipoprotein (HDL), and low density lipoprotein (LDL) in blood by contacting the blood with the ME nanoparticles of the subject invention. Another aspect concerns methods for treating atherosclerosis by administering the ME nanoparticles of the subject invention to a patient in need thereof.12-18-2008
20090285903METHODS FOR DENDRITIC CELL THERAPY USING PHARMACOLOGICALLY ACTIVE MICROCARRIERS - Monocytes and dendritic cells are grafted to the surface of microparticles for use as a therapeutic device for stimulating a post-injection immune response in vivo. Various embodiments include an injectable composition, an apparatus for grafting cells to the surface of polymer microspheres, and methods of facilitating activation and delivery of an injectable therapeutic device are disclosed.11-19-2009
20080241259Method for production of bioresorbable microparticles, microparticles thus obtained and use thereof - The present invention relates to a method for preparing nonlamellar bioresorbable microparticles to which protein substances are bonded, characterized in that it comprises the steps of: 10-02-2008
20080213375Drying of Drug-Containing Particles - A secondary drying process is disclosed for removing residual solvent from drug-containing particles that have been formed by solvent-based processes, the secondary drying process utilizing a combination of vacuum, agitation, and a stripping gas.09-04-2008
20080206345Methods for Control of Soil-Dwelling Pests and/or Soil-Borne Diseases - A method for the control of soil-dwelling pests and/or soil-borne diseases comprising treating a plant propagation material with an effective amount of the pesticidal composition and/or applying an effective amount of a pesticidal composition to a locus where control is desired, provided that the composition comprises, as active ingredient, one or more pesticides (A) having a water solubility of at most 100 μg/litre, at 25° C. at neutral pH, and at least one formulation auxiliary, wherein the size of particles in the composition is in the range 3.60 μm to 0.70 μm at X08-28-2008
20110171313COMPOSITION CONTAINING ULTRA-MICRONIZED PALMITOYL-ETHANOLAMIDE - The present invention relates to a composition for pharmaceutical or veterinary use, comprising palmitoylethanolamide. In particular, the present invention relates to a pharmaceutical composition for human or veterinary use, containing a therapeutically efficient amount of palmitoylethanolamide in the ultra-micronized form, wherein more than 90% by weight of palmitoylethanolamide has particle sizes lower than 6 microns, together with pharmaceutically acceptable excipients.07-14-2011
20090291141METHOD OF QUENCHING ELECTRONIC EXCITATION OF CHROMOPHORE-CONTAINING ORGANIC MOLECULES IN PHOTOACTIVE COMPOSITIONS - The photostabilizing electronic excited state energy—particularly singlet state energy from a UV-absorbing molecule has been found to be readily transferred to (accepted by) α-cyanodiphenylacrylate compounds of formulas (I) and (V) having an alkoxy radical preferably in the four (para) position (hereinafter methoxycrylenes) on one or both of the phenyl rings:11-26-2009
20090274764Hollow Foam Beads for Treatment of Glioblastoma - Compositions and methods for the treatment of tumors are disclosed. Specifically, the present invention provides hollow foam beads having a chemotherapeutic agent incorporated therein. A method of making such beads is disclosed. In addition, a method for treating a glioblastoma tumor and other types of tumors with the compressible hollow foam beads is disclosed.11-05-2009
20090297609Method of Biomolecule Immobilization On Polymers Using Click-Type Chemistry - The present invention provides a method for the covalent immobilization of biomolecules on polymers for delivery of the biomolecules, which has the advantage of being simple, highly efficient, environmentally friendly and free of side products relative to traditional immobilization techniques. The invention provides a modified micro/nanoparticle system, which uses a functionalized polymer formed into micro or nanoparticles to bind a molecule to the particles using uses facile chemistry, the Diels-Alder cycloaddition between a diene and a dienophile with the polymer being functionalized with one of them and the molecule with the other, or the Huisgen 1,3-dipolar cycloaddition between a terminal alkyne and an azide to bind the molecule to the particle. The molecules and/or other therapeutic agents may be encapsulated within the polymer particles for intravenous therapeutic delivery. The invention also provides a novel synthetic biodegradable polymer, a furan/alkyne-functionalized poly(trimethylene carbonate) (PTMC)-based polymer, whose composition can be designed to meet the defined physical and chemical property requirements. In one example, the particle system self-aggregates from functionalized PTMC-based copolymers containing poly(ethylene glycol) (PEG) segments. The composition of the copolymers can be designed to meet various particle system requirements, including size, thermodynamic stability, surface PEG density, drug encapsulation capacity and biomolecule immobilization capacity.12-03-2009
20090285902DIETARY SUPPLEMENT COMPOSITION FOR BLOOD LIPID HEALTH - A human or animal dietary supplement composition comprising one or more long chain (C24-C36) primary alcohols (policosanols) dispersed in food-grade oils or fats where the policosanol particle size is substantially less than ten (10) microns. The composition (Nanocosanol™) is effective and convenient for supporting blood lipid health.11-19-2009
20090285901Polyamino acid for use as adjuvant - Use of a polyamino acid as an adjuvant; an application of a polyamino acid as an adjuvant in the production of a vaccine; a vaccine comprising a polyamino acid as an adjuvant; a biodegradable nanoparticle having a virus antigen immobilized thereon; and a vaccine comprising the biodegradable nanoparticle.11-19-2009
20110076334METHODS AND COMPOSITIONS FOR TREATMENT OF RAYNAUD'S PHENOMENON - Administration of a calcium channel blocker such as clevidipine or nicardipine in aerosol dry powder form directly to a patient's lungs for treating Raynaud's Phenomenon.03-31-2011
20090291142NANOPARTICULATE BICALUTAMIDE FORMULATIONS - The present invention is directed to compositions comprising an acylanilide, such as bicalutamide, having improved solubility in water. The bicalutamide particles of the composition have an effective average particle size of less than about 2000 nm, and are useful in the treatment of prostate cancer.11-26-2009
20090297608BONE MARROW-DIRECTING DRUG DELIVERY MATERIALS AND THEIR APPLICATIONS - The present invention pertains to a bone marrow-directing drug delivery material that includes at least one fine particle, wherein the fine particle includes an anionic moiety on a surface of the particle. Also disclosed are uses of the material set forth herein for the prevention, treatment, or diagnosis of a disease of bone, cartilage, bone marrow, or a joint. Also disclosed are methods of preventing, treating, or diagnosing a disease of bone, cartilage, bone marrow, or a joint in a subject, involving administering to the subject a pharmaceutically effective amount of the material of the present invention.12-03-2009
20090169631MICRONIZED OPIOID COMPOSITIONS, FORMULATIONS AND DOSAGE FORMS AND METHODS OF MAKING SAME - Novel compositions, formulations and dosage forms comprising stabilized micronized opioid particles are disclosed. Exemplary opioids include oxycodone, oxymorphone, hydrocodone, and hydromorphone, including as free bases or as salts. Stabilized micronized opioid particles having a Dv90 particle size distribution of less and or equal to 10μ or less than or equal to 20μ are disclosed. Methods for micronizing an opioid to provide stabilized micronized opioid particles are also disclosed.07-02-2009
20110200677PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED NANOPARTICLES FOR THERAPY OF PROSTATE CANCER - The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.08-18-2011
20100112066Prostaglandin fat emulsion, method for producing the same, method for stabilizing the same, and emulsifying agent - A fat emulsion comprises a prostaglandin as an active ingredient, the fat emulsion comprising a phospholipid that comprises phosphatidylcholine (PC) and phosphatidylglycerol (PG) and has a ratio of PC to PG (PC:PG) of 85:15 to 99.7:0.3.05-06-2010
20100285140ANTIMICROBIAL AGENT FOR GRAM-POSITIVE BACTERIA - A novel antibacterial agent for Gram-positive bacteria which disregards the drug-resistant mechanisms of bacteria is disclosed. The antibacterial agent contains as an effective ingredient particles having a particle diameter of not more than 5 μm, which particles are adhesive to cell wall of Gram-positive bacteria and not adhesive to mammalian cell membrane and substantially do not contain an active antibacterial ingredient effective against Gram-positive bacteria. By the antibacterial agent according to the present invention, the growth of the multidrug-resistant Gram-positive bacteria such as MRSA and VRE can be inhibited, as well as the occurrence of novel multidrug-resistant bacteria, which is a big problem in use of antibiotics, can be avoided.11-11-2010
20080213373Particles for Treatment of Pulmonary Infection - Formulations have been developed to treat or reduce the spread of respiratory infections, especially chronic or drug resistant infections, particularly tuberculosis (TB), severe acute respiratory syndrome (SARS), meningococcal meningitis, Respiratory syncytial virus (RSV), influenza, and small pox. Formulations include a drug or vaccine in the form of a microparticle, nanoparticle, or aggregate of nanoparticles, and, optionally, a carrier, which can be delivered by inhalation. Giving the drugs via an inhaler sidesteps the problems associated with oral or injectable drugs by bypassing the stomach and liver, and delivering the medication directly into the lungs. In one embodiment, the particle containing the agent is a large porous aerosol particle (LPPs). In another embodiment, the particles are nanoparticles, which can be administered as porous nanoparticle aggregates with micron diameters that disperse into nanoparticles following administration. Optionally, the nanoparticles are coated, such as with a surfactant or protein coating. The formulation may be administered as a powder or administered as a solution or via an enteral or non-pulmonary parenteral route of administration. The formulation is preferably administered as a pulmonary formulation. In the preferred embodiment for treatment of TB, the vaccine is a BCG vaccine that is stable at room temperature, or is an antibiotic effective against TB, such as capreomycin or PA-824, loaded at a very high percentage into the microparticles or nanoparticles. In one embodiment, a patient is treated with formulations delivering both antibiotic and vaccine.09-04-2008
20080213378Nanoparticulate statin formulations and novel statin combinations - The present invention is directed to nanoparticulate compositions comprising statin such as lovastatin or simvastatin. The statin particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of statins and other cholesterol lowering agents are described and methods of using same are taught.09-04-2008
20080213372Gel and Apparatus for Cleaning and Deodorizing Fluids - A gel for cleaning and deodorizing air includes an organic binder with ultraviolet light permeable polymeric molecules and particles of inorganic semi-conductors. The gel includes acrylic molecules, a polar diluent and an ultraviolet light inert charge including particles of silica, of rutile cristalline form of titanium oxide and/or of clay.09-04-2008
20110268805ADJUVANT INCORPORATION IN IMMUNONANOTHERAPEUTICS - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is an adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.11-03-2011
20100278919Dendritic cell targeting compositions and uses thereof - The present invention provides compositions and methods for targeting dendritic cells of the immune system. In particular, the compositions comprise carbon nanoparticles, optionally magnetic carbon nanoparticles comprising iron, which are preferentially endocytosed by dendritic cells compared to macrophages when contacted with a biological sample. The nanoparticles of the present invention may be functionalized to enhance delivery of biomolecules to dendritic cells.11-04-2010
20100278922METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF INSULIN - The present invention provides a pharmaceutical composition formulated for oral delivery of insulin, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and insulin suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same for oral delivery of insulin.11-04-2010
20100086602PHARMACEUTICAL COMPOSITION CONTAINING STATIN-ENCAPSULATED NANOPARTICLE - The present invention provides a novel nanotechnology-based strategy for therapeutic neovascularization. Said statin-loaded nanoparticle allows local delivery of statin and thus improves therapeutic efficacy of several kind of diseases which may treated by statin such as ischemic neovascularization.04-08-2010
20090169629MICELLAR COMPOSITIONS WITH OPHTHALMIC APPLICATIONS - This invention relates to micellar compositions comprising at least one pharmaceutically active substance and a mixture of n-alkyl dimethyl benzyl ammonium chlorides, wherein the mixture comprises more than 30% n-alkyl dimethyl benzyl ammonium chlorides having a chain length superior or equal to C07-02-2009
20100136115Pharmaceutical Titanium Dioxide Composite Allowing Disappearance of Drug Efficacy By Light Irradiation - Disclosed is a titanium dioxide composite material which can be dispersed in an aqueous solvent stably and can be administered to a living body in a simple manner and in which the pharmacological effect of a therapeutic compound carried on the composite material can be eliminated by irradiation with light. Also disclosed is a dispersion product of the composite material. The composite material comprises titanium dioxide which has a photocatalytic activity and a therapeutic compound attached to the titanium dioxide through a hydrophilic polymer. The composite material is stable in an aqueous solvent and can be administered to a living body in a simple manner. After the composite material is administered to a living body, a site on the living body where the pharmacological effect of the therapeutic compound is not needed to be developed can be irradiated with light to induce the light excitation of titanium dioxide at the site, thereby decomposing the therapeutic compound to reduce any adverse side effect of the therapeutic compound.06-03-2010
20080241253Formulations for Spray-Drying Large Porous Particles - Particles having a tap density less than about 0.4 g/cm3 are formed by spray drying from a colloidal solution including a carboxylic acid or salt thereof, a phospholipid, a divalent salt and a solvent such as an aqueous-organic solvent. The colloidal solution can also include a therapeutic, prophylactic or diagnostic agent. Preferred carboxylic acids include at least two carboxyl groups. Preferred phospholipids include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phophstidylserines, phosphatidylinositols and combinations thereof. The particles are suitable for pulmonary delivery.10-02-2008
20110206770ATOVAQUONE WITH A PARTICLE SIZE DIAMETER RANGE (D90) OF GREATER THAN 3 MICRONS TO ABOUT 10 MICRONS - Atovaquone or a pharmaceutically acceptable salt thereof having a particle size diameter range with a D08-25-2011
20100129457Nanodiamond Enhanced Drugs05-27-2010
20100129453EMULSIONS COMPRISING RUBBER ARABICUM - The invention relates to micelles, micellar solutions and pre-concentrates of emulsions comprising active ingredient and Gum Arabic; products comprising such micelles or pre-concentrates of emulsions, respectively; processes for manufacturing micelles, pre-concentrates of emulsions and products.05-27-2010
20100209513PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND - Provided is a pharmaceutical composition having excellent in vivo absorption properties by increasing solubility and absorption rate of a sparingly-soluble naphthoquinone-based compound via incorporation of micronized particles of a certain naphthoquinone-based compound.08-19-2010
20100209512Particle size-structured parenteral dispersions - A Drug/Adjuvant Delivery System (D/A DS), and associated method, are disclosed. An exemplary D/A DS system includes a liquid carrier; and a particle-size structured dispersion of solid and/or liquid particles suspended in the liquid carrier.08-19-2010
20080268060Methods and apparatus for producing nanoscale particles - Liquid nanoscale particle precursor materials for generating nanoscale particles include at least one high volatility carrier and a second component. A nanoscale particle generating device generates nanoscale particles by passing a liquid nanoscale particle precursor material through a flow passage heated to convert the carrier into a vapor and the second component into nanoscale particles. The nanoscale particles preferably consist essentially of the second component and can consist essentially of dry, solid particles. The particle generator can be incorporated in a hand held inhaler, and can be delivered to a targeted portion of the lung using the inhaler. Composite controlled release particles of micron or nanoscale size can be produced by flowing a solution of medicament, control release agent and carrier liquid through a capillary heater.10-30-2008
20080274196Oral Pharmaceutical Suspension Compositions Of Fexofenadine - An oral, pharmaceutical suspension composition of Fexofenadine. Fexofenadine is a mixture of compacted Fexofenadine and plain fexofenadine in a ratio of 0.01:0.99 to 0.99 to 0.01 having a mean particle size of fexofenadine particles in the range of 10μ and 250 μ.An oral, pharmaceutical suspension composition of Fexofenadine, which is bioequivalent to a tablet dosage form of fexofenadine marketed under the trade name of Allegra®. Bioequivalence between a suspension formulation and the commercially tablet formulation of fexofenadine i.e. ‘Allegra®’ is achieved by the use of a mixture of compacted Fexofenadine.11-06-2008
20080274194Stabilized Hme Composition With Small Drug Particles - A hot-melt extruded composition having finely divided drug-containing particles dispersed within a polymeric and/or lipophyllic carrier matrix is provided. The carrier softens or melts during hot-melt extrusion but it does not dissolve the drug-containing particles during extrusion. As a result, a majority or at least 90% wt. of the drug-containing particles in the extrudate are deaggregated during extrusion into essentially primary crystalline and/or amorphous particles. PEO is a suitable carrier material for drugs insoluble in the solid state in this carrier. Various functional excipients can be included in the carrier system to stabilize the particle size and physical state of the drug substance in either a crystalline and/or amorphous state. The carrier system is comprised of at least one thermal binder, and may also contain various functional excipients, such as: super-disintegrants, antioxidants, surfactants, wetting agents, stabilizing agents, retardants, or similar functional excipients. A hydrophilic polymer, such as hydroxypropyl methylcellulose (HPMC E15), polyvinyl alcohol (PVA), or poloxamer, and/or a surfactant, such as sodium lauryl sulfate (SLS), can be included in the composition. A process for preparing the extrudate is conducted at a temperature approximating or above the softening or melting temperature of the matrix and below the point of solubilization of drug-containing particles in the carrier system, and below the recrystallization point in the case of amorphous fine drug particles.11-06-2008
20080274193Retinoic Acid-Containing Antidiabetic Agent - The present invention aims to provide a novel agent for treating and/or preventing diabetes which agent can not only control a blood sugar level but also fundamentally treat a patient with type I diabetes suffering from destruction of β cells and a patient with type II diabetes suffering from dysfunction in insulin secretion. The present invention provides an agent for treating and/or preventing diabetes, the agent containing retinoic acid as an active ingredient. Retinoic acid incorporated as an active ingredient may be all-trans retinoic acid, an isomer thereof, a derivative thereof, a salt thereof or a prodrug thereof. Retinoic acid may be incorporated singly. Alternatively, composite particles of retinoic acid and an appropriate inorganic or organic substance are prepared, and the retinoic acid composite particles may be incorporated.11-06-2008
20080279949NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS - Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.11-13-2008
20080286365Method For Producing Solid-Lipid Composite Drug Particles - A method of producing solid composite lipid/drug nanoparticles that includes the steps of: (1) dissolving a lipid and a drug in a suitable organic solvent to form a solution; (2) emulsifying the solution in a liquid to form an emulsion having a discontinuous phase of micelles comprising the organic solvent, the drug and the lipid, and a continuous phase comprising the liquid; and (3) contacting the emulsion with a supercritical fluid under conditions suitable to keep the supercritical fluid in a supercritical state, whereby the supercritical fluid extracts the organic solvent from the micelles, causing them to precipitate as organic-solvent free solid composite lipid/drug nanoparticles suspended or dispersed in the liquid.11-20-2008
20080286367Compositions containing benefit agent composites pre-emulsified using colloidal cationic particles - A cleansing or a surface-conditioning composition comprising a mixture of (i) and (ii) in water: i) a surfactant selected from the group consisting of anionic, non-ionic, zwitterionic, cationic, and mixtures thereof; and ii) a hydrophobic benefit agent in a particulate form having a mean particle size in the range of 1-1,000 micron, and a specific gravity of ≧1, not encapsulated within a film or a capsule-like enclosure, the particulate hydrophobic benefit agent comprising: a) a physically-modified form of the hydrophobic benefit agent; and b) a deposition-aid material bonded to the surface of the physically-modified benefit agent material, wherein the bonding between the two said materials is achieved prior to addition to i), wherein said deposition-aid material is not a surfactant having a weight average molecular weight of less than 5,000 Dalton.11-20-2008
20080286368Pharmaceutical composition for the treatment of acute disorders - A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.11-20-2008
20080286363Pharmaceutical Compositions for the Treatment of Inflammatory and Obstructive Airways Diseases - A medicament comprising, separately or together (A) a compound of formula I11-20-2008
20080305171PYRROLOPYRAZINE, FORMULATIONS, METHODS OF MANUFACTURE, AND METHODS OF USE THERE - Disclosed herein is a pyrrolopyrazine COMPOUND I having defined amounts of R isomer, particle size, and stability. Also disclosed are pyrrolopyrazine oral dosage forms comprising the described COMPOUND I material as well as methods of treating disorders amenable to therapy using COMPOUND I.12-11-2008
20080305172OPHTHALMIC DEPOT FORMULATIONS FOR PERIOCULAR OR SUCONJUNCTIVAL ADMINISTRATION - The present invention relates to ophthalmic depot formulations comprising an active agent, e.g. embedded in a pharmacologically acceptable biocompatible polymer or a lipid encapsulating agent, e.g. for periocular or subconjunctival administration.12-11-2008
20080286361Gene Delivery - The present invention relates to a method of delivery of a therapeutic agent to a target cell the method comprising targeting particles comprising the therapeutic agent to the cell using magnetic means to apply a magnetic force to said particles so as to tend to move said particles towards said magnetic means and at the same time moving said magnetic means.11-20-2008
20120294945DRUG DELIVERY SYSTEM USING HYALURONIC ACID-PEPTIDE CONJUGATE MICELLE - The present invention relates to a drug delivery composition comprising a hyaluronic acid-peptide conjugate micelle and a production method thereof. According to the drug delivery composition and the production method of the drug-loaded, hyaluronic acid-peptide conjugate micelle of the present invention, the reaction for encapsulating can proceed in a mixed solvent of an aqueous solvent and an organic solvent. Therefore, the present invention can be applied to various types of water-insoluble active components and the biocompatible and biodegradable derivative can encapsulate a drug to provide a drug-loaded micelle, which is safe to be applied for human bodies. Moreover, the micelle has a therapeutic effect from the peptide contained therein, which can act in combination with the drug as packing therein. Therefore, the drug delivery composition and its production method can be utilized in the field of producing a sustained release formulation with an extended duration of the medicinal effect.11-22-2012
20080274197LYOPHILIZED FORMULATION - For clinical application of cis[((1R,2R)-1,2-cyclohexanediamine-N,N′)bis(R11-06-2008
20090311332Method for forming mesoporous silica nanoparticles, mesoporous silica nanopartices, and applications thereof - A method for synthesizing a mesoporous silica nanoparticle, a mesoporous silica nanoparticle, and applications thereof are provided. The method includes fractionating a mesoporous silica nanoparticle suspension to produce size-fractionated mesoporous silica nanoparticle. The method further includes etching the size-fractionated mesoporous silica nanoparticle to produce synthesized mesoporous silica nanoparticle having a hollow, porous morphology configured to receive one of a therapeutic agent and an imaging material. The etching includes differential etching of silica from areas of low polymeric density within the mesoporous silica nanoparticle and re-depositing of the silica in areas of higher polymeric density existing near the surface of the mesoporous silica nanoparticle. A target material is loaded into the synthesized mesoporous silica nanoparticle and a controlled released of the target material is provided by decreasing the physiological pH of the surface of the mesoporous silica nanoparticle.12-17-2009
20090311328Bulking of Soft Tissue - A soft tissue bulking material includes a plurality of particles. Each particle comprises a rounded polymeric shell defining an internal cavity and having a maximum outer dimension of 50 μm-250 μm. A port or opening is provided in the shell. The port or opening thus provides access to the cavity. The port or opening has a size or dimension that ranges from one tenth of the particle's outer dimension up to the particle's outer dimension.12-17-2009
20080241251Method of Producing Microparticles - A method of producing microparticles having a median diameter up to 100 μm and the microparticles so produced are described. The method includes the steps of providing a solvent having a bioactive dispersed or dissolved therein and a vehicle dissolved therein, carrying out an emulsification in a non-solvent phase to produce an emulsion containing the bioactive and the vehicle in a solvent phase, and evaporating the solvent to leave the microparticles, wherein a mixture of at least two surfactants is employed to stabilize the emulsion and wherein the mixture has a hydrophilic-lipophilic balance (HLB) of up to 8.10-02-2008
20080279947Menthol-Containing Solids Composition - A menthol-containing solids composition comprising or consisting of 11-13-2008
20080274199CONTROLLED RELEASE CERAMIC PARTICLES, COMPOSITIONS THEREOF, PROCESSES OF PREPARATION AND METHODS OF USE - Controlled release ceramic particles, processes for their preparation, controlled release ceramic particles prepared by such processes, compositions comprising such controlled release ceramic particles and methods of using controlled release ceramic particles are described. In one form each of the controlled release ceramic particles has an active material(s) substantially homogeneously dispersed throughout the particles, wherein the active material(s) is capable of being released from said particles, and the active material(s) in said particles is substantially protected from degradation until release of the active material(s) from the particles.11-06-2008
20090004280 KIT FOR CARING FOR THE SKIN INTENDED TO SOFTEN CUTANEOUS SIGNS OF AGEING - A kit for skin care intended to soften cutaneous signs of ageing, contains in separate packagings, a microdermabrasion composition, a peeling composition, a soothing composition and an anti-ageing composition.01-01-2009
20090004278Enzymatically Crosslinked Protein Nanoparticles - It is an object of the present invention to provide highly safe nanoparticles made from highly biocompatible materials without the use of a surfactant or synthetic polymer. The present invention provides a protein nanoparticle which is obtained by enzymatic crosslinking during and/or after the formation of protein nanoparticle.01-01-2009
20090004277Nanoparticle dispersion containing lactam compound - Disclosed is a nanoparticle dispersion comprising nanoparticles dispersed in an aqueous medium in the presence of at least one stabilizer. The nanoparticles comprise at least lactam compound of formula I:01-01-2009
20090004279 Method For Improvement Of Tolerance For Therapeutically Effective Agents Delivered By Inhalation - A method for improvement of tolerance for therapeutically effective agents delivered by inhalation comprising a pretreatment of a patient with a nebulized lidocaine or a lidocaine-like compound administered immediately or up to about thirty minutes before administration of the primary therapeutically effective agent. The pretreatment of the patient with the nebulized lidocaine or a lidocaine-like compound improves airway tolerance and deposition of the agent in the lungs and makes such deposition more safe, efficacious, controllable and predictable. The method of the invention is especially useful for enhancement of deposition of immunosuppressive agents in the lung(s) of transplant patients, improved tolerance of the drugs by reducing cough, and improving pulmonary drug deposition.01-01-2009
20100159014POLYMERIC MICELLAR CLUSTERS AND THEIR USES IN FORMULATING DRUGS - Polymeric micellar clusters formed from amphiphilic carbohydrate polymers and their uses in formulating drugs is disclosed, and in particular the finding that amphiphilic carbohydrate polymers are capable of self assembling to form micellar clusters in which the carbohydrate amphiphiles aggregate into hierarchically organised micellar clusters of individual aggregates. The micellar clusters may be transformed into stable nanoparticles with drugs, especially hydrophobic drugs that have poor aqueous solubility, and may improve the transfer of hydrophobic drugs across biological barriers.06-24-2010
20100136120COMPOSITIONS AND METHODS FOR FORMING AND STRENGTHENING BONE - Compositions are provided which stimulate bone growth. Also provided are methods for utilizing the compositions for filling in bone defects, promoting rapid fusion of bone fractures, grafts, and bone-prostheses, and promoting strengthening of osteoporotic bones.06-03-2010
20100136117HYDROXYAPATITE TISSUE FILLER AND ITS PREPARATION AND USE - The invention pertains to a biocompatible composition, suitable for use in soft or hard tissue augmentation, wherein the composition is an aqueous suspension containing a carrier fraction of ceramic particles of less than 15 &mgr;m and an augmentation fraction of ceramic particles of at least 20 &mgr;m. The ceramics typically comprise calcium phosphate. The composition is a may be used in soft tissue repair as well as hard bone replacement. It advantageously avoids the need for foreign body materials which are conventionally applied to stabilize augmentation suspensions.06-03-2010
20090304798Methods and compositions for therapeutic use of RNA interference - The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an amount sufficient to attenuate expression of a target gene by an RNA interference mechanism, e.g., in a sequence-dependent, PKR-independent manner. In particular, the subject method can be used to alter the growth, survival or differentiation of cells for therapeutic and cosmetic purposes.12-10-2009
20090081301MICROPARTICLE DISPERSION LIQUID MANUFACTURING METHOD AND MICROPARTICLE DISPERSION LIQUID MANUFACTURING APPARATUS - In a dissolving step, a poorly soluble drug and a dispersion stabilizer are dissolved in a volatile organic solvent. In a fixing step, the organic solvent, contained in a solution obtained in the dissolving step, is removed by evaporation, pellet-form residues 03-26-2009
20110268802DELIVERY PARTICLE - The present application relates to encapsulated benefit agents, compositions comprising such encapsulated benefit agents and processes for making and using compositions comprising such encapsulated benefit agents. Such encapsulated benefit agents eliminate or minimize one or more of the drawbacks of current encapsulated benefit agents and thus provide formulators with additional perfume delivery opportunities.11-03-2011
20120141588DENTIFRICE COMPOSITIONS CONTAINING CALCIUM SILICATE AND A BASIC AMINO ACID - An oral care composition includes an effective amount of a basic amino acid in free or salt form; and an effective amount of calcium silicate particles. The calcium silicate particles have an average diameter of less than about 5 microns, such that they can occlude dentinal tubules of the teeth. An oral care method includes applying the composition to an oral cavity of a subject to reduce or inhibit hypersensitivity of the teeth and to achieve other benefits.06-07-2012
20100143479METHOD OF MAKING SUSTAINED RELEASE MICROPARTICLES - Various embodiments of a method of preparing sustained release microparticles are described. In one embodiment, the method includes the steps of forming a dispersed phase of an active agent in a polymer and combining the dispersed phase with a continuous phase to form a microparticle dispersion. The method further includes the step of adding a measured amount of a dilution composition to the microparticle dispersion. It has been found herein that the various embodiments for preparing sustained release microparticles using various amounts of the dilution composition alters the release rate of the sustained microparticle for the specific active agent.06-10-2010
20090162442MULTI-PHASIC, NANO-STRUCTURED COMPOSITIONS CONTAINING A COMBINATION OF A FIBRATE AND A STATIN - The present invention discloses a pharmaceutical formulation containing a multi-phasic pharmaceutical composition in an oral dosage form. The multi-phasic pharmaceutical composition contains: (a) a fibrate, or a pharmaceutically acceptable salt, ester, hydrate, or prodrug thereof; (b) a statin, or a pharmaceutically acceptable salt, ester, hydrate, or prodrug thereof; (c) a solvent; (d) a non-miscible liquid; (e) a stabilizer; and (f) water. The fibrate or the statin or both is in a particulate state and/or a solubilized state. Such pharmaceutical formulations are capable of reducing the fed/fast variability and improving oral bioavailability to which a number of active pharmaceutical ingredients are susceptible. The pharmaceutical formulations of the invention, therefore are bioequivalent in fed and fasted states and have improved oral bioavailability.06-25-2009
20090081302PULMONARY DELIVERY OF POLYENE ANTIFUNGAL AGENTS - The present invention provides spray-dried polyene compositions for oral inhalation to the lung. The polyene antifungal compositions demonstrate superior aerosol properties, do not exhibit appreciable degradation of the polyene upon spray-drying, and are useful in the treatment and prophylaxis of both pulmonary and systemic fungal infections.03-26-2009
20090081299SUSTAINED RELEASE OF APO A-I MIMETIC PEPTIDES AND METHODS OF TREATMENT - A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.03-26-2009
20090081300AGENT FOR USE IN THE CASE OF FRUCTOSE INTOLERANCE - The present invention refers to an agent for use in the case of fructose intolerance and any form of impairment and affliction of health and well being which is caused by the administration of fructose or fructose containing foodstuffs or by the release of fructose in the digestive tract of humans or animals from other substances, such as e.g. sucrose. The agent according to the invention comprises 03-26-2009
20090162445Composition for Repair of Defects in Osseous Tissues - Tissue repair compositions, particularly bone repair compositions, containing demineralized bone fragments and homogenized connective tissues. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form.06-25-2009
20090186091Methods of Treating Cardiovascular Disorders Associated with Atherosclerosis - Layered phyllosilicates are useful for adsorbing and/or binding to cholesterol and, thereby, reducing blood cholesterol in a patient. Accordingly, provided herein is a method of reducing hypercholesteremia in a mammal comprising administering to said mammal a protonated and at least partially exfoliated layered phyllosilicate material alone and in combination with other cholesterol-reducing agents in an amount effective to reduce hypercholesteremia in said mammal. Also provided are methods of treating a cardiovascular disorder associated with atherosclerosis in a mammalian subject comprising administering to the subject a layered phyllosilicate material in an amount effective to reduce atherosclerotic lesion formation in the subject.07-23-2009
20120070498Submicron Particles of Antineoplastic Agents - The present invention is concerned with the formation of submicron particles of an antineoplastic agent, particularly paclitaxel, by precipitating the antineoplastic agent in an aqueous medium to form a pre-suspension followed by homogenization. Surfactants with phospholipids conjugated with a water soluble or hydrophilic polymer such as PEG are used as coating for the particles. The particles produced generally have an average particle size of less than about 1000 nm and are not rapidly soluble.03-22-2012
20090136577Intestinal Absorptive Anti-Tumor Agent - An objective of the present invention is to provide intestinal absorptive antitumor agents with an excellent intestinal absorptive effect by using injectable antitumor agents. In the intestinal absorptive pharmaceutical agents of the present invention, antitumor components that can be used only as injections are supported by hydroxyapatite particles.05-28-2009
20090136579Nanoparticles Comprising a PDGF Receptor Tyrosine Kinase Inhibitor - The present invention relates to nanoparticles comprising a platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitor, especially a PDGF receptor tyrosine kinase inhibitor having a water-solubility at 20° C. between about 2.5 g/100 ml and 250 g/100 ml, more specifically nanoparticles comprising an N-phenyl-2-pyrimidine-amine derivative of formula I,05-28-2009
20090136581Copper-Based Fungicide/Bactericide - The present invention discloses an improved copper-based fungicide/bactericide composition. The improved composition offers higher biological activity over typical copper-based products, while requiring significantly less copper in the composition. The present invention also discloses methods of making the improved copper-based fungicide/bactericide composition. The present invention further discloses methods of using the improved copper-based fungicide/bactericide composition.05-28-2009
20090136578Pharmaceutical Composition Comprising Perindopril or Its Salts - The present invention relates to a stable pharmaceutical composition of the ACE inhibitor perindopril or its salts having a defined particle size distribution.05-28-2009
20100003334Combination of loteprednol etabonate and tobramycin for topical ophthalmic use - This invention relates to formulations for topical use comprising antibiotics in combination with anti-inflammatory steroids for treating ophthalmic infections and attendant inflammation. More specifically, this invention relates to pharmaceutical ophthalmic formulations comprising a pH stabilizing amount of tobramycin and the soft steroid loteprednol etabonate.01-07-2010
20090028949CALCIUM PHOSPHATE-BASED ADHESIVE FORMULATION FOR BONE FILLING WITH SWELLING PROPERTIES - The present invention relates to a calcium phosphate-based formulation for bone filling, comprising at least one adjuvant giving adhesion properties, said at least one adjuvant can be selected from the sugar and sugar derivative group.01-29-2009
20090142403ORGAN REGENERATION DEVICE - An organ regeneration device adapted to be used by placing it into a defective portion of an organ to regenerate the organ is provided. The organ regeneration device has a base body having a shape corresponding to a shape of the defective portion of the organ. The organ regeneration device also has particles carried on the base body, wherein the particles are composed of a different material from that of the base body. The organ regeneration device also has a growth-related substance contained in the organ regeneration device for growth and differentiation of cells around the defective portion. The growth-related substance contains an angiogenesis factor. Further, the growth-related substance contains nucleic acid containing a base sequence coding for amino-acid sequence of a growth factor different from the angiogenesis factor. Furthermore, the nucleic acid is introduced into a host cell.06-04-2009
20080317862Organic Compounds Comprising a Glycopyrrolium Salt - Medicaments comprising (A) an antimuscarinic agent and (B) a corticosteroid for the treatment of inflammatory or obstructive airways diseases.12-25-2008
20090208581FORMULATIONS LIMITING SPREAD OF PULMONARY INFECTIONS - Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as vital infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles. These may include proteins such as albumin or polysaccharides such as dextran, which also has surface active properties, or polymers such as polyethylene oxide (PEO) or biodegradable synthetic polymers which can be used to encapsulate or deliver the materials to be delivered. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.08-20-2009
20130122097ANTIFUNGAL THERAPY - Described here are various compositions for the delivery active agents, e.g., antifungal agents. The compositions may be beneficial due to the particular release kinetics associated with them. Various locations and methods for placement of the compositions into the tissues of the nail unit, as well as tissues surrounding the nail unit are also described.05-16-2013
20090324724SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS - The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.12-31-2009
20110223255IMPLANTABLE PRODUCTS COMPRISING NANOPARTICLES - The present disclosure relates to nanoparticle-containing implantable and preferably biodegradable medical products and their use for the thermotherapeutic after-treatment after surgical removal of tumors and cancerous ulcers.09-15-2011
20090285899COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A METHYLXANTHINE DERIVATIVE FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a methylxanthine derivative for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.11-19-2009
20110142943TAMPER-RESISTANT PHARMACEUTICAL COMPOSITIONS OF OPIODS AND OTHER DRUGS - Tamper-resistant pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.06-16-2011
20110142946DRUG SUSTAINED-RELEASE AGENT, ADSORBENT, FUNCTIONAL FOOD, MASK AND ADSORPTION SHEET - Provided is a drug sustained-release agent including a carbon material (porous carbon material) which has an inverse opal structure. The drug sustained-release agent includes a porous carbon material which has spherical pores having an average diameter of 1×1006-16-2011
20090053316NANOCLUSTERS FOR DELIVERY OF THERAPEUTICS - The present invention discloses a nano-cluster that includes a plurality of nano-particles, wherein the nano-particles can disperse in response to an environmental cue. Also disclosed is a method of preventing, treating, or diagnosing a disease or condition in a subject comprising administering a therapeutically effective amount of a composition comprising nano-clusters of the present invention.02-26-2009
20090053315Thermo-Kinetic Mixing for Pharmaceutical Applications - Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.02-26-2009
20090098210COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.04-16-2009
20090081303PHARMACEUTICAL FORMULATION FOR CONTRACEPTION AND HORMONE-REPLACEMENT THERAPY - The present invention provides slow release estradiol-progesterone formulations that can be used in either contraception or hormone replacement therapies. The formulations comprise shaped particles of estradiol that is in a hemicrystalline form that exhibits especially low dissolution rates. The shaped particles comprise estradiol compounded in a 1:1 molar ratio with cholesterol, and are administered in combination with progesterone. The slow release formulations of the present invention afford the dual advantages of a low dose estradiol formulation with a low frequency administration regimen. The formulations can be parenterally administered once a month or less often.03-26-2009
20090068271EMBOLIZATION PARTICLES - Embolic particles, embolic particle chains, and methods for making embolic particles and embolic particle chains are described.03-12-2009
20090202644FUNCTIONAL NANOPARTICLE FILLED CARBON NANOTUBES AND METHODS OF THEIR PRODUCTION - Carbon nanotubes filled with a suspension or colloidal solution of functional nanoparticles and methods for production of carbon nanotubes loaded with functional nanoparticles are provided.08-13-2009
20110229575DEEP IMMERSION FLOTATION THERAPY FOR BURN VICTIMS - This invention provides compositions for and methods of treating burn wounds in a subject.09-22-2011
20090162443COMPOSITIONS AND METHODS FOR REDUCING OR PREVENTING WATER LOSS FROM THE SKIN - Moisturizing compositions comprising microspheres for the purpose of preventing or reducing moisture loss from the skin.06-25-2009
20090162444RALOXIFENE COMPOSITION - A pharmaceutical composition comprising raloxifene or a pharmaceutically acceptable salt thereof, a mixed cellulose excipient, and a disintegrant can be conveniently made.06-25-2009
20090142401Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release - Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed.06-04-2009
20100159015Systems and Methods to Treat Pain Locally - Disclosed herein are systems and methods for contributing to the local treatment of pain. More specifically, the disclosed systems and methods contribute to the local treatment pain by inhibiting the NFκB family of transcription factors.06-24-2010
20090186090Oral Care Composition to Reduce or Eliminate Dental Sensitivity - The invention includes an oral care composition that reduces and/or eliminates the perception of tooth sensitivity. The composition includes an adherent material and includes, in part, particles having a particle size of 2-5 microns. Also included within the scope of the invention are methods comprising the use of such compositions, such as methods of reducing dental sensitivity.07-23-2009
20090202647SOLID FORM OF RACEMIC ROTIGOTINE - Disclosed herein are solid state forms, amorphous and crystalline forms, of racemic rotigotine having high purity, adequate stability, good flowability and good dissolution properties, a process for preparation, and pharmaceutical compositions comprising amorphous racemic rotigotine.08-13-2009
20090252802Compositions Including Relatively Water Insoluble/Unwettable Drugs And Methods For Using Same - Compositions including therapeutic components and surfactant components which enhance the utility of the therapeutic components and methods of using such compositions are provided.10-08-2009
20090220610 Suspension Comprising Benzimidazole Carbamate and a Polysorbate - This invention is directed to a pharmaceutical composition for drinking water administration comprising benzimidazole carbamate particles having an effective average particle size of less than 450 nm and a TWEEN-type surfactant; a method for making the composition; use of the composition to make a medicament for controlling parasites; and a method for protecting an animal from a parasitic infection.09-03-2009
20120141589PARTICLES FOR DRUG DELIVERY AND OTHER APPLICATIONS - The present invention generally relates to particles for drug delivery and other applications. In one aspect, the present invention relates to a technique for reacting precursor compounds in the presence of a pharmaceutically-active agent to form product (e.g., in the form of particles) in which the agent is substantially contained within the product, and the product is soluble within typical gastric fluid of a mammal. In another aspect, the present invention is generally directed to particles comprising an inorganic pharmaceutically acceptable carrier, such as CaCO06-07-2012
20090098205pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES - The present invention provides a pH sensitive nanoparticulate delivery system for the administration of peptide hormones and drugs. In particular it provides a pH sensitive nanoparticulate for oral insulin administration. The nanoparticles developed by this process are fatty acid nanoparticles and a polymer is used as a stabilizer and also to incorporate pH sensitivity so that these particles shrink in the gastric acidic pH thereby protecting the incorporated insulin. These particles being also hydrophobic in nature and by virtue of their small size get absorbed through the intestinal cell wall and Peyer's patches. These nanoparticles are novel and unique in the sense that polymer content is only 0.03-0.06 g/g product and the polymer is hydrophilic in nature.04-16-2009
20100003333COMPOSITIONS AND METHODS FOR TREATING DIGESTIVE DISORDERS - Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating digestive disorders or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said digestive disorders by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids and therapeutic compositions.01-07-2010
20090258068Titanium Oxide-Zinc Oxide Aggregate Powder And Production Method Thereof - The present invention provides a powder that can display excellent protection ability in both UV-A and UV-B regions. The titanium oxide-zinc oxide aggregate powder comprises an aggregate formed by the aggregation of porous titanium oxide particles and zinc oxide particles, and said porous titanium oxide particle is an aggregate of primary fine particles of titanium oxide. The production method of the titanium oxide-zinc oxide aggregate powder comprises the steps of: (a) hydrolyzing, with heating, an aqueous solution containing a titanium salt and an aliphatic alcohol; (b) adding a water-soluble zinc salt to a suspension of a precipitate obtained by the hydrolysis with heating in step (a), and then neutralizing the suspension with an alkali; and (c) calcining a precipitate obtained by the neutralization in step (b).10-15-2009
20090258069Delivery of LFA-1 antagonists to the gastrointestinal system - The present invention provides compositions and methods for treating disorders and diseases by delivery of LFA-1 antagonists to the gastrointestinal system. Methods include delivery of LFA-1 antagonists to effect localized treatment.10-15-2009
20100151030Use of MgO Doped with a Divalent or Trivalent Metal Cation for Removing Arsenic from Water - Systems and methods for use of magnesium hydroxide, either directly or through one or more precursors, doped with a divalent or trivalent metal cation, for removing arsenic from drinking water, including water distribution systems. In one embodiment, magnesium hydroxide, Mg(OH)06-17-2010
20100151031DISCRETE SIZE AND SHAPE SPECIFIC ORGANIC NANOPARTICLES DESIGNED TO ELICIT AN IMMUNE RESPONSE - The presently disclosed invention is broadly directed to therapeutic micro- and/or nanoparticles designed to target an immune cell with an active agent. More particularly, the particles have a predetermined geometry and a broadest dimension of less than about 10 μm. The immune cell-targeted micro and/or nanoparticles may additionally comprise a biocompatible polymer.06-17-2010
20100015233anti-parasitic compositions - The present invention relates to nanodisperse antiparasitics and provides a composition comprising at least one water insoluble anti-parasitic drug and a water-soluble carrier material, wherein the water-insoluble anti-parasitic drug (preferably an Artemisinin-type drug or a quinine type drug) is dispersed through the carrier material in nano-disperse form having a peak diameter of the nano-disperse form below 1000 nm. The invention further provides an aqueous dispersion of a water insoluble anti-parasitic drug and a water-soluble carrier material, wherein the anti-parasitic drug is in nano-disperse form having a peak diameter of the nano-disperse form below 1000 nm, the invention further subsists in a process for preparing an anti-parasitic composition comprising a water insoluble anti-parasitic agent and a water-soluble carrier, which comprises the steps of either: a) providing an emulsion comprising a solution of the anti-parasitic agent in a water-immiscible solvent for the same, and an aqueous solution of the carrier, or providing a mixture comprising at least one non-aqueous solvent optional water a water-soluble carrier material soluble in the mixture and a water-insoluble anti-parasitic agent soluble in the mixture, and, b) drying the emulsion (preferably by spray drying) to remove water and the water-immiscible solvent to obtain a substantially solvent-free nano-dispersion of the anti-parasitic agent in the carrier.01-21-2010
20100178347Method of treating traumatic brain injury - This invention provides for methods of treating a subject suffering from central nervous system injury, including traumatic brain injury, comprising administering to the subject an amount of a perfluorocarbon. This invention also provides for use of a perfluorocarbon in the manufacture of a medicament for treating a subject suffering from central nervous system injury including traumatic brain injury. This invention further provides for a pharmaceutical composition comprising a perfluorocarbon for use in treating a subject suffering from central nervous system injury, including traumatic brain injury.07-15-2010
20100178348Myostatin Inhibition for Enhancing Muscle and/or Improving Muscle Function - The present invention relates to methods for inhibiting myostatin, a regulator of muscle mass, for muscle enhancement (including inducing hypertrophy and/or hyperplasia) as well as improving muscle function (including decreasing atrophy and/or increasing endurance, force and/or strength). The methods involve delivering genes to cells using gene delivery in order to inhibit myostatin. Examples of genes to be delivered are genes encoding’ proteins such as Follistatin, Follistatin-related gene-1 (FLRG-I), growth differentiation factor associated protein-1 (GASP-I) and myostatin precursor propeptide. The genes are delivered using a recombinant Adeno-associated virus (rAAV) lacking rep and cap DNA capable of infecting the cells. Following introduction, the genes are expressed in the cell body of the infected cell and the encoded proteins are secreted systemically. In other methods-of the invention expression of proteins such as activin lib and myostatin is inhibited by oligonucleotide techniques to effect muscle enhancement. All the methods have applications in the treatment of musculoskeletal and neurodegenerative disorders among others, as well as enhancing muscle in livestock.07-15-2010
20100183727Immunonanotherapeutics that Provide IgG Humoral Response Without T-Cell Antigen - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides synthetic nanocarriers capable of eliciting an immune system response in the form of antibody production, wherein the nanocarriers lack any T cell antigens. In some embodiments, the invention provides nanocarriers that comprise an immunofeature surface, which provides high avidity binding of the nanocarriers to antigen presenting cells. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.07-22-2010
20100260851Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium - The present invention provides a novel polymorphic form of atorvastatin calcium, designated as form Al, process for preparation, pharmaceutical compositions, and method of treating thereof. The present invention further provides a process for the preparation of highly pure amorphous atorvastatin calcium using the novel atorvastatin calcium form Al. The present invention also relates to novel amorphous form of atorvastatin tert-butyl ester, chemically known as [R-(R*,R*)]-2-(4-fluorophenyl)-[β],[δ]-dihydroxy -5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl-1H-pyrrole-1-heptanoicacid tert-butyl ester, process for the preparation, and its application for preparing highly pure atorvastatin and its pharmaceutically acceptable salts thereof. The present invention also relates to use of the novel amorphous atorvastatin tert-butyl ester and novel atorvastatin calcium form al for preparing amorphous atorvastatin calcium.10-14-2010
20100260855DELIVERY OF AS-OLIGONUCLEOTIDE MICROSPHERES TO INDUCE DENDRITIC CELL TOLERANCE FOR THE TREATMENT OF AUTOIMMUNE TYPE 1 DIABETES - AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.10-14-2010
20100183726COMPOSITIONS AND METHODS FOR TREATING CANCER WITH DACARBAZINE NANOEMULSIONS - A uniform microfluidized nanoemulsion is disclosed containing an anti-cancer agent, such as dacarbazine. The microfluidized nanoemulsion improves the combination's cell membrane permeability by at least four-fold over conventional nanoemulsion compositions, which significantly increases the intracellular concentration of anti-cancer agents. As a nanoemulsion, dacarbazine has a greater anti-cancer efficacy than when applied as a free solution.07-22-2010
20100260852LAXATIVE AGENT - A laxative agent comprising composite magnesium oxide particles represented by the following formula (1) as an effective component:10-14-2010
20100260854GRANULATE FOR THE FORMULATION OF ORODISPERSIBLE TABLETS - This invention relates to a granulate comprising mannitol and sorbitol in a weight ratio of between 70:30 and 97:3. This invention also relates to the use of the said granulate in the preparation of orodispersible tablets, to the orodispersible tablets obtained with the said granulate and to a process of production for obtaining the said granulate.10-14-2010
20100260853COMPOSITIONS FOR PULMONARY DELIVERY - The present invention relates to methods of direct pulmonary delivery of polypeptides e.g. of domain antibodies, and to particular polypeptide compositions suitable for direct pulmonary delivery. The invention also relates to use of such compositions in medicine, e.g. for the treatment and diagnosis of lung disease, for example for treating Chronic Obstructive Pulmonary Disease (COPD) and asthma.10-14-2010
20100183729Novel Process - The invention relates to a stable pharmaceutical composition useful in the treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease (COPD) and a novel micronisation process for manufacturing a stable formulation for formoterol or its enantiomers and a carrier/diluent comprising a carbohydrate such as lactose.07-22-2010
20100178350AMINO-ACID-CONTAINING MEDICINAL GRANULAR PREPARATION HIGHLY EASY TO TAKE - The present invention aims to provide an amino acid-containing granule preparation improved in the ease of taking medication than conventional products, which disintegrates rapidly. The amino acid-containing granule preparation of the present invention containing granules having a maximum particle size of substantially not more than 1000 μm and a bulk density of not less than 0.57 g/mL markedly improves ease of taking medication without impairing disintegration property, as compared to conventional amino acid-containing granule preparations.07-15-2010
20100226989Nanoparticulate megestrol formulations - The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.09-09-2010
20100221348THERAPEUTIC USES OF DUNALIELLA POWDER - A method for treating a disease selected from diabetes mellitus and atherosclerosis, and a method for reducing triglycerides and/or increasing HDL cholesterol levels in the plasma of a subject. The method comprises administrating to a subject an effective amount of crude 09-02-2010
20100239674PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE - Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.09-23-2010
20100239677NONAEROSOL/AEROSOL DISPENSING OF SUNSCREEN SPRAYS COMPRISING SILICA MICROPARTICLES - Nonaerosol/atomizer pumps or aerosol dispensers comprise (A) a reservoir confining at least one vaporizable sunscreen composition suited for UV-photoprotecting the skin and/or hair against the damaging effects of UV radiation, the at least one vaporizable sunscreen composition comprising (1) a UV-photoprotecting amount of at least one UV-sunscreen and (2) an SPF-enhancing amount of generally spherical silica microparticles, formulated into (3) a topically applicable, cosmetically acceptable carrier therefor, and (B) at least one agent for pressurizing the at least one vaporizable sunscreen composition into a spray of fine sunscreen particles.09-23-2010
20100215751METHODS AND COMPOSITIONS FOR TREATING RECURRENT CANCER - The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as Nab-paclitaxel or Abraxane®) comprising nanoparticles comprising a taxane and a carrier protein.08-26-2010
20100215754Delivery System for Functional Compounds - A delivery system for various functional compounds is disclosed. The delivery system incorporates a composition containing alumina. Various functional materials containing particular moieties may be adsorbed onto the alumina and used as desired. The functional compounds can be, for instance, pharmaceuticals, xenobiotics, anti-microbial agents, anti-viral agents, UV absorbers, odor control agents, fragrances, and the like. In one particular embodiment, for instance, certain dyes can be adsorbed onto the alumina surfaces. Once the dye is adsorbed onto the alumina surface, the resulting particles can be combined with a liquid vehicle for use in any suitable printing process.08-26-2010
20110111037ORODISPERSIBLE MANNITOL - Coagglomerates of mannitol, whose laser volume-average diameter D4,3 is between 1 and 200 μm, and of granular starch, are characterized in that they have a disintegration behaviour determined according to a test A such that the relaxation time measured is between 30 and 100 seconds and the swelling force is between 0.8 and 3.0 N.05-12-2011
20100226993COMPOSITION FOR REGENERATIVE TREATMENT OF CARTILAGE DISEASE - A composition for regenerative treatment of cartilage disease, which comprises a PDE4 inhibitor as an active ingredient, specifically a composition comprising a PDE4 inhibitor and a biocompatible and biodegradable polymer is provided, which composition, when formulated into a form suited to administer locally to affected cartilage region, such as microsphere preparation, can provide a pharmaceutical composition showing an excellent effect in regenerative treatment of cartilage.09-09-2010
20100233268POWDER FORMULATIONS FOR INHALATION CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS - The present invention relates to powder formulations for inhalation containing enantiomerically compounds of general Formula (I) wherein the groups R09-16-2010
20100215752POLICOSANOL NANOPARTICLES - The present invention provides nanoparticulate policosanol, formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.08-26-2010
20100239678IONICALLY FUNCTIONALIZED NANODIAMONDS - The present invention is directed to attaching drugs 09-23-2010
20130216621BIFUNCTIONAL CONJUGATE COMPOSITIONS AND ASSOCIATED METHODS - Bifunctional conjugate compositions are provided comprising a Signal-1 moiety bound to a first polymer carrier, wherein the combined size of the Signal-1 moiety and the first polymer carrier is about 1 nanometer to about 500 nanometers; and a Signal-2 moiety bound to a second polymer carrier, wherein the combined size of the Signal-2 moiety and the second polymer carrier is about 1 nanometer to about 500 nanometers. In some embodiments, the Signal-1 moiety and the Signal-2 moiety are bound to the same polymer carrier. Associated methods are also provided.08-22-2013
20100233271SLOW RELEASE OF ORGANIC SALTS OF LOCAL ANESTHETICS FOR PAIN RELIEF - Particles of an organic acid salt of an amino acid amide or ester local anesthetic are employed as agents for the improved alleviation of pain. Particularly, the particles find use with surgically created wounds, where the particles may be administered directly into the bed of the wound or topically for transdermal transport.09-16-2010
20100239676Stable Aerosolizable Suspensions of Proteins in Ethanol - Stable suspensions of a biologically active protein are disclosed that are suited for aerosol delivery to the lungs of a patient in need of treatment, which comprise particles of biologically active protein suspended in ethanol. In a preferred embodiment, the invention describes a stable suspension of insulin useful for aerosol delivery to the lungs of a patient in need of treatment comprising particles of a pharmaceutically effective amount of insulin suspended in ethanol. A method of delivering a therapeutically effective amount of a protein to the respiratory tract of a patient is described which comprises producing an aerosol of a stable liquid suspension of a protein using an electrohydrodynamic spraying means wherein the liquid suspension comprises particles of the protein suspended in ethanol. The stable ethanol suspensions of the invention may optionally contain up to about 20% (V/V) of a pharmaceutically acceptable formulation additive such as glycerol, propylene glycol and polyethylene glycol as well as minor amounts (from about 0.05% to about 5.0% W/V) of a pharmaceutically acceptable excipient.09-23-2010
20100255106BENZOTHIOPHENES, FORMULATIONS CONTAINING SAME, AND METHODS - This invention provides compounds of formula I10-07-2010
20100255103Mesoporous Silica Nanoparticles for Biomedical Applications - A submicron structure includes a silica body defining a plurality of pores that are suitable to receive molecules therein, the silica body further defining an outer surface between pore openings of said plurality of pores; and a plurality of anionic molecules attached to the outer surface of the silica body. The anionic molecules provide hydrophilicity to the submicron structure and are suitable to provide repulsion between other similar submicron structures, and the submicron structure has a maximum dimension less than one micron.10-07-2010
20090175947PHARMACEUTICAL COMPOSITION FOR INJECTIONAL PARTICULARLY TARGETED LOCAL ADMINISTRATION - The invention relates to a pharmaceutical composition for injectional, in particular targeted local administration, characterized in that it comprises a sterile suspension of platinum complex of general formula (I), wherein A and A′ independently of one another are an NH07-09-2009
20080286366Delivery of micro- and nanoparticles with blood platelets - The invention is directed to platelets containing micron or nanometer size particles wherein the micron or nanometer sized particles comprises an active agent. The invention is also directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the above platelets. The invention is further directed to methods of delivering the micron or nanometer size particles containing an active agent to a site of interest in a patient.11-20-2008
20100136119CONTROLLED-RELEASE PREPARATION CONTAINING CILOSTAZOL AND PROCESS FOR THE PREPARATION THEREOF - A controlled release preparation which comprises particles containing cilostazol or its pharmaceutically acceptable salt dispersed in a solubilizing agent and an erodible material encasing said particles which is capable of forming a hydrogel, can maintain a constant level of cilostazol in the blood through its slow release during its prolonged residence time in the stomach and intestines, thereby minimizing adverse effects caused by rapid release of the drug or solubilizing agent.06-03-2010
20100221346Method For Transfecting Cells Using A Magnetic Field - Described is a method for transfecting a cell comprising bringing a complex comprising vector(s) and magnetic particle(s) in contact with a cell by applying a magnetic field and methods of treatment using said method. Furthermore, described is such a complex as well as methods for making it. Finally, pharmaceutical compositions, uses of such complexes and a kit are described. The method described is particularly useful where automatizable high-throughput transfection is required for large scale screening processes.09-02-2010
20100086606Active Agent Loaded Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same - Uniform, rigid, spherical nanoporous calcium phosphate particles that define an internal space and an amount of active agent present in the internal space are provided. Also provided are topical delivery compositions that include the active agent loaded particles, as well as methods of making the particles and topical compositions. The particles and compositions thereof find use in a variety of different applications, including active agent delivery applications.04-08-2010
20090074873Nanoparticulate beclomethasone dipropionate compositions - There is disclosed an aerosol comprising droplets of an aqueous dispersion of nanoparticles, said nanoparticles comprising insoluble therapeutic or diagnostic agent particles having a surface modifier on the surface thereof. There is also disclosed a method for making the aerosol and methods for treatment and diagnosis using the aerosol.03-19-2009
20090074871Composition for filling bone defects - The invention is directed toward an improved formable bone composition for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth inducing compound of demineralized lyophilized allograft bone particles ranging from about 100 to 850 microns. The bone particles are mixed in an excipient carrier combination containing carboxymethylcellulose, sodium hyaluronate, and a sodium phosphate saline buffer, the carboxymethylcellulose component of the carrier ranging from about 5.0 to about 11.0% of the composition and the sodium hyaluronate component of the carrier ranging from about 0.3 to about 0.7% of the composition, the composition having a pH between 6.5-7.5.03-19-2009
20090074870Alteration of cell membrane for new functions - Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene therapy, without the introduction of exogenous DNA. DNA sequences, the proteins and polypeptides embodying these sequences are disclosed for modulating the immune system. The modulations include down-regulation, up-regulation and apoptosis.03-19-2009
20100196485RARE EARTH METAL COMPOUNDS, METHODS OF MAKING, AND METHODS OF USING THE SAME - Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.08-05-2010
20100221344Functionalized Nanoceria Composition For Ophthalmic Treatment - The invention provides a composition comprising a plurality of nanoceria particles, a sufficient amount of at least one inhibitor of human carbonic anhydrase II associated with said plurality of nanoceria particles, and a pharmaceutically acceptable carrier containing said plurality of nanoceria particles with associated inhibitor. One preferred inhibitor of human carbonic anhydrase II comprises 4-carboxybenzene sulfonamide. The disclosed composition is useful in treatment of glaucoma.09-02-2010
20100196486METHODS FOR PRODUCING ARIPIPRAZOLE SUSPENSION AND FREEZE-DRIED FORMULATION - Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10 μm, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g., a high shear pulverizing machine, a dispersion machine that applies shear force to a material to be processed, a colloid mill, an ultrasonic dispersion machine, or a high-pressure jet type emulsifying dispersion machine to form a secondary suspension; and (c) subjecting the secondary suspension to second pulverization using e.g., a high-pressure jet type emulsifying dispersion machine to form a sterile final suspension; and a method for producing a freeze-dried formulation from the aripiprazole suspension.08-05-2010
20090047355PROCESS FOR PRODUCING PULVERULENT PHYTOSTEROL FORMULATIONS - A process for the production of pulverulent phytosterol formulations, includes preparing an aqueous solution, suspension or dispersion of the phytosterol in an aqueous molecular dispersion or colloidal dispersion of a protective colloid and drying.02-19-2009
20090246281Soft steroid compositions for use in dry powder inhalers - A medicament and a method of producing a medicament are disclosed. The medicament contains a soft steroid and is suitable for administration via a dry powder inhaler.10-01-2009
20100203143SYSTEMS AND METHODS FOR NANOMAGNETIC ACTUATION OF MOLECULAR CELL SIGNALING - The present invention relates to signaling mechanisms that transduce magnetic inputs into physiological cellular outputs. More particularly, the present invention relates to systems and methods for non-invasively controlling cellular signaling functions and behaviors by harnessing receptor-mediated and intracellular molecular-mediated signal transduction using nanomagnetic cellular switches.08-12-2010
20100221345OSTEOGENIC BIOMATERIAL CONTAINING OSTEOGENESIS PROMOTING SUBSTANCE AND NANOGEL - An object of the present invention is to provide an osteogenic biomaterial which achieves long-term sustained release and localized functional expression of a substance which promotes the formation of bone tissue. The present inventors have found out that a nanogel efficiently encloses an osteogenesis promoting substance to suppress the substance from diffusion into blood, and that the nanogel functions as a carrier for local administration of the osteogenesis promoting substance. Furthermore, they have found out that the osteogenesis promoting substance-containing nanogel can be cross-linked with a water-soluble polymer to allow sustained release of the osteogenesis promoting substance at a local area over a long period of time. Based on these findings, the present invention was completed. The osteogenic biomaterial of the present invention which contains the osteogenesis promoting substance and the nanogel shows osteogenesis promoting activity over a long period of time, and can be used as a preventive and therapeutic agent against bone diseases.09-02-2010
20080279946METHODS AND COMPOSITIONS FOR INCREASING INFRARED ABSORPTIVITY OF A TARGET - Disclosed herein are compositions and methods for increasing the infrared absorptivity of a therapeutic target. Also disclosed are methods for detecting or ablating a therapeutic target that include providing a nanoparticle composition for increasing the infrared absorptivity of the therapeutic target. Subsequently, the therapeutic target having increased infrared absorptivity is exposed to a therapeutically effective dose of infrared irradiation to effect its detection or ablation. In addition, a method is disclosed for treating a subject suffering from a tumor by providing to the tumor a nanoparticle composition for increasing its infrared absorptivity. The tumor having increased infrared absorptivity is then heated by exposing it to a therapeutically effective dose of infrared irradiation.11-13-2008
20080268058PARTICLES - Particles, such as particles including a polymer including vinyl formal monomer units, and related compositions and methods, are disclosed.10-30-2008
20100297245METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEIN AND PEPTIDE THERAPEUTIC AGENTS - The present invention provides a pharmaceutical composition formulated for oral delivery, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and a biologically active protein or peptide suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same for oral delivery of a therapeutic protein or peptide.11-25-2010
20100297243PRION FREE NANOPARTICLE COMPOSITIONS AND METHODS OF MAKING THEREOF - The present invention provides prion-free compositions comprising nanoparticles comprising albumin and substantially water insoluble drugs. Also provided are methods of making prion-free compositions and methods of removing prion proteins from the nanoparticle compositions. Methods of using the compositions, as well as kits useful for carrying out the methods are also provided.11-25-2010
20110117200RASAGILINE MESYLATE PARTICLES AND PROCESS FOR THE PREPARATION THEREOF - Provided herein is rasagiline mesylate having a 90 volume-percent of the particles (D05-19-2011
20110123628RARE EARTH METAL COMPOUNDS, METHODS OF MAKING, AND METHODS OF USING THE SAME - Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.05-26-2011
20110123625Compositions of Less Immunogenic and Long-Circulating Protein-Lipid Complexes - Provided are lipidic particles comprising phosphatidylcholine, phosphatidylinositol and cholesterol. Also provided are compositions comprising the lipidic particles and having associated therewith therapeutic agents such as peptides, polypeptides or proteins. In these compositions, the therapeutic agents have reduced immunogenicity and/or longer circulating time. These compositions can be used for therapeutic administration of the peptides, polypeptides and/or proteins.05-26-2011
20110123622OPHTHALMIC FORMULATION AND METHOD OF MANUFACTURE THEREOF - Provided herein is an ophthalmic formulation that comprises a fine particle of an A05-26-2011
20100303915THERAPEUTIC OPTHALMIC EMULSIONS - Disclosed herein are non-irritating ophthalmic emulsion compositions useful for treating ocular disorders including dry eye and related methods. More specifically, the ophthalmic compositions disclosed herein combine a high HLB surfactant and a low HLB surfactant together with a plant-derived triglyceride having non-polar aliphatic side chains to form a therapeutic non-irritating eye drop.12-02-2010
20100303918COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS - Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential and/or conductance, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)). Additional aspects include therapeutic compositions, and combination therapies comprising administration of the electrokinetically generated fluids with at least one additional therapeutic agent.12-02-2010
20100303916ENHANCED DRUG DELIVERY WITH ORIENTABLE PARTICLES - Small airway deposition of orientable drug particles in the lung due to interception is increased through alignment of these particles with an externally applied force such as a magnetic field. Drug particles in one embodiment are made magnetically responsive by loading them with magnetic nanoparticles. Elongated particles have a natural tendency to align parallel to the direction of flow through an airway, and therefore also parallel to airway walls; accordingly, alignment with a magnetic field to any other orientation increases interception, with a maximum increase for alignment perpendicular to airway walls. By positioning a magnetic field across a specific site within the lung, for example in the area of a tumor, the increase in deposition by interception allows localized targeting of inhaled drug particles to that area.12-02-2010
20100310663PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES AND A RESUSPENDING MATERIAL - A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and a poorly aqueous soluble polymer, and a resuspending material selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethylcellulose, and pharmaceutically acceptable salt forms thereof.12-09-2010
20100310661ORAL FORMULATIONS FOR PICOPLATIN - The invention provides formulations for the organoplatinum anticancer drug picoplatin. Self emulsifying compositions, stabilized nanoparticulate compositions, solid dispersions, and nanoparticulate suspensions in oils are provided, along with methods for preparation of the formulations. The formulations can provide improved oral availability of picoplatin relative a to a simple solution of picoplatin such as in water or normal saline solution and can be used in combination therapy.12-09-2010
20100310662Oral Drug Delivery System for Azole, Moxifloxacin and Rifampicin - An oral drug delivery system for treatment of tuberculosis is described. The oral drug delivery system includes (e.g., a mixture or combination of): poly DL-lactide-co-glycolide nano particles having encapsulated an azole therein; poly DL-lactide-co-glycolide nano particles having moxifloxacin encapsulated therein; and poly DL-lactide-co-glycolide nano particles having RIF encapsulated therein12-09-2010
20090130217Cosmetic Composition Containing Nanoparticulate a-Alumina - Cosmetic or dermatological preparations which contain modified or unmodified nanocrystalline a-alumina having particle sizes of from 10 to 100 nm and d50 values of from 30 to 60 nm are described.05-21-2009
20090068274HIGHLY EFFICIENT DELIVERY OF A LARGE THERAPEUTIC MASS AEROSOL - A method for delivering an agent to the pulmonary system, in a single, breath-activated step or a single breath, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm03-12-2009
20110212179MICRO-SPHERICAL POROUS BIOCOMPATIBLE SCAFFOLDS AND METHODS AND APPARATUS FOR FABRICATING SAME - Provided herein are bimodal porous polymer microspheres comprising macropores and micropores. Also provided herein are methods and apparatus for fabrication such microspheres. Further provided herein are methods of using bimodal porous polymer microspheres.09-01-2011
20110008447CARRIER COMPRISING NANODIAMOND - The present invention provides a carrier including a nanodiamond (ND) particle and a linker covalently bound to the ND particle, in which the linker is presented by the formula: —R01-13-2011
20110008448Diketopiperazine Salts for Drug Delivery and Related Methods - Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.01-13-2011
20110008445SUSPENSION OF ASCORBIC ACID IN GLYCERIN AND PROCESS FOR PRODUCTION THEREOF - A suspension of ascorbic acid in glycerol or in glycerol comprising diglycerol, in which the content of ascorbic acid is 13% by mass or greater, and further in which 8 to 12% by mass of the ascorbic acid is dissolved in glycerol or in glycerol comprising diglycerol, and the rest of ascorbic acid is precipitated in the form of microcrystals having a particle diameter of 25 μm or smaller and is uniformly dispersed in the suspension. The suspension of ascorbic acid in glycerol is useful as a base material for cosmetics containing ascorbic acid which exhibits excellent feel in the use (spreadability and smooth feel on application to the skin).01-13-2011
20100183725MULTIPLE ACTIVE PHARMACEUTICAL INGREDIENTS COMBINED IN DISCRETE INHALATION PARTICLES AND FORMULATIONS THEREOF - The present disclosure describe inhalation particles where each discrete unagglomerated inhalation particle comprising 2 or more active pharmaceutical ingredients. In one embodiment, the inhalation particles comprise a first and a second API where the second API covers, at least partially, and protects the first API from degradation or instability. Inhalation particles comprising a first and a second API as described herein have many advantages over present means of delivering two or more APIs. Formulations comprising such inhalation particles are also described.07-22-2010
20100021547PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALKANOL COMPOUNDS - The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.01-28-2010
20100124571Use of pH-sensitive, Acid-Stable Metal-Binding Nanoparticles - Methods of preventing and/or treating cancer are disclosed. The methods comprise administering to the patient a pharmaceutically effective amount of a water-soluble, acid-stable organometallic nanoparticles, optionally in combination with another therapeutic agent. In particular, nanoparticles that consist of polymerized citric acid and various different types of metals including, but not limited to, iron, calcium, zinc, silver and magnesium. These nanoparticles are acid-stability and self-degradation leading to constituent metal release when pH rises closer to the neutral pH of 7 or higher.05-20-2010
20100034888GRANULATE CONTAINING A PHARMACEUTICALLY ACTIVE SUBSTANCE AND METHOD FOR ITS MANUFACTURE - One aspect of the present invention relates to a granulate having a volume weighted mean diameter of 1-200 m and containing: at least 0.1 wt. % of a pharmaceutically active substance; at least 10 wt. % of emulsifier 0-89.9 wt. % of a water-dispersible saccharide; the combination of the pharmaceutically active substance, the emulsifier and the water-dispersible saccharide together representing at least 60 wt. % of the granulate; wherein the granulate is monophasic or wherein the granulate comprises a dispersed phase containing the pharmaceutically active substance, said dispersed phase having a volume weighted mean diameter of less than 300 nm. Another aspect of the invention relates to a process for the preparation of said granulate containing a pharmaceutically active substance, which process employs.02-11-2010
20100034884LUMINESCENT CONDUCTING NANO-DRUG CRYSTAL ULTRA-THIN FILM SELF-ASSEMBLY AND USES - This invention involves two fields of photoelectron information materials and pharmaceuticals, especially refers to the self-assembly of conducting photoluminescence nanomedicine crystals and thin films and their preparation processes. In the invention, self-assembling unitary, binary, ternary and quaternary complexes of an antioxidase antioxidant, an agonist of the β-adrenergic receptors, an agonist of the P02-11-2010
20100047352COMPOSITIONS AND METHODS FOR TREATING EXCESSIVE BLEEDING - The inventive material is a unique family of externally used wound sealants based upon a binding agent of reactive submicron silica particles that, when hydrated, agglomerate in the form of a supramolecular cross-linked network serving as the structural framework facilitating clot formation. A thrombolytic cascade accelerant can be provided, optionally with additional clotting factors, to further accelerate the clotting process.02-25-2010
20110091558Pharmaceutical Compositions of Entacapone, Levodopa and Carbidopa with Improved Bioavailability - The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapon, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone, levodopa and carbidopa combination formulation marketed under the trade name Stalcvo200®. The invention also relates to processes for making such compositions.04-21-2011
20110244046Charge Reversible Polymers - Described are charge reversible polymers, peptides and their resulting colloidal particles, comprising polymers and peptides having primary and secondary amines that are protected as easily hydrolysable amides. The amides are charge-reversible such that at neutral pH they are negatively charged but become positively charged at pH less than 6 and thus are relatively stable at neutral pH but quickly hydrolyze at pH below 6. Incorporating a drug in a micelle or a polymer comprised of the charge-reversible polymers or peptides provides a drug carrier for delivering the drug preferentially to the solid tumor or other targeted cells.10-06-2011
20110244047FILM-FORM PREPARATION AND METHOD FOR PRODUCING THE SAME - The present invention provides a film-form preparation having a rapid dissolution profile in the mouth and sufficient film strength, and also having excellent appearance and feel. More specifically, the present invention provides a film-form preparation including: a water-soluble edible polymer; and water-insoluble drug particles, wherein an average particle size of the drug particles is 0.1 to 60 μm.10-06-2011
20110142941Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof - Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.06-16-2011
20100221347ENHANCING SOLUTE TRANSPORT WITHIN A TISSUE SCAFFOLD - This document provides materials and methods related to tissue scaffolds for use in replacing or augmenting various tissues in the body. For example, flexible tissue scaffolds with controlled pore geometry and methods of enhancing solute transport using rhythmic compression (e.g., 1.0 Hz) of tissue scaffolds are provided09-02-2010
20100196484Use of expanded amorphous mineral particles for increasing the tenacity of a fragrance, scenting composition and method for treating body odours - The subject-matter of the invention is a cosmetic method for scenting a human keratinous substance which consists in applying, to the said substance, a scenting composition comprising, in a cosmetically acceptable medium, at least 0.3% by weight of at least one scenting substance and at least particles of an expanded amorphous mineral material and in particular of an expanded amorphous mineral material resulting from at least one volcanic rock and more particularly expanded perlite particles.08-05-2010
20110091560COMPOSITIONS OF NANOPARTICLES AND METHODS OF MAKING THE SAME - Disclosed herein are compositions of nanoparticles. In some embodiments, the nanoparticles are Janus particles, where each particle includes a first component and second component that are exposed to the surface of the particle. Also, disclosed are methods and systems for making a composition of nanoparticles. Finally, a method of treating a mammal by administering a composition of nanoparticles is disclosed.04-21-2011
20100178349PHARMACEUTICAL FORMULATION FOR THE PRODUCTION OF RAPIDLY DISINTEGRATING TABLETS - Pharmaceutical formulation in the form of agglomerates comprising 07-15-2010
20090311333FEED OR FOOD PRODUCT COMPOSITION - The present invention relates to a feed or food product composition which comprises a mixture of bovine colostrum, comprising bioactive components, and organic particulate matter having a size between 0.3 and 7 mm in diameter. The composition is especially adapted to deliver the mixture of bioactive bovine colostrum components to the digestive tract of a mammal.12-17-2009
20100015235COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS - Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.01-21-2010
20100055194PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT - This invention relates to microparticles and/or nanoparticles containing a delivery agent and/or an active agent. This invention also relates to pharmaceutical formulations and solid dosage forms, including controlled release solid dosage forms of active agent and a delivery agent.03-04-2010
20100040692TWO PHASE BIOACTIVE FORMULATIONS - The present invention relates to two-phase systems of a bioactive ingredient in particle form that has limited or no solubility in a liquid medium, which provides stability to the active ingredient that is similar to the active ingredient when in the solid state. The active ingredient may be capable of therapeutically treating for the presence of a cholinesterase inhibitor.02-18-2010
20100062068CISTUS EXTRACTS - The present invention relates to the use of a nasal spray made from 03-11-2010
20100055193Stable powder formulation containing an anticholinergic agent - The invention relates to a spray-dried powder formulation comprising particles that contain the following components i) to iii): i) anticholinergic agents, in particular at least one compound of formula 1, in which X03-04-2010
20100055188NANO-VALVES FOR SMALL-MOLECULE DRUG DELIVERY - A system for drug delivery including a plurality of molecular-valves that are responsive to an exterior stimulus so as to selectively open in response to the stimulus. A quantity of a drug is initially contained within the molecular-valves. The molecular-valves are associated with the surface (e.g., both the exterior surface, as well as within the internal pore structure) of the substrate. Upon exposure to a selected stimulus, the molecular-valves open, resulting in release of the drug molecules.03-04-2010
20090028952Hydroxy sulfonate of quinone compounds and their uses - The present invention provides sodium 6-hydroxy-2,2-dimethyl-5-oxo-3,4,5,6-tetrahydro-2H-benzo(h)chromene-6-sulfonate, and its synthesis and uses in the treatment of cancer.01-29-2009
20090028954PRECURSOR FOR THE PREPARATION OF A PASTY BONE REPLACEMENT MATERIAL BY ADMIXTURE OF A LIQUID - The precursor is used for the preparation of a pasty bone replacement material by admixture of a liquid. The precursor comprises a biocompatible substance swellable by the action of water or of an aqueous solution thereby forming a hydrogel; and solid particles made of a substance which is suitable as a bone replacement material. The swellable substance is in the form of discrete particles having a mean dimension in the range of 18 μm to 2000 μm.01-29-2009
20090028953METHOD OF TREATMENT USING MICROPARTICULATE BIOMATERIAL COMPOSITION - Compositions of microspheres formed of stabilized hyaluronic acid are disclosed. The unique biological properties of hyaluronic acid provide for very inert properties when exposed to tissues. Microsphere formulations of hyaluronic acid have medical utility due to the resultant properties of flowability, physical stability, and degradability. High concentration formulations of the microspheres have utility when injected to form a localized mass within tissues by providing physical stability and anti-fibrotic biological activity, especially suitable for certain surgical reconstructions. Low concentration formulation of the microspheres of the appropriate size range have utility when injected into the blood system to delivery diagnostic and therapeutic compounds.01-29-2009
20090028950GRANULE DISPERSION COMPOSITION, PROCESS FOR PRODUCING THE SAME, AND GRANULAR MATERIAL AND MEDICINE - The subject matter of the present invention is to provide a new particulate material dispersion composite in which a material poorly soluble in water is micronized and dispersed. For the above purpose, a particulate material dispersion composite is produced in the present invention, wherein a particulate material containing a specific material which is poorly soluble in water, a polymer and a lipid is dispersed in water, the mean diameter of said particulate material is 1 μm or less, and the ratio of the combined weight of said polymer and said lipid to the weight of said specific material is 1.5 or larger.01-29-2009
20090028947USING OF NANOSILVER IN POULTRY, LIVESTOCK AND AQUATICS INDUSTRY - Nanosilver material is disclosed. Said material is nano silver based disinfectant and disease preventer for poultry, livestock and aquatics. The material contains silver nano particle and pure water and can be used as a surface disinfectant, water disinfectant and therapentic material for poultry, livestock and aquatic disease caused by bacteria's viruses, fungi and other monocellular microorganism.01-29-2009
20110151008Pulmonary Delivery for Levodopa - In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.06-23-2011
20110104289METHOD AND PHARMACEUTICAL COMPOSITION FOR OBTAINING THE PLASMATIC PROGESTERONE LEVELS REQUIRED FOR DIFFERENT THERAPEUTIC INDICATIONS - The invention relates to the development of a method and pharmaceutical compositions for obtaining plasmatic progesterone levels in humans and for maintaining a plasmatic progesterone concentration between 42 and 3.5 ng/mL for eight days as well as maximum plasmatic concentrations (Cmax) between 12 and 42 ng/mL, sufficient for use in different therapeutic options that require said progesterone concentrations.05-05-2011
20110104286PHARMACEUTICAL COMPOSITIONS CONTAINING THE ENZYME CYPROSIN, AN ASPARTIC PEPTIDASE FROM CYNARA CARDUNCULUS AND ITS INCLUSION IN ANTITUMOUR FORMULATIONS - An aspect of the present invention is the use of a preparation containing a phytepsin, more specifically a cyprosin, containing the heterodimer, its N-terminal pro-peptide, the mature N-terminal peptide, and mature C-terminal peptide, as well as other precursor species, processing products, and aggregate species, either isolated or in any combinations of the former, native, extracted and partially purified from flowers of 05-05-2011
20100129456SUSTAINED-RELEASE NANOPARTICLE CONTAINING LOW-MOLECULAR-WEIGHT DRUG WITH NEGATIVELY CHARGED GROUP - A nanoparticle containing a low-molecular-weight drug having a negatively charged group is provided that is effectively targeted to an affected site, is capable of sufficiently sustained release of the drug, and has a reduced tendency to accumulate in the liver to cause reduced side effects. The nanoparticle containing a low-molecular-weight drug having a negatively charged group is obtained by hydrophobicizing the low-molecular-weight drug having a negatively charged group with a metal ion, and reacting the hydrophobicized drug with poly L-lactic acid or poly(L-lactic acid/glycolic acid) copolymer and poly DL- or L-lactic acid-polyethylene glycol block copolymer or poly(DL- or L-lactic acid/glycolic acid)-polyethylene glycol block copolymer.05-27-2010
20090214655Method and Device for Obtaining Micro and Nanometric Size Particles - The invention relates to a method and device for obtaining micro and nanometric particles in a controlled, reproducible manner. The aforementioned particles have a spherical shape and a very narrow, uniform size distribution. More specifically, the invention relates to a novel method of forming emulsions and to the application thereof in micro and nanoencapsulation techniques involving the extraction/evaporation of the solvent. In particular, the invention relates to the encapsulation of the fluorescent compounds and the subsequent application thereof.08-27-2009
20090214657Orally Absorbed Pharmaceutical Formulation and Method of Administration - A pharmaceutical formulation for absorption through oral mucosae comprising an effective amount of (a) a pharmaceutical agent in mixed micellar form, (b) at least one micelle-forming compound selected from the group comprising an alkali metal alkyl sulfate and a polyoxyethylene sorbitan monooleate, (c) a block copolymer of polyoxyethylene and polyoxypropylene, (d) at least one additional micelle-forming compound, and (e) a suitable solvent. The invention also provides a metered dose dispenser (aerosol or non-aerosol) containing the present formulation and a method of administering insulin using the metered dose dispenser comprising administering split doses of a formulation containing insulin before and after each meal.08-27-2009
20090214656ITRACONAZOLE COMPOSITIONS WITH IMPROVED BIOAVAILABILITY - A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>ΔH08-27-2009
20110250277Modified release compositions comprising tacrolimus - A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.10-13-2011
20110086103NOVEL MANDELATE SALT OF FESOTERODINE - Provided herein is a novel raantlelate sail of fesoterodine, process for the preparation, pharmaceutics!! compositions, and method of treating thereof. Provided also herein are solid state forms of fesoterodine mandelate, process for the preparation, pharmaceutical compositions, and method of treating thereof. The raandelate salt of fesoterodine is useful for preparing fesoterodine free base or a pharmaceutically acceptable salt thereof; particularly fesoterodine fumaraie, in high purity.04-14-2011
20110070310TOPICAL OPHTHALMIC PHARMACEUTICAL FORMULATION OF (2S,3S,4R)-N''-CYANO-N-(6-AMINO-3,4-DIHYDRO-3-HYDROXY-2-METHYL-2-DIMETHOX- YMETHYL-2H-BENZOPYRAN-4-YL)-N'-BENZYLGUANIDINE - A topical ophthalmic pharmaceutical formulation may include particles of the compound (2S,3S,4R)—N″-cyano-N-(6-amino-3,4-dihydro-3-hydroxy-2-methyl-2-dimethoxymethyl-2H-benzopyran-4-yl)-N′-benzylguanidine suspended in a solution comprising monobasic sodium phosphate monohydrate, disodium phosphate heptahydrate, edetate disodium, benzalkonium chloride, sodium chloride, polysorbate 80, and water. A method of treating glaucoma may include topically applying to the eye of a patient in need thereof a therapeutically effective amount of this formulation.03-24-2011
20110076333METHOD AND COMPOSITIONS FOR SELECTIVELY TREATING SKIN - This invention relates to compositions, methods and kits for selectively depositing a benefit agent on skin without depositing the benefit agent on the hair. The method relates to exposing the skin to a composition containing anionic proteins, anionic polymers, anionic dyes, anionic pigments, or mixtures thereof which have an isoelectric point of less than about 4.5, the compositions having a pH of about 3.5 to about 5.5. In accordance with the methods of this invention, the benefit agent becomes deposited on the skin; however, any hair that is also contacted by the benefit compositions remains substantially untreated.03-31-2011
20110070308BED BUG INSECTICIDE - The insecticide comprises an insecticide particularly for killing bed bugs comprising nanospheres and primary ingredients of Organic Andirobia, Orange, Citronella, Organic Neem and Australian Myrtle oils. The insecticide can further comprise Isopropyl Alcohol as a carrier, Phenoxyethanol, Lavandox and Leucojum Aestivum Bulb Extrac.03-24-2011
20110070309PHARMACEUTICAL FORMULATION COMPRISING A WATER-INSOLUBLE ACTIVE AGENT - A method of preparing a pharmaceutical formulation comprises providing a solution comprising a first solvent, a second solvent, an active agent, and an excipient. The second solvent is less polar than the first solvent and the excipient is more soluble in water than the active agent. The first and second solvents are removed from the solution to produce particles comprising the active agent and the excipient. In one version, the excipient comprises an amino acid and/or a phospholipid. A pharmaceutical formulation made by a version of the invention comprises particles comprising an active agent and an excipient which at least partially encapsulates the active agent, wherein the excipient is more soluble in water than the active agent.03-24-2011
20110059177Cardioplegia Solution for Cardiac Surgery - The invention relates to improved cardioplegia solutions. The invention provides cardioplegia solutions and compositions that produce a readily reversible, rapid electrochemical arrest with minimal tissue ischaemia. The cardioplegia solutions and compositions are used for arresting, protecting and/or preserving organs, in particular the heart during open-heart surgery, transplanting, cardiovascular diagnosis or therapeutic intervention.03-10-2011
20110151010ANTI-SNORING TREATMENT COMPRISING POSITIVELY CHARGED MULTILAMELLAR MICROPARTICLES - A composition for nasal or buccal application comprising a distribution of multilayer microparticles in an inactive base, at least one ingredient having activity on the mucosa of the nose/throat, being adsorbed within the layers of the microparticles so as to be progressively released over time in use.06-23-2011
20110151007CARBIDE-DERIVED-CARBON-BASED OXYGEN CARRIERS - An oxygen delivery system is disclosed. The basis of the oxygen deliver system is a carbide-derived carbon (CDC). The CDC can be tuned to carry O06-23-2011
20100310664COMPOSITIONS AND METHODS FOR TREATING INSULIN RESISTANCE AND DIABETES MELLITUS - Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.12-09-2010
20100255102STERILIZATION OF DISPERSIONS OF NANOPARTICULATE ACTIVE AGENTS WITH GAMMA RADIATION - The present invention relates to methods for sterilization of dispersions of one or more nanoparticulate active agents via gamma irradiation.10-07-2010
20100291219METHODS AND COMPOSITIONS RELATING TO PROGENITOR CELLS - The invention provides compositions and methods for harvesting and enriching cells such as connective tissue progenitors cells using stirred bioreactors, and in some embodiments fibrin microcarriers.11-18-2010
20100062070Pulverzed crystals of olmesartan medoxomil - An olmesartan medoxomil having a particle diameter at 90% cumulative volume of 75 μm or less, which provides an improved dissolution property. The olmesartan medoxomil is advantageously used to treat or prevent hypertension or a disease caused by hypertension.03-11-2010
20100112067Compositions and methods for biological remodeling with frozen particle compositions - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.05-06-2010
20110045084LIGHT-CURABLE BONE GROWTH MATERIAL FOR TREATING DENTAL BONE DEFECTS - Improved compositions comprising a mixture of particulate bone growth material and polymeric carrier are provided. The particulate is preferably porous, resorbable, anorganic bone material. The polymeric carrier can be light-cured to form a cross-linked, biodegradable hydrogel. In one version, the bone growth material is a synthetic peptide bound to anorganic bone matrix particles and the carrier is methacrylated sodium hyaluronate (MHy) or methacrylated hydroxyethylcellulose (MHEC). The composition is particularly suitable for repairing defective dental and orthopedic bone tissue. The particulate and hydrogel carrier are biodegradable so the composition can be replaced by new bone formation over time.02-24-2011
20110045080Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto - The present invention includes single-walled carbon nanotube compositions for the delivery of siRNA and methods of making such single-walled carbon nanotube compositions. A single-walled carbon nanotube composition for delivery of siRNA includes a nonfunctionalized single-walled carbon nanotube; and siRNA noncovalently complexed with the nonfunctionalized single-walled carbon nanotube, wherein the siRNA solubilizes such nonfunctionalized single-walled carbon nanotube.02-24-2011
20110045081MAGNETIC, PARAMAGNETIC AND/OR SUPERPARAMAGNETIC NANOPARTICLES - The present invention relates to nanoparticles having a mean diameter of <500 nm and comprising, at their surface, a selected material. The nanoparticles are taken up by cells under physiological conditions and can be used to isolate interaction partners of the selected material within the cells. The present invention provides important advantages in that it opens up new ways of identifying cellular components and of delivering a substance of interest specifically to a selected cell compartment. The nanoparticles are also useful as a tool of diagnosis and for the constitution of chemical libraries.02-24-2011
20090311329CASEIN MICELLES FOR NANOENCAPSULATION OF HYDROPHOBIC COMPOUNDS - The present invention relates to the field of food technology and delivery of hydrophobic biologically active compounds, particularly nutrients, via food products and beverages. In particular the present invention provides isolated casein micelles useful for the encapsulation of hydrophobic nutrients, therapeutic and cosmetic compounds, compositions thereof and methods of preparing the micelles.12-17-2009
20100015232NANOPARTICLES FOR NUCLEIC ACID DELIVERY - The present invention provides chitosan/RNA nanoparticles that are useful as research tools or medicaments. Preferably, the RNA part of the nanoparticle is a siRNA capable of modulating the expression of a target mRNA. The invention also provides methods for the preparation of chitosan/RNA nanoparticles.01-21-2010
20100003332Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug - A powder comprising nanoparticles of a sparingly water-soluble drug prepared in accordance with the present invention exhibits enhanced bioavailability without generating adverse side effects caused by impurities, while the nano-particle size of the drug remains unchanged when administered. Accordingly, the powder can be useful for the development of a formulation of a sparingly water-soluble drug for oral and parenteral administration.01-07-2010
20080248119Production method of drug containing composite particle - A strong pressure and a strong shearing force are exerted to a mixture, constituted of two kinds or more of powder materials including a drug powder, while causing the mixture to pass between a press section (10-09-2008
20110151009USE OF FREE RADICAL SCAVENGERS FOR PROTECTING AND TREATING SKIN AND HAIR DAMAGES CAUSED BY CHEMOTHERAPY - The present invention relates to the use of one or more free radical scavengers as prophylactically or therapeutically effective substances and microparticles having an average particle size ranging from 5 to 200 μm for the preparation of a topical pharmaceutical composition for the protection or treatment of skin or hair damages caused by chemotherapeutic treatment.06-23-2011
20090317475COMBINATION ANTITUMOR THERAPIES - Improved methods of treating cancers that are characterized by unwanted angiogenesis employ combinations of therapies designed to inhibit the VEGF mediated angiogenesis pathway with therapies designed to inhibit the bFGF-mediated angiogenesis pathway.12-24-2009
20090297612HOMOGENEOUS, INTRINSIC RADIOPAQUE EMBOLIC PARTICLES - The invention is directed to embolic material comprising spherical, homogeneous and substantially non-porous radiopaque polymer particles based on at least one hydrophilic monomer and at least one radiopaque monomer according to general formula12-03-2009
20110256224METHODS AND COMPOSITIONS FOR TARGETED DELIVERY - The disclosure provides compounds and compositions, and methods of using these compounds and compositions, for the targeted delivery of therapeutic agents. In one embodiment, these compositions are used for the tumor-targeted delivery of chemotherapeutic agents useful for treating cancer.10-20-2011
20090142402MICROPARTICLES, MICROPARTICLE DISPERSION AND METHOD AND APPARATUS FOR PRODUCING THE SAME - A method and an apparatus enabling manufacture of a microparticle dispersion liquid at high efficiency in a short time while suppressing drug degradation, etc., are provided. In a dissolving step, a poorly soluble drug and a dispersion stabilizer are dissolved in a volatile organic solvent in a container 06-04-2009
20080286362Compositions Exhibiting Improved Flowability - Powder compositions exhibiting improved flow properties. The compositions generally contain a bulk solid material in the form of a powder and surface-modified nanoparticles. Methods of improving the flow of powder compositions and devices and articles made using such compositions are also disclosed.11-20-2008
20080241255DEVICE AND METHOD FOR DELIVERY OF A MEDICAMENT - The disclosure relates to a method of enhancing nicotine or other medicament concentrations in a gaseous carrier. The methods are adaptable to the delivery of nicotine or other medicaments for therapeutic effect in various diseases, in particular nicotine for tobacco product use cessation, substitution and/or harm reduction. The disclosure further relates various devices and device design principles for practicing these methods.10-02-2008
20080213377Delivery of Nanoparticles and/or Agents to Cells - The present invention provides systems, methods, and compositions for targeted delivery of nanoparticles and/or agents to tissues, cells, and/or subcellular locales. In general, compositions comprise a nanoparticle (e.g. quantum dot, polymeric particle, etc.), at least one modulating entity (such as a targeting moiety, transfection reagent, protective entity, etc.), and at least one agent to be delivered (e.g. therapeutic, prophylactic, and/or diagnostic agent). The present invention provides methods of making and using nanoparticle entities in accordance with the present invention.09-04-2008
20100285135Nanoparticles For Use In Immunogenic Compositions - Disclosed herein are sterile-filtered lyophilized nanoparticle compositions which contain at least one biodegradable polymer, at least one surfactant, at least one cryoprotective agent and at least one antigen. Also disclosed are methods of making and using such compositions and kits supplying such compositions.11-11-2010
20120121710Mucosal Immunization - Methods and compositions for eliciting an immune response to an antigen are disclosed. In certain aspects, these methods concern eliciting an immune response in a subject by administering to the mucosa of the subject a composition comprising a virus-like particle (“VLP”) and Murabutide.05-17-2012
20120121708Acetazolamide Microparticle And Its Preparation Method And Use - A method for preparing an acetazolamide microparticle having a mean particle size ranged between 0.36 μm and 18 μm is provided. The method includes steps of dissolving an acetazolamide in a solvent to form an acetazolamide solution; and mixing the acetazolamide solution with a supercritical fluid at a temperature and a pressure above a critical point of the supercritical fluid for forming the acetazolamide microparticle, wherein the solvent is miscible with the supercritical fluid.05-17-2012
20080254130Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction - The present invention relates to a topical method of treatment for dysfunction of certain dermal enzymes, and the treatment of skin condition or disorder caused by said dysfunction. The said method of treatment consists of (i) an extra-cellular, matrix metalloprotease regulating agent, and (ii) an intra-cellular ubiquitin—proteasome regulating agent, and (iii) an epidermal melanocyte-regulating agent; and, wherein, said extra-cellular agent, said intracellular agent, and said epidermal agent can, surprisingly and unexpectedly, be a single multi-function compound having chemical formula (I). Additionally, the method of the present invention provides treatment of skin condition or disorder caused by dysfunction of said dermal enzymes; wherein said skin disorder is skin aging, skin wrinkles, dark skin, age spots, acne, skin inflammation, loss of cellular antioxidants, loss of collagen, loss of skin pliability, loss of skin suppleness, oily skin, or a combination thereof:10-16-2008
20080254129Use of avian anti-methanogen antibodies for reduction of methane production - Herein, it is shown that strong specific anti-methanogen avian antibodies can be produced when chickens are immunized with an optimal dose of methane producing bacterial antigen (methanogen) formulated with an appropriate adjuvant. The antibodies can in turn be used to reduce methane gas production from an animal by administering an effective amount of the anti-methanogen antibodies to the animal, thereby reducing methane gas evolved by the animal compared to an untreated or mock treated control animal of similar age and condition.10-16-2008
20110165253NICOTINE-CONTAINING GRANULATE - A dust-reduced nicotine-containing granulate comprising a homogenous mixture of nicotine or a pharmaceutically acceptable nicotine derivative and an excipient, the granulate having a particle size of at least 150 μm. Method for the preparation of a dust-reduced nicotine-containing granulate, and use of the nicotine-containing granulate for the preparation of pharmaceutical products.07-07-2011
20110008446Method of Drug Delivery - A drug delivery method for effective drug application is disclosed in this invention. In this method, a micro-carrier delivers an encapsulated, desired drug directly to targeted sites without significant interactions with other components in the biological system in the pathway. In one embodiment, a micro-carrier containing encapsulated drug is first delivered to the general area for treatment. It then scans the area and selectively attaches itself the cell site or organ location to be treated. Finally, the desired drug contained in the micro-carrier is released to the attached cell or organ. In another embodiment, a micro-device is first used to process the general area to be treated to enhance differentiation in properties (such as surface charge) between healthy cells and unhealthy cells (such as cancer cells). Drug encapsulated in the micro-carrier is next applied to preferentially attach onto the targeted sites (such as cancer cell sites) to be treated. Finally, drug is released from the micro-carrier onto the sites to be treated. Such micro-carrier preferably contains multiple functions comprised of at least two functions from the group of sensing, analyzing, logic processing, surface treatment, position detection, motion, injecting, delivering, cutting functions, removing functions, biodegradation and disintegration.01-13-2011
20110165252MEMANTINE FORMULATIONS - The present invention relates to pharmaceutical compositions prepared from equant-shaped crystals of memantine, such as orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs), and to methods of treating conditions, including childhood behavioral disorders (e.g., autism) and Alzheimer's disease by administering the same.07-07-2011
20110020453Topical Formulations Comprising Ion Channel Modulators - Disclosed herein are pharmaceutical formulations comprising particles of formula 1:01-27-2011
20100129454ABSORBENT COMPOSITION FOR SURFACE TREATMENT - The invention concerns an absorbent composition comprising: (a) at least 50 wt.-% of the overall composition have a particle size of less than 150 μm and are comprised of at least one absorbent component; and (b) at least 1.0 wt.-% of the overall composition have a particle size of at least 250 μm and are comprised of at least one particulate component, and its preferred uses.05-27-2010
20110027371Nanoparticulate statin formulations and novel statin combinations - The present invention is directed to nanoparticulate compositions comprising statin such as lovastatin or simvastatin. The statin particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of statins and other cholesterol lowering agents are described and methods of using same are taught.02-03-2011
20100285136SYSTEM COMPRISING BACTERIOPHAGES AND PARTICLES THAT CONTAIN ACTIVE SUBSTANCES - The present invention concerns a system, comprising bacteriophages and particles comprising active agents, in which a first additional peptide is fused to proteins of the bacteriophage, the first additional peptide adheres to the surface of the particle and furthermore a second additional peptide is fused to proteins of the bacteriophage. The second additional peptide can adhere on substrate surfaces. The present invention furthermore concerns the use of the system for delayed release of active agents and also a method for production of the system. The present invention furthermore concerns a method for the selection of phage species from a combinatorial phage population.11-11-2010
20100285139PHARMACEUTICAL COMPOSITION FOR THE PROPHYLAXIS AND/OR SYMPTOMATIC TREATMENT OF CYSTIC FIBROSIS - A pharmaceutical composition for prophylaxis and/or treatment of infections and/or infectious diseases occurring in cystic fibrosis includes at least one antidepressant; at least one dispersant; and at least one pharmaceutically tolerable carrier material.11-11-2010
20110111036INTRACELLULAR ANTIBODY DELIVERY - The present invention concerns a composition comprising vesicles and encapsulated within the vesicles, an antibody, wherein the vesicles comprise an amphiphilic block copolymer having a hydrophilic and a hydrophobic block.05-12-2011
20110052705CARTILAGE COMPOSITION AND PROCESS FOR PRODUCING THE CARTILAGE COMPOSITION - Disclosed is a method for regenerating articular cartilage in an animal comprising administering a therapeutically effective amount of a non-demineralized particulate articular cartilage having a distribution of particle sizes within the range of from about 60 microns to about 500 microns.03-03-2011
20110052704TOCOTRIENOL COMPOSITIONS - Compositions containing tocotrienol, non-tocotrienol lipids and surface active agents; compositions containing particles having a statin and a tocotrienol wherein the particle size is less than 1000 nm; and microemulsions containing a statin and a tocotrienol are disclosed. Methods relating to the creation of such compositions and the use of such compositions are further disclosed.03-03-2011
20110052703BETA-CASEIN ASSEMBLIES FOR MUCOSAL DELIVERY OF THERAPEUTIC BIOACTIVE AGENTS - Nanoparticulate assemblies of isolated beta-casein, are useful for encapsulation of bioactive therapeutic substances, particularly therapeutic agents with poor bioavailability. These nano-sized beta-casein assemblies are preferably formed at pH values which are at least one or more pH units below or above the pI of the protein. Pharmaceutical compositions comprising the beta-casein micelles may be used to administer the agents to the GI tract for treatment of local or systemic conditions. These carriers are stable over a wide temperature range (optionally at least from about 1° C. to at least about 45° C.).03-03-2011
20110052702Method and Apparatus for Producing Organic Nanotubes - An object of the present invention is to provide a method and apparatus capable of continuously producing organic nanotubes, wherein an organic nanotube material dispersion solution consisting of an organic nanotube material and an organic solvent is pressurized and caused to pass through a very narrow orifice.03-03-2011
20110052701PARTICULATES OF A CRTH2 ANTAGONIST - Provided herein are particulates of {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl} acetic acid in amorphous or crystalline forms, processes for their preparation, pharmaceutical compositions comprising them, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a CRTH2-mediated disorder or disease.03-03-2011
20110135735PROCESS FOR PRODUCTION OF A COMPOSITE MATERIAL HAVING ANTIMICROBIAL ACTIVITY - The invention relates to a process for production of a composite material having antimicrobial activity, having the following steps: provision of a metal powder produced from a metal having antimicrobial activity, wherein the metal powder is formed from discrete agglomerates having a porosity of 30 to 98%, wherein the agglomerates have a spongy structure formed by solid material bridges; melting a thermoplastic and setting a predetermined viscosity; mixing the metal powder with the molten thermoplastic in a predetermined quantitative ratio; and cooling the mixture, wherein the metal powder is firmly bound to a matrix formed by the plastic.06-09-2011
20110135740TISSUE SUBSTITUTES COMPRISING STEM CELLS AND REDUCED CERIA - A biocompatible composite includes a solid biocompatible material and a plurality of living human progenitor or living stem cells attached thereto. The composition resulting in accelerated repair to damaged bones and tissues.06-09-2011
20110135737COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS - Compositions, methods and systems are provided for pulmonary or nasal delivery of active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.06-09-2011
20110135736Compositions and Methods for Producing Vascular Occlusion using a Solid-phase Platelet Binding Agent - The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent causing vessel occlusion.06-09-2011
20110135734Method For the Preparation of Nanoparticles From Nanoemulsions - The invention relates to a method for the production of nanoparticles from oil-in-water nanoemulsions, in which the nanoemulsion is prepared by phase inversion techniques. The phase inversion may be achieved by using a constant temperature, where the inversion occurs by continuous addition of water or by varying the temperature involving heating and rapid cooling.06-09-2011
20110262543PROCESS FOR PROVIDING PARTICLES WITH REDUCED ELECTROSTATIC CHARGES - Carrier particles for dry powder formulations for inhalation having reduced electrostatic charges are prepared.10-27-2011
20110020456LANTHANUM COMPOSITION - The present invention discloses stable, solid oral pharmaceutical composition comprising Lanthanum carbonate having more than 6 molecules of water per molecule of lanthanum carbonate and pharmaceutically acceptable carriers or diluents, wherein said carrier or diluent excludes monosaccharide/s or disaccharide/s, such that the composition has comparable in-vitro dissolution profile similar to that of FOSRENOL®.01-27-2011
20100323019Microparticles for the treatment of disease - Microparticle-bioactive agent based treatments for local treatment of diseased tissues/organs are disclosed.12-23-2010
20100323017Escitalopram and Solid Pharmaceutical Composition Comprising the Same - The present invention relates to Escitalopram having a small median particle size and a solid pharmaceutical composition comprising the same.12-23-2010
20100323022CALCIUM PHOSPHATE COMPOSITION AND PROCESS FOR PRODUCTION THEREOF - A calcium phosphate composition comprising calcium phosphate particles (A) and a sulfonic acid salt (B), wherein the calcium phosphate composition contains 0.5 to 20 parts by weight of the sulfonic acid salt (B) based on 100 parts by weight of the calcium phosphate particles (A). This provides a calcium phosphate composition that has a time between the addition of a liquid agent to the calcium phosphate composition and the completion of setting in the use at a clinical site and the like, i.e., a setting time which is within an appropriate range and that is high in mechanical strength and good in marginal sealing ability.12-23-2010
20100323018Branched DNA/RNA monomers and uses thereof - The invention provides compositions and methods relating to delivery of agents in vivo or in vitro. More specifically, the invention provides nanoparticles synthesized from crosslinked nucleic acids, optionally having a lipid shell or coating, and may further comprise for example small molecule or high molecular weight compounds as therapeutic or diagnostic agents.12-23-2010
20100330186MEDICAMENTS FOR INHALATION COMPRISING AN ANTICHOLINERGIC AND A BETAMIMETIC - A pharmaceutical composition comprising a compound of formula 112-30-2010
20110256225BIODEGRADABLE NANOPARTICLES AS NOVEL HEMOGLOBIN-BASED OXYGEN CARRIERS AND METHODS OF USING THE SAME - Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding compound in a polymer vesicle. Oxygen-binding compounds may include hemoglobin, myoglobin, or other oxygen binding compounds having characteristics similar to hemoglobin. Oxygen carriers may include nanoparticles, polymers and/or polymersomes comprising of poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) and related diblock copolymers of poly(ethylene oxide)-block-poly(γ-methyl ε-caprolactone) (PEO-b-PMCL). The oxygen carriers may have tunable oxygen-binding capacities, uniform and appropriately small size distributions, and human bloodlike viscosities and oncotic properties.10-20-2011
20110165250COMPOSITIONS AND METHODS FOR TREATMENT OF NEOPLASTIC DISEASE - The present invention is concerned with immunostimulant compositions, in particular compositions comprising microparticulate form of murmyl dipeptide, and their use in the treatment of neoplastic disease.07-07-2011
20110097409PARTICLES COMPRISING A SALT OF 8-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO]ETHYL]-2(1H)-Q- UINOLINONE HAVING IMPROVED ADHESION PROPERTIES FOR POWDER FORMULATIONS FOR INHALATION - Powder particles comprising a pharmaceutically acceptable salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone (carmoterol) having a specific properties exhibit improved adhesion properties for dry powder formulations for inhalation. Such particles are useful for formulations in the form of powders for inhalation and the treatment of certain conditions and diseases.04-28-2011
20110097412METHODS OF TREATMENT OF ENDOBRONCHIAL INFECTIONS - The present invention provides methods for the treatment of an endobronchial infection in a patient by administering to the endobronchial system of the patient a dry powder aerosol composition comprising from 90 to 130 mg of an aminoglycoside antibiotic one to three times a day for a first treatment period of 20 to 36 days.04-28-2011
20110097411CARRIER PELLETS, METHOD FOR PRODUCTION THEREOF AND USE THEREOF - The invention relates to a method for the production of carrier pellets for pharmaceutical active substances. Likewise, the invention relates to such carrier pellets and also to pharmaceutical formulations containing these. The carrier pellets according to the invention are used for transporting and releasing pharmaceutical active substances, in particular in the human body.04-28-2011
20100166869METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION - The present invention features methods for treating, stabilizing, preventing, and/or delaying pulmonary hypertension by administering nanoparticles that comprise rapamycin or a derivative thereof and/or nanoparticles that comprise a taxane (e.g., paclitaxel) or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof and/or nanoparticles that comprise a carrier protein and a taxane (e.g. paclitaxel) or a derivative thereof.07-01-2010
20100166868Filmy Compositions - Washing with conventional filmy soaps cannot bring about clean detergent effect because of the remaining sliminess due to the ingredient essential for forming soap into films. Further, when moisture adheres to conventional filmy compositions, the water-soluble polymer or other ingredients contained in the compositions dissolve in the moisture to cause the blocking of filmy compositions, which makes it impossible to take out the filmy compositions one by one. Detergent effect without sliminess and the antiblocking of filmy compositions can be attained by incorporating a granular component into a filmy composition containing a water-soluble polymer. The filmy compositions of the invention are used as filmy facial masks, whitening masks, sheet soap, cleansing sheets, sheet shampoos, sheet rinses, sheet bath additives, and so on.07-01-2010
20100272812RGD-MODIFIED ALGINATE MICROPARTICLES AS A DRUG RELEASE SYSTEM - The object of the present invention is to provide particles of a polymeric material containing cells therein, wherein said particles have a strength that is substantially greater than the microcapsules known in the state of the art. Said strength is achieved by means of functionalizing the polymeric material forming the microcapsule with a peptide which can bind to the adhesion proteins of the cell membrane, such that the cells act as cross-linking agents of the matrix resulting in an improvement of the mechanical properties of the matrixes10-28-2010
20100159016PAIN RELIEF COMPOSITION COMPRISING PARAMAGNETIC SILVER NANOPARTICLES - The present invention relates to a pain relief composition comprising paramagnetic silver nanoparticles. More specifically, the composition is characterized in that it comprises from 0.03 to 0.05% by weight of paramagnetic silver nanoparticles having specific properties that were not revealed by conventional diamagnetic silver nanoparticles. The pain relief composition according to the present invention shows excellent effect of relieving pain of arthritis due to antibiotic property and anti-toxicity of paramagnetic silver nanoparticles. By using the paramagnetic silver nanoparticles having small particle size, the composition is rapidly absorbed into cells upon being applied to skin. In addition, by virtue of using silver (Ag), no complication such as skin coloration or edema was observed. According to the present invention, pain is relieved by simple application, so that the usage is easy as compared to surgical treatment such as arthroscopic operation to provide high satisfaction to a patient.06-24-2010
20100196487COMPOSITION WITH ANTIMICROBIAL EFFECT - A composition with antimicrobial efficacy has at least one or more polymers; or polymerizable or crosslinkable monomers; or polymerizable or crosslinkable prepolymers; or polymerizable or crosslinkable polymers; and porous glass particles which contain an antimicrobial silver additive.08-05-2010
20100196490COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS - The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.08-05-2010
20100196483METHOD FOR TREATMENTOF SEVERE AND UNCONTROLLABLE ASTHMA - A method for treatment of severe and uncontrollable asthma by providing means for delivery of high doses of a suitable inhalable corticosteroid directly to the small airways of the lower lungs with substantial decrease in need for simultaneous administration of oral corticosteroids and with a significant reduction in undesirable secondary side effects in an oropharyngeal area. The method utilizes devices allowing individualization of treatment parameters in asthmatic patients having compromised breathing pattern due to severe and uncontrollable asthma.08-05-2010
20100068288MIXTURES OR ORGANIC COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES - A medicament comprising, separately or together, (A) a compound of formula (I) in free or pharmaceutically acceptable salt or solvate form and (B) a corticosteroid, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease, the molar ratio of (A) to (B) being from 100:1 to 1:300.03-18-2010
20100068285Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.03-18-2010
20100068283Ex VIVO modifiable particle or polymeric material medicament carrier - Described embodiments include a final dosage form, an article of manufacture, and method. A final dosage form for administering a medicament to an animal is described. The final dosage form includes the medicament. The final dosage form also includes a particle or polymeric material carrying the medicament in a first medicament-release state wherein the medicament is available to the animal in a first bioavailability if the final dosage form is administered to the animal. The particle or polymeric material is modifiable ex vivo by an exposure to a stimulus to carry the medicament in a second medicament-release state wherein the medicament is available to the animal in a second bioavailability if the final dosage form is administered to the animal. In an embodiment, the final dosage form further includes a transport medium suitable for delivering the particle or polymeric material binding the medicament to the animal.03-18-2010
20090202646Method For Preparing Nano-Scale Particle of Active Material - Disclosed herein is a method for preparing nanoscale particles of active material with using a gas of a supercritical fluid, by dissolving an active material into a solvent which is in solid phase at room temperature, to produce nanoscale particles of the active materials which can be advantageously used in medicine, cosmetics, functional foods or the like.08-13-2009
20090202648AGRICULTURAL COMPOSITIONS - Compositions have been discovered that are suitable for forming a stable dispersion. The compositions comprise an agriculturally active compound and a multivalent metal oligomeric or polymeric compound having a molecular weight of from about 150 to about 15,000 Daltons.08-13-2009
20090202643Oil-in-water emulsions containing lignan-class compounds and compositions containing the same - An object of the present invention is to increase the rate at which lignan-class compounds are absorbed into the body, namely, to provide fast-acting lignan-class compounds.08-13-2009
20090196930AEROSOLIZED NITRITE AND NITRIC OXIDE -DONATING COMPOUNDS AND USES THEREOF - Disclosed herein are formulations of nitrite, nitrite salt, or nitrite- or nitric oxide-producing compounds suitable for aerosolization and use of such formulations for aerosol administration of nitrite, nitrite salt, or nitrite- or nitric oxide-donating compounds for the treatment of pulmonary arterial hypertension, intra-nasal or pulmonary bacterial infections, or to treat or prevent ischemic reperfusion injury of the heart, brain and organs involved in transplantation. In particular, inhaled nitrite, nitrite salt, or nitrite- or nitric oxide-donating compound specifically formulated and delivered to the respiratory tract for the indications is described. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures and manufacturing processes for production and use of the compositions described.08-06-2009
20110189294PESTICIDAL COMPOSITIONS - A formulated composition suitable for controlling or preventing pathogenic damage in a plant comprising (A) at least one solid active ingredient having a water solubility of at most 100 μg/litre at 25° C. at neutral pH, in an amount of at least 1 weight %, based on the total weight of the formulated composition, (B) at least one non-ionic surface active compound having a hydrophile-lipophile balance (HLB) of between 10 and 18, one or more customary formulation auxiliaries, and water; wherein active ingredient (A) is suspended or dispersed in the water, the weight ratio of surface active compound (B) to active ingredient (A) is in the range of from 1.5 to 15.0, provided the minimum amount of surface active compound (B) is at least 6 weight %, based on the total weight of the formulated composition. Also a method of improving pesticide residue levels in agriculture.08-04-2011
20100189796CRYSTALLINE FORM OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]-AMINO]-2-PYRIMIDINYL]AMINO- ]BENZONITRILE - This invention concerns polymorph I of TMC278, its use and preparation. It further concerns pharmaceutical formulations comprising this polymorph.07-29-2010
20110189296BONE SUBSTITUTE CONTAINING POROUS BIO-GLASS AND CALCIUM SULPHATE - The invention relates to a composition for a bone substitute that includes powdery or populated porous bio-glass and powdery alpha hemihydrate calcium sulphate. The invention also relates to an injectable composition for forming a bone substitute that includes said composition of powdery or granulated porous bio-glass and powdery alpha hemihydrate calcium sulphate, with 10 to 50 wt % of added water.08-04-2011
20110189297STABLE SOLID ORAL DOSAGE CO-FORMULATIONS - Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics of drugs that undergo in vivo degradation by cytochrome P450 enzymes. Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Specifically, methods of inhibiting metabolic degradation of atazanavir sulphate for administering to a patient suffering from HIV infection are disclosed.08-04-2011
20110189295TELMISARTAN TABLETS - A composition containing the active substance telmisartan, which consists of granules of a telmisartan mixture, in which there is the active substance in the form of alkali salts, further contained is an organic or inorganic base selected from meglumine, sodium or potassium hydroxide, or a mixture of said bases, a binder, most preferably polyvinylpyrrolidone, sorbitol, and optionally other auxiliary substances; the composition further containing, outside the granules, particles of sorbitol, and optionally of other auxiliary substance, the size of 99% by\ weight of all particles of the telmisartan mixture being smaller than 1.0 mm and the size of 95% by weight of all particles of sorbitol contained in the composition inside as well as outside the granules of the telmisartan mixture being within the range of 0 to 0.250 mm.08-04-2011
20110189293THERAPEUTIC REGIMENS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS - A method for treating an immunoinflammatory disorder in a subject in need thereof, said method comprising administering to said subject a unit dosage form comprising dipyridamole coated onto acid beads and formulated for controlled release. The method further including administering a corticosteriod concurrently with administration of the dipyridamole.08-04-2011
20110135739Oral Formulations of a Hedgehog Pathway Inhibitor - Oral formulations of the drug product IPI-926 are described. Pharmaceutical formulations (e.g., solid dosage forms) that are useful for the oral administration of a compound of formula (I), or a pharmaceutically acceptable salt thereof (e.g., IPI-926), to a human or animal subject are disclosed.06-09-2011
20100055187NANOVITAMIN SYNTHESIS - Stable nanoparticulate vitamin compositions are prepared from agglomerated or larger sized vitamin particles of at least one vitamin compound by breaking down and/or solubilizing the agglomerated or larger sized vitamin particles and associating the particles with a surface modifying agent.03-04-2010
20100028446TRANSPORT OF DRUGS VIA THE BLOOD-BRAIN BARRIER BY MEANS OF APOLIPOPROTEINS - Combination preparations comprising at least one apolipoprotein as one component, and a medicinal agent to be transported via the blood-brain barrier to the central nervous system as a further component. The components are administered simultaneously, separately or sequentially. A method for administering a medicinal agent to the central nervous system is also provided.02-04-2010
20100028448IMMUNOGENIC COMPOSITIONS AND METHODS OF USE - Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the antigenic polypeptide and the one or more surface adsorption regions have the same polarity. The immunogenic compositions may be employed in methods of eliciting an immune response in a vertebrate organism.02-04-2010
20100028447Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs - The present invention generally relates to pharmaceutical compositions for the intranasal, buccal, or sublingual administration of metanicotine analogs.02-04-2010
20100028445POLYMER - The invention provides compositions comprising a polyamidoamine (PAA) polymer comprising a pendant disulphide, sulphydryl, or activated sulphydryl moiety, and methods for their manufacture. The invention extends to the use of such polyamidoamine polymers to form cross-linked compositions, and hydrogels comprising the same, and the use of such compositions in various biological and non-biological applications, such as the delivery of biomolecules to target sites, and for tracking fluid flows. The invention also provides carrier particles, which may be used to deliver biomolecules, and to methods of treatment. The invention also provides a fluid tracking system for monitoring fluid flow.02-04-2010
20100028444USE OF WATER-DISPERSIBLE CAROTENOID NANOPARTICLES AS TASTE MODULATORS, TASTE MODULATORS CONTAINING WATER-DISPERSIBLE CAROTENOID NANOPARTICLES, AND, METHOD FOR TASTE MODULATION - Use of at least one type of water-dispersible carotenoid nanoparticles as taste modulators in compositions of matter; process for taste modulation of compositions of matter in which at least one type of water-dispersible carotenoid nanoparticles is added to compositions of matter; and also taste modulators for compositions of matter comprising02-04-2010
20100028443COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION - Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating inflammation or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (electrokinetically-generated gas-enriched fluids and solutions) and therapeutic compositions.02-04-2010
20100028442METHODS OF THERAPEUTIC TREATMENT OF EYES - Provided are electrokinetically-altered aqueous fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating an irritation, infection or inflammatory eye condition, comprising administering to, by contacting the eye of a subject in need thereof a therapeutically effective amount of an electrokinetically-altered aqueous fluid. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids) and therapeutic compositions for use in treating eye conditions. Certain embodiments relate to cosmetic and/or therapeutic fluids and/or methods of treatment utilizing the fluids to treat a cosmetic and/or therapeutic symptom related to eye conditions and/or diseases.02-04-2010
20100028441COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS - Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.02-04-2010
20100028439Nanoparticulate stabilized anti-hypertensive compositions - The present invention is directed to anti-hypertensive compositions comprising a nanoparticulate temocapril, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate temocapril particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of hypertension and related diseases.02-04-2010
20100021548USE OF MICROPARTICLES WITH ADSORBED ANTIGEN TO STIMULATE IMMUNE RESPONSES - The use of poly(lactide) or poly(lactide-co-glycolide) microparticles with adsorbed antigen is disclosed. The microparticles are useful for enhancing CTL responses to a selected antigen.01-28-2010
20100021546CONTROLLED-RELEASE IMMUNOGENIC FORMULATIONS TO MODULATE IMMUNE RESPONSE - Single-dose controlled-release immunogenic formulations, such as vaccines, based on bioerodible polyanhydride copolymer or homopolymer microparticles for the control of immune response mechanisms are provided. The copolymer or homopolymer microparticles degrade by surface-erosion from in vivo hydrolysis of anhydride linkages at the surface of the microparticle, which results in controlled release of immunogen(s) to a patient.01-28-2010
20080274195Compositions and Methods for Making and Using Nanoemulsions - The present invention discloses an improved nanoemulsion comprising a uniform and discrete range of very small particle nano-sized diameters. This uniformity results in improved bioavailability of incorporated compounds (i.e., pharmaceuticals or nutraceuticals) as reflected in various pharmacokinetic parameters including, but not limited to, decreased T11-06-2008
20080220076Active Agent Formulations, Methods of Making, and Methods of Use - Active agent compositions comprising active agent particles having an effective average particle size of less than 2000 nm, wherein the compositions comprise a particle sequestrant are disclosed. Compositions having an effective average particle size of less than 2000 nm, wherein the compositions comprise no added surfactants, phospholipids, or combinations thereof, are also disclosed.09-11-2008
20080241252METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS - Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include TKI component solutions or particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps.10-02-2008
20090074872Active Agent Formulations, Methods of Making, and Methods of Use - Stable fenofibrate suspensions are disclosed herein. A fenofibrate composition includes fenofibrate nanoparticles having an average particle size of less than 500 nm, and a particle sequestrant, wherein the average particle size of the nanoparticulate suspension changes by less than 50% after standing at room temperature for 21 or more days.03-19-2009
20110097413SOLID STATE FORMS OF DEFERASIROX SALTS AND PROCESS FOR THE PREPARATION THEREOF - Provided herein are novel solid state forms of deferasirox salts, process for the preparation, pharmaceutical compositions, and method of treating thereof. The solid state forms of deferasirox salts are useful for preparing deferasirox (I) in high purity.04-28-2011
20090252801Process for the Preparation of Micronised Sterile Steroids - The present invention relates to a process for the preparation of micronised sterile steroids, comprising sterilisation of the steroids in crystalline form by means of irradiation with gamma or beta rays, and subsequent sterile micronisation.10-08-2009
20090324726Non-Viral Gene Therapy Using Chitosan-Containing Nanoparticles - The present invention concerns a new drug delivery system and more particularly, a non-viral drug delivery system comprising a polymer according to the following formula and useful for treating a disease characterized by over-expression of folic acid receptors on the cell surface.12-31-2009
20100068286Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.03-18-2010
20090202645INTRASYNOVIAL FORMULATIONS OF STANOZOLOL - Disclosed are intrasynovial formulations comprising stanozolol and a suitable carrier.08-13-2009
20080311210PHARMACEUTICAL COMPOSITION FOR USE AS A LAXATIVE - The invention relates to a pharmaceutical composition which is suitable in particular for use as purgative (cathartic), where the composition comprises in combination and in each case in pharmaceutically effective amounts (A) senna fruit dry extract and (B) plantago seeds (12-18-2008
20090155367Occlusion of Fallopian Tubes - The present invention provides a method for inducing Fallopian tube blockage as a means for female contraception. The method comprises contacting the inner surface tissue of a Fallopian tube with a silver nitrate bearing substrate, delivering an amount of silver nitrate to the tissue sufficient to induce blockage of the Fallopian tube. Preferably, the substrate is a bead. In one embodiment, at least one silver nitrate bearing bead is introduced through the uterine opening of the Fallopian tube by use of a catheter or other device suitable for manipulating the bead. Alternatively, a plurality of beads can be introduced into the Fallopian tube. In a preferred embodiment, one or more silver nitrate bearing beads are arranged on a string to facilitate later removal of the beads. The method of the present invention delivers an amount of silver nitrate to the tissue sufficient to cause tissue necrosis and blockage of the Fallopian tube. The silver nitrate is delivered to the tissue by the substrate in a controlled and localized manner.06-18-2009
20080241256TARGETED ACTIVE AGENT DELIVERY SYSTEM BASED ON CALCIUM PHOSPHATE NANOPARTICLES - Calcium phosphate nanoparticle active agent conjugates are described. Specifically, anticancer agent conjugates are prepared which are suitable for targeted active agent delivery to tumor cells and lymphatics for the treatment of cancer and the treatment or prevention of cancer metastasis.10-02-2008
20100196489BONE GROWTH PARTICLES AND OSTEOINDUCTIVE COMPOSITION THEREOF - A biocompatible synthetic bone growth composition comprising a fibrillar collagen component and a calcium phosphate component. The composition is formed into particles, and then formed into a unitary article that may be provided at the site of a skeletal defect. An osteoinductive component may be further added, either before or after forming the unitary article. The composition may be formulated as a paste or putty and facilitates bone growth and/or repair.08-05-2010
20090028951Compositions for Oral Administration of Sustained Release Glutathione, Methods for Their Production and Uses Thereof - A composition suitable for oral administration for sustained-release of glutathione, the composition having from about 50% by weight to about 90% by weight glutathione; from about 0% by weight to about 10% by weight binder; from about 10% by weight to about 50% by weight of at least one sustained release agent; and a granule size of from about 850 μm to about 5000 μm, is provided. Methods for preparing such compositions are also provided. Uses and methods of medical treatment by orally administering a composition for sustained release of glutathione to a patient suffering from or at risk of suffering from a neurological disorder are also provided.01-29-2009
20090238879DELIVERY SCAFFOLDS AND RELATED METHODS OF USE - The present invention relates to delivery systems. In particular, the present invention provides microporous scaffolds having thereon agents (e.g., extracellular matrix proteins, exendin-4) and biological material (e.g., pancreatic islet cells). In some embodiments, the scaffolds are used for transplanting biological material into a subject. In some embodiments, the scaffolds are used in the treatment of diseases (e.g., type 1 diabetes), and related methods (e.g., diagnostic methods, research methods, drug screening).09-24-2009
20090258070Topical LFA-1 antagonists for use in localized treatment of immune related disorders - This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for topical delivery. In particular, the LFA-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders using the LFA-1 topical formulations of the present invention.10-15-2009
20100297241Amorphous Fesoterodine Fumarate - The present invention provides a novel amorphous form of fesoterodine fumarate, process for preparation, pharmaceutical compositions, and method of treating thereof.11-25-2010
20100062072Method for the delivery of a biologically active agent - A method of manufacturing a stable nanosuspension for delivery of a biologically active agent into the bloodstream of a subject is disclosed. A microfluidizable mixture is initially formed and processed via a microfluidization process to form the stable nanosuspension, which may be administered via the buccal mucosa or other suitable routes of administration. This product demonstrates increased bioavailability, enhanced period of onset, and enhanced stability for a controlled-release product.03-11-2010
20080248118METHOD AND COMPOSITION FOR INHIBITING REPERFUSION INJURY IN THE BRAIN - The present invention relates to a method for inhibiting reperfusion injury in the brain. The method involve injecting via the carotid artery or jugular vein an antioxidant-loaded nanoparticle. A nanoparticle formulation containing an inert plasticizer is also provided for sustained release of an active agent.10-09-2008
20100015236PESTICIDE NANOPARTICLES OBTAINED FROM MICROEMULSIONS AND NANOEMULSIONS - The present invention provides a redispersible powder and aqueous dispersions of nanoparticles of water insoluble organic pesticides. The invention further provides methods for preparing the redispersible powder and the aqueous dispersion, wherein the methods include preparation of an oil-in-water nanoemulsion or microemulsion and solvent removal. The present invention also provides pesticidal compositions of the redispersible powder or aqueous dispersions, and their agricultural use in combating pests.01-21-2010
20100008993Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs - An ophthalmic composition comprises an ophthalmic drug that has a low solubility in water and a surfactant, wherein the ophthalmic drug is present at a concentration from about 3 to about 7000 times the solubility of the drug in water. A volume of about 1-15 microliter is administered topically to an eye of a subject to treat or control a condition for which the drug is effective.01-14-2010
20090280185Particulate wood preservative and method for producing the same - A wood preservative includes injectable particles comprising one or more sparingly soluble copper salts. The copper-based particles are sufficiently insoluble so as to not be easily removed by leaching but are sufficiently soluble to exhibit toxicity to primary organisms primarily responsible for the decay of the wood. Exemplary particles contain for example copper hydroxide, basic copper carbonate, copper carbonate, basic copper sulfates including particularly tribasic copper sulfate, basic copper nitrates, copper oxychlorides, copper borates, basic copper borates, and mixtures thereof. The particles typically have a size distribution in which at least 50% of particles have a diameter smaller than 0.25 μm, 0.2 μm, or 0.15 μm. At least about 20% and even more than 75% of the weight of the particles may be composed of the substantially crystalline copper salt. Wood or a wood product may be impregnated with copper based particles of the invention.11-12-2009
20100136118CALCIUM ABSORPTION ENHANCER - The present invention provides a calcium absorption enhancer that places no burden on the body of a human or a domestic animal to which a calcium compound is administered and can increase the efficiency with which a calcium content is absorbed into the body by supplying calcium ions in the stomach or the like of the human or the domestic animal in a sustained-release manner after administration of the calcium compound. The calcium absorption enhancer of the present invention contains, as an active ingredient, water-soluble calcium particles that can release calcium ions in an aqueous solution in a sustained-release manner.06-03-2010
20100151032Silver and Zinc Containing Body Care Agent - The invention relates to a body care agent containing metal particles which release zinc and silver ions in said body care agent by contacting body liquid or body humidity and whose metallic silver content at least equal or greater than 99 % (m/m).06-17-2010
20110117201COMPOSITION FOR TREATMENT OF WATER - The invention relates to a composition for treatment of water comprising rice husk ash and at least one bactericidal agent bonded to the rice husk ash. The bactericidal agent bonded to the rice husk ash is preferably silver and more particularly the bactericidal agent is nano silver. The invention also relates to a method of water purification using a composition comprising rice husk ash and at least one bactericidal agent bonded to the rice husk ash.05-19-2011
20090028948NANOPARTICLE COMPOSITION AND METHODS OF SYNTHESIS THEREOF - The present invention relates to improved therapeutically active nanocomposite microstructure compositions, including nanoparticle compositions and nanoparticle preparations. Preferred embodiments include nanoparticle compositions comprising nanoparticles of a therapeutically active agent dispersed in a carrier matrix. The invention also relates to a method for preparing said compositions and preparations using solid-state mechanochemical synthesis. Further, it relates to therapeutic products produced using said compositions and to methods of treatment using the compositions.01-29-2009
20090104269Nanoformulations - Methods, and the products thereof, for producing nanoparticles that in some embodiments are at least partially encapsulated by an encapsulant; and methods, and products thereof, for producing nanoformulations that are suspensions of nanoparticles in a liquid formulation. Typically the nanoparticles include agrochemicals, pharmaceuticals, catalysts, and other active ingredients.04-23-2009
20080220069Long Acting Injectable Crystal Formulations of Estradiol Metabolites and Methods of Using Same - The present invention provides sustained release formulations of estradiol metabolites whereby the in vivo pharmacokinetics are manipulated by a method selected from the group consisting of chemical modification, crystal packing formation, particle size or a combination thereof. Such compositions are useful in the long-term treatment of a wide variety of diseases.09-11-2008
20090252803GLYCYRRHETINIC ACID-MEDIATED NANOPARTICLES OF HEPATIC TARGETED DRUG DELIVERY SYSTEM, PROCESS FOR PREPARING THE SAME AND USE THEREOF - Disclosed are a hepatic targeted drug delivery system and a process for preparing the same. Also disclosed is a method for treating liver cancer.10-08-2009
20090068273Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases - The invention provides inhalation devices comprising a compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; or a salt or solvate thereof, inhalation devices comprising formulations and combinations of the compound or a salt or solvate thereof, and methods for the treatment or prophylaxis of a clinical condition in a mammal by employing the inhalation devices03-12-2009
20080213374NANOPARTICULATE SORAFENIB FORMULATIONS - The present invention is directed to compositions comprising a nanoparticulate sorafenib, or a salt, such as a sorafenib tosylate, or derivative thereof, having improved bioavailability. The nanoparticulate sorafenib particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of cancer, renal cancer, and related diseases.09-04-2008
20090238878Solid Nanoparticle Formulation of Water Insoluble Pharmaceutical Substances With Reduced Ostwald Ripening - The present invention belongs to the fields of pharmacology, medicine and medicinal chemistry. The present invention provides novel pharmaceutical compositions composed of solid nanoparticles dispersed in aqueous medium of substantially water insoluble pharmaceutical substances such as docetaxel with reduced Ostwald ripening.09-24-2009
20110045079DRY POWDERS OF CELLULAR MATERIAL - Methods and compositions of spray drying cellular material are provided that allow preservation of the cellular material. In one aspect, the cellular material is spray dried with a quantity of excipient. In another aspect, the cellular material is spray dried using a cryoprotectant.02-24-2011
20100226992Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye - The present invention relates to development of efficacious pharmaceutical compositions in the form of intraocular suspensions comprising an anti-angiogenic compound in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000, preferably at least 3000.09-09-2010
20100183728NANOPARTICLE COMPRISING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENT - The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.07-22-2010
20110305763LANTIBIOTICS AND USES THEREOF - The present invention provides isolated lantibiotics that inhibit. Gram negative and Gram positive microbes. The antibiotic includes an amino acid sequence, wherein the amino acid sequence of the compound and the amino acid sequence of SEQ ID NO:21 or SEQ ID NO:22 have at least 80% identity. The lantibiotics have the characteristic of inhibiting growth of a Gram negative microbe in conditions that do not damage the outer membrane of the Gram negative microbe. The present invention also provides methods for making and using the lantibiotics.12-15-2011
20110305762PHARMACEUTICAL COMPOSITION COMPRISING N-[3-CHLORO-4-[(3-FLUOROPHENYL)METHOXY]PHENYL]-6-[5[[[2-(METHYLSULFONYL)E- THYL]AMINO]METHYL]-2-FURYL]-4- QUINAZOLINAMINE - The present invention relates to a pharmaceutical composition comprising N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine as active pharmaceutical ingredient and a process of preparing such composition.12-15-2011
20110305761POLYMERSOMES, COLLOIDOSOMES, LIPOSOMES, AND OTHER SPECIES ASSOCIATED WITH FLUIDIC DROPLETS - The present invention relates generally to vesicles such as liposomes, colloidosomes, and polymersomes, as well as techniques for making and using such vesicles. In some cases, the vesicles may be at least partially biocompatible and/or biodegradable. The vesicles may be formed, according to one aspect, by forming a multiple emulsion comprising a first droplet surrounded by a second droplet, which in turn is surrounded by a third fluid, where the second droplet comprises lipids and/or polymers, and removing fluid from the second droplet, e.g., through evaporation or diffusion, until a vesicle is formed. In certain aspects, the size of the vesicle may be controlled, e.g., through osmolarity, and in certain embodiments, the vesicle may be ruptured through a change in osmolarity. In some cases, the vesicle may contain other species, such as fluorescent molecules, microparticles, pharmaceutical agents, etc., which may be released upon rupture. Yet other aspects of the invention are generally directed to methods of making such vesicles, kits involving such vesicles, or the like.12-15-2011
20090324728PHARMACEUTICAL COMPOSITIONS COMPRISING AMORPHOUS BENZIMIDAZOLE COMPOUNDS - Compositions comprising amorphous substituted benzimidazole compounds.12-31-2009
20100323021ANTITUMORAL TREATMENTS - The present invention relates to colloidal metal nanoparticles conjugated with Kahalalide F, or an analogue thereof, and their use in the treatment of cancer. The invention also relates to a method for increasing the antitumoral activity of Kahalalide F, or an analogue thereof, which comprises conjugating the Kahalalide F, on an analogue thereof, with a colloidal metal nanoparticle.12-23-2010
20090136580PREFERENTIAL KILLING OF CANCER CELLS AND ACTIVATED HUMAN T CELLS USING ZnO NANOPARTICLES - Here we disclose the response of normal human cells to ZnO nanoparticles under different signaling environments and compare it to the response of cancerous cells. ZnO nanoparticles exhibit a strong preferential ability to kill cancerous T cells (˜28-35X) compared to normal cells. Interestingly, the activation state of the cell contributes toward nanoparticle toxicity as resting T cells display a relative resistance while cells stimulated through the T cell receptor and CD28 costimulatory pathway show greater toxicity in direct relation to the level of activation. The novel findings of cell selective toxicity towards potential disease causing cells indicate a potential utility of ZnO nanoparticle in the treatment of cancer and/or autoimmunity.05-28-2009
20090022806Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof - Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.01-22-2009
20090148530METHOD FOR PREVENTION AND TREATMENT OF REFLUX INJURY IN THE AERODIGESTIVE TRACT AND LARYNGOPHARYNX CAUSED BY PEPSIN - A method for treating or preventing disorders, diseases, and symptom of reflux, that is laryngopharyngeal reflux (LPR), in the laryngopharynx caused by pepsin comprises orally administering to the laryngopharynx of a patient an effective amount of cellulose powder. A method for treating or preventing damage to the lining membranes of at least some of the aerodigestive tract, the damage caused by pepsin, comprises coating at least some of the lining membranes with an effective amount of a cellulose powder. Upon inhalation of the powder, the powder coats the lining membranes. Upon coating the lining membranes, the powder becomes a gel. The gel prevents the pepsin from binding with the lining membranes, thereby preventing damage caused by pepsin in laryngopharyngeal reflux or in extra-esophageal reflux.06-11-2009
20100330185ACTIVE INGREDIENT FORMULATIONS CONTAINING 2-THIAZOLE-4YL-1H-BENZOIMIDAZOL (THIABEN-DAZOLE OR TBZ) FOR THE PRODUCTION OF WPC - Use of a biocidal mixture containing IPBC and TBZ for protecting wood-plastic composites (WPC), containing thermoplastic polymer and wood particles, from attack and/or destruction by microorganisms.12-30-2010
20090258071COMPOSITIONS AND METHODS FOR PH TARGETED DRUG DELIVERY - The invention provides compositions and methods for the targeted, in particular, pH targeted, delivery of pharmaceutically active agents in mammals. The compositions comprise pH sensitive diblock copolymers, which permit the release of the pharmaceutically active agent when exposed to an environment having a particular pH. The compositions are particularly useful for the oral delivery of water insoluble pharmaceutically active agents.10-15-2009
20090214659MINERAL COMPOSITION - The invention relates to a mineral composition for improving well-being and fitness of living beings in general as well as in the presence of equipment emitting non-ionising electromagnetic radiation, comprising a layered phyllosilicate comprising paramagnetic ions and having a conductivity, measured in non-conductive water at a concentration of 1 wt. % of the mineral clay composition relative to the total weight of the non-conductive water and the mineral clay composition, of at most 20 μS/cm.08-27-2009
20100226991SOLID INORGANIC/ORGANIC HYBRID WITH MODIFIED SURFACE - The invention relates to solid organometallic hybrids with modified surface. Said solid may be used for example for the encapsulation and vectoring of molecules of interest such as active pharmaceutical agents, compounds of interest in cosmetics and markers, for example, contrast agents. Said solids show good results in terms of loading capacity in medicament agents and in biocompatibility.09-09-2010
20130011480CYTOTOXIC THERAPY BY PROTON FLUX MODULATION - Compositions and methods for treating cancer are described. Some of the methods include administering to a cancer patient in need thereof a substance, such as a carbonic anhydrase inhibitor, that at a therapeutic dose produces a metabolic acidosis in humans; and administering to the patient at least one of: (a) a monocarboxylate transport inhibitor; (b) a sodium-hydrogen exchange inhibitor; (c) a chloride-bicarbonate exchange inhibitor; or (d) a proton pump inhibitor; wherein the at least one of (a) through (d) is in an amount effective to induce selective cytotoxicity in cancer cells relative to noncancerous cells in humans.01-10-2013
20120040004TREATMENT OF RADIATION-INDUCED FIBROSIS - The present invention relates to treatment or prevention of radiation induced fibrosis using TNF-alpha antagonism. Preferably, TNF-alpha is antagonized by direct binding or by inhibition of synthesis. In a preferred embodiment, the invention comprises intraperitoneal administration of a chitosan-siRNA nanoparticle, wherein the siRNA is targeted to the mRNA encoding TNF-alpha.02-16-2012
20110033545TOPICAL PHARMACEUTICAL PREPARATIONS HAVING BOTH A NANOPARTICLE SOLUTION AND A NANOPARTICLE SUSPENSION AND METHODS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN THEREWITH - This invention relates to topical pharmaceutical preparations and methods for the treatment of acute and chronic pain and inflammation therewith. The preparations have a saturated solution of an active pharmaceutical ingredient in a solvent therefor in intimate combination and contact with a suspension of nanoparticles of the active pharmaceutical ingredient in the solvent, and a pharmaceutically acceptable carrier therefor, and are administered topically.02-10-2011
20120040003ANTI-DANDRUFF COMPOSITIONS WITH CITRUS FIBERS - A shampoo composition is described which includes from 1 to 25% by weight of mild surfactants, from 0.001 to 5% by weight of citrus fibers, from 0.01 to 5% by weight of anti-dandruff zinc salts, and a cosmetically acceptable carrier. The citrus fibers help structure the composition to maintain phase stability, provide appropriate viscosity and achieve deposition of the anti-dandruff zinc salts.02-16-2012
20090104268Nanoparticles Comprising Antigens and Adjuvants, and Immunogenic Structures - Nanoparticles comprising adjuvants and antigens, such as tumour and pathogen antigens, are disclosed and their use in a range of applications such as for the treatment of cancer and infectious diseases. Immunogenic structures based on nanoparticles or antibodies with carbohydrate ligands, and their use for therapeutic and prophylactic purposes, and for the isolation and detection of antibodies directed against the carbohydrate structures.04-23-2009
20120148676ARTIFICIAL CELL CONSTRUCTS FOR CELLULAR MANIPULATION - The present invention contemplates induction of immunological tolerance thereby providing permanent allogcaft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive agents which can increase the risk of infection, autoimmunity, and cancer. Immunological tolerance is thought to be mediated by regulatory T lymphocytes (T06-14-2012
20120148675TESTOSTERONE UNDECANOATE COMPOSITIONS - The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier.06-14-2012
20100323020STABLE NANOPARTICULATE DRUG SUSPENSION - A liquid pharmaceutical composition comprises an aqueous medium having suspended therein a solid particulate Bc1-2 family protein inhibitory compound such as ABT-263, having a D12-23-2010
20090068272MESOPOROUS CALCIUM SILICATE COMPOSITIONS AND METHODS FOR SYNTHESIS OF MESOPOROUS CALCIUM SILICATE FOR CONTROLLED RELEASE OF BIOACTIVE AGENTS - Mesoporous calcium silicate compositions for controlled release of bioactive agents and methods for producing such compositions are disclosed herein. In one embodiment, mesoporous calcium silicate is synthesized by acid modification of wollastonite particles using hydrochloric acid. A hydrated silica gel layer having abundant Si—OH functional groups can be formed on the surface of wollastonite after acid modification. Bruhauer-Emmett-Teller (BET) surface area increased significantly due to acid modification and, in one arrangement, reached over 350 m03-12-2009
20080220077MICROSPHERES FOR ACTIVE EMBOLIZATION - The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions.09-11-2008
20080220075Nanoparticulate compositions of angiogenesis inhibitors - Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.09-11-2008
20080220070Controlled release system and manufacturing method thereof - A controlled release system and manufacturing method thereof. The method comprises providing a first aqueous solution containing a hydrophilic drug and an alkaline agent, providing an organic solution containing a hydrophobic molecule, providing a second aqueous solution containing a hydrophilic surfactant, mixing the first hydrophilic solution with the organic solution to form a first emulsion, and mixing the first emulsion with a second aqueous solution to form a second emulsion containing delayed-release microsphere.09-11-2008
20110020455SOLID DISPERSION AND PHARMACEUTICAL COMPOSITION OF THE SAME, AND PRODUCTION PROCESSES THEREOF - A powdery porous carrier comprising a porous silicon-containing carrier is impregnated with a solution containing an organic solvent and an active ingredient hardly soluble in water, and the organic solvent is removed to give a solid dispersion having the active ingredient supported to the porous carrier without a treatment with a supercritical fluid. The porous silicon-containing carrier has a heating loss of not more than 4% by weight at a temperature of 950° C. for 2 hours (e.g., a spherical silicon-containing carrier such as a spherical porous silica). The porous silicon-containing carrier may be a spherical silica having a mean pore size of 10 to 40 nm and an oil absorption of 175 to 500 ml/100 g. A pharmaceutical composition (e.g., tablets, granules, or capsules) may be prepared from the solid dispersion and a pharmaceutically acceptable carrier. This invention provides a solid dispersion and a pharmaceutical composition (or a pharmaceutical preparation) which allows improvement in a solubility and a bioavailability of an active ingredient hardly soluble in water (e.g., a fibrate compound).01-27-2011
20110064812Oral Solid Dosage Form Containing Nanoparticles and Process of Formulating the Same Using Fish Gelatin - An oral solid dosage form containing nanoparticles is made by (a) reducing the particle size of at least one pharmaceutically active ingredient dispersed in a solution containing fish gelatin to form a nanosuspension and (b) freeze-drying the nanosuspension of step (a) to form the oral solid dosage form.03-17-2011
20110064816ATORVASTATIN COMPOSITIONS - Compositions containing atorvastatin, including its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, polymorphs and their mixtures, and processes for preparing the same. Further aspects relate to pharmaceutical formulations comprising compositions containing atorvastatin, or a salt thereof, processes for preparing the same, and their methods of use, treatment and administration.03-17-2011
20110064813USE OF SALSALATE WITH OR WITHOUT CAFFEINE AND WITH OR WITHOUT OMEGA 3, AND OTHER PHARMACEUTICAL COMPOUNDS IN A DISTINCTIVELY UNIQUE NANO-PARTICULATE CAPSULE AND TABLET - The invention relates to a compound and administration of the compound to mammals containing salsalate in a nanofied form to reduce inflammation. This compound and administration may be combined with caffeine, omega 3 fatty acids, sodium bicarbonate, and/or simvastatin to further benefit that administration.03-17-2011
20110064815SILICIA FOR THE INHINITION OF A PROTEASE - There is provided a silica for use to inhibit a protease. In particular there is provided a silica for treatment or prevention of a disease or condition associated with adverse protease activity or adverse proteolytic degradation within the gastrointestinal tract.03-17-2011
20110064814STABLE PHARMACEUTICAL PRODUCTS - Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide.03-17-2011
20110064811Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide - The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.03-17-2011
20110318418COMPOSITIONS OF 5-ETHYL-2--PYRIMIDINE - This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.12-29-2011
20110318420FULVESTRANT NANOSPHERE/MICROSPHERE AND PREPARATIVE METHOD AND USE THEREOF - Fulvestrant nanosphere/microsphere and preparation method and use thereof are provided in the present invention. The carrier material of the fulvestrant nanosphere/microsphere is methoxy ended polyethylene glycol-polylactic acid block copolymer. The nanosphere/microsphere is prepared by solvent-nonsolvent method, in-liquid drying method and/or spray drying method, and has the features of high drug loading and high encapsulation efficiency, controllable release of medicine and no irritant to application site or blood vessel. The fulvestrant nanosphere/microsphere can be used to treat metastatic advanced breast cancer in post-menopausal woman.12-29-2011
20110318419GRAFT MATERIALS CONTAINING BIOACTIVE SUBSTANCES, AND METHODS FOR THEIR MANUFACTURE - Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.12-29-2011
20110318417HIGHLY PURE CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - Provided herein are impurities of cinacalcet, (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-(5,6,7,8-tetrahydronaphthalene)methaneamine (tetrahydro cinacalcet impurity), (R)-α-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethaneamine-N-oxide (cinacalcet N-oxide impurity) and (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]methyl]-1-naphthalenemethaneamine (benzylamine impurity); and processes for preparation and isolation thereof. Provided further herein is a highly pure cinacalcet or a pharmaceutically acceptable salt thereof substantially free of impurities, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure cinacalcet or a pharmaceutically acceptable salt thereof substantially free of impurities.12-29-2011
20120045514ANTI-CANCER MICROPARTICLE - The present invention relates to a microparticle and its use. The microparticle has a width of at least about 1 micron. The microparticle includes a biocompatible polymer, a nanoparticle, and an anti-cancer agent.02-23-2012
20090087492Processes and Apparatuses for the Production of Crystalline Organic Microparticle Compositions by Micro-Milling and Crystallization on Micro-Seed and Their Use - The present invention relates to a process, for the production of crystalline particles of an active organic compound The process includes the steps of generating a micro-seed by a wet-milling process and subjecting the micro-seed to a crystallization process. The resulting crystalline particles have a mean particle size of less than about 100 μm. The present invention also provides for a pharmaceutical composition which includes the crystalline particles produced by the method described herein and a pharmaceutically acceptable carrier.04-02-2009
20120045515HOLLOW SILICA PARTICLE WITH A POLYMER THEREON - The present invention provides a hollow silica micro- or nanoparticle with a polymer immobilized thereon. The polymer is covalently linked to the silica particle via urethane groups. Provided is also a method of covalently coupling a polymer to a silica surface. The method comprises contacting a silica surface that carries amino functional groups with a polymer with a carbonate group of the general Formula (2). R02-23-2012
20120003318UNIT DOSES, AEROSOLS, KITS, AND METHODS FOR TREATING HEART CONDITIONS BY PULMONARY ADMINISTRATION - Methods of treating atrial arrhythmia include administering an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof, such that the at least one antiarrhythmic pharmaceutical agent first enters the heart through the pulmonary vein to the left atrium. Other methods of treating atrial arrhythmia include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. An amount of the at least one antiarrhythmic pharmaceutical agent may peak in the coronary sinus of the heart at a time ranging from 10 seconds to 30 minutes from initiation of the administering. Unit doses, aerosols, and kits are also contemplated.01-05-2012
20120003317STABLE PROBIOTIC GRANULATE, AND METHOD FOR PREPARING SAME - The invention pertains to the field of probiotic compositions useful for human and/or animal food and health. The invention particularly relates to compositions containing stable probiotic microorganisms during the production of tablets or granules for final use. The works of the applicant of the present invention show that the mortality of probiotic microorganisms during granulation is closely linked with granulation operating conditions and with the characteristics of the selected microorganisms. Said works have led to the establishment of a mathematical expression for defining both the characteristics of the yeast as well as the parameters of the method so that the microorganism losses after granulation are lower than 1 log CFU/g of granulated food.01-05-2012
20120064165TREATMENT OF TISSUE ADHESION - Dry powder compositions are useful in the treatment or prevention of tissue adhesions during or after surgery or during wound therapy. The dry powder compositions may contain trehalose. The dry powder compositions may be fibrin sealant compositions comprising fibrinogen and/or thrombin.03-15-2012
20100172993PARTICLES FOR DELIVERY OF ACTIVE INGREDIENTS, PROCESS OF MAKING AND COMPOSITIONS THEREOF - The present invention discloses compositions having particles comprising, inorganic element; one or more active ingredient and optionally a release rate modulating agent, suitable for the delivery of active ingredients to human and animal tissues. The particles are nanoparticles or microparticles or mixtures thereof, made preferably by sol-gel method. The compositions are useful for application to the topical or mucosal surfaces preferably in the form of creams, gels, lotions, dry powders, spray, foam and other suitable forms.07-08-2010
20090081297Use of surface tension reducing agents in aerosol formulations - The present disclosure describes aerosol formulations that are particularly effective for pulmonary aerosol delivery. The aerosol formulations comprise an aqueous dispersion of active agent particles, said aqueous dispersion having an excess of a surface tension reducing agent. As a result of the reduced surface tension of the aqueous dispersion, the resulting aerosol droplets formed have a particle size less in one embodiment of than 10 microns in size or in an alternate embodiment of less than 6 microns in size. The present disclosure also provides for a method for forming an aerosol from said aerosol formulation, a method of treating a mammal in need of said treatment using said aerosol formulation, and a method of diagnosing a mammal in need of such diagnosis using said aerosol formulation.03-26-2009
20080248120Aerosol Composition and Method - A method of dispensing periodic metered doses of a single phase aerosol composition wherein: the aerosol composition comprises a propellant and at least one active component selected from the group comprising fragrances, perfumes, air fresheners, deodorants and sanitisers; the metered dose spray rate is between 0.1 and 2 g/s of aerosol composition; and the mean particle size of each dose of the aerosol composition is between 1 μm and 40 μm.10-09-2008
20090220609PROCESS TO CONTROL PARTICLE SIZE - A multi-stage process to control the particle size of a pharmaceutical substance comprising the steps of: passing the pharmaceutical substance through a first stage of a particle size reduction process with a first set of particle size control parameters to obtain a feedstock of reduced median particle size and lesser distribution of median particle size for a second stage of a particle size reduction process; passing the feedstock, through a second stage of a particle size reduction process with a second set of particle size control parameters; optionally, using the product of the second stage or subsequent stages as a feedstock in further stages of a multi-stage particle size reduction process with a set of particle size control parameters for each stage; and collecting a pharmaceutical substance with a median particle size greater than 10 μm and with a narrow, reproducible distribution of median particle sizes.09-03-2009
20120207839Mineralized Collagen/Bioceramic Composite and Manufacturing Method Thereof - The present invention discloses a mineralized collagen/bioceramic composite useful as a hard tissue replacement material or substitute material, comprising about 10% to 95% by weight of mineralized collagen and about 5% to 90% by weight of bioceramics, and a method of manufacturing the same. Wherein, the mineralized collagen is used as a binder for the bioceramics, such as calcium phosphate ceramics, calcium sulfate ceramics, calcium carbonate ceramics, and other biocompatible ceramics. The bioceramic used in the mineralized collagen/bioceramic composite can be either in powder form or in granular form.08-16-2012
20120009264DRUG CARRIER FOR TREATING OF GASTROINTESTINAL ULCER - A drug carrier for treating of gastrointestinal ulcer comprises a microspheroid having a substrate and a plurality of particles distributed over and covered by the substrate, wherein the substrate is alginate and the plurality of particles is a drug for treating of gastrointestinal ulcer; and a coat covering up the surface of the microspheroid, which contains chitosan.01-12-2012
20120009265DRUG CARRIER - A drug carrier comprises a substance, a paramagnetic particle, a rod-shaped light-absorbing particle and a drug. The paramagnetic particle, the drug and the rod-shaped light-absorbing particle absorbing light and generating heat are provided in the substance.01-12-2012
20080279950NANO-PARTICLES COMPRISING CUCURBITURIL DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND PROCESS FOR THE PREPARATION THEREOF - Provided are nanoparticles prepared by the aggregation of cucurbituril derivatives and having a particle size of 1 to 1,000 nm, a pharmaceutical composition in which a pharmaceutically active substance is loaded into the nanoparticles, and preparation methods thereof.11-13-2008
20120015035Implantable Delivery Vehicle for Ocular Delivery of Muscarinic Antagonists - The present invention provides compositions and methods for treating ocular disorders such as myopia.01-19-2012
20080311211Easily Dispersible Lipidic Phase - The present invention relates to the use of a lipidic phase comprising an oil and a lipophilic additive (LPA), which is suitable to make an oil-in-water emulsion by application of low energy or a manual operation. The lipidic phase contains a Lipophilic Additive (LPA) which forms self-assembly structures inside the emulsion oil droplets. The aqueous phase contains a hydrophilic emulsifier and the lipidic and aqueous phases are mixed without using classical high shearing devices or homogenisers.12-18-2008
20100297242LDL-LIKE CATIONIC NANOPARTICLES FOR DELIVERYING NUCLEIC ACID GENE, METHOD FOR PREPARING THEREOF AND METHOD FOR DELIVERYING NUCLEIC ACID GENE USING THE SAME - Disclosed are a LDL-like cationic nanoparticle for delivering a nucleic acid gene with improved transfection efficiency and stability, which is surface modified and re-constructed by mimicking lipid components of a natural LDL, a method for preparation of the same, and a method for delivering nucleic acid genes using the same. The cationic nanoparticle of the present invention could effectively be applied in treatment of cancer that overexpress LDL receptors.11-25-2010
20090110737Orally Disintegrating Powder Comprising Cilostazol and Mannitol - The present invention provides an orally disintegrating powder comprising cilostazol as an active ingredient and mannitol in an amount of 70% by weight or more, which can be taken without water and can be disintegrated in oral cavity. Said powder is suitable for patients to whom cilostazol is applied, especially for aged patients and patients suffering from dysphagia.04-30-2009
20100291221Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation - Disclosed are methods, and related compositions, that include administering a dose-sparing amount of a formulation that includes inhalation particles to a subject by inhalation; wherein the inhalation particles comprise formoterol fumarate and budesonide, the formoterol fumarate and budesonide being in a distributed encapsulated morphology with respect to one another within said inhalation particles and the formoterol fumarate being in a predetermined mass ratio with regard to the budesonide within said inhalation particles.11-18-2010
20090061001SUNSCREEN AEROSOL SPRAY - A sunscreen formulation and a method of dispensing the sunscreen formulation is described in which the sunscreen formulation in the form of an emulsion includes one or more sunscreen agents and one or more propellants contained within an aerosol can such that the sunscreen composition is dispensed from the aerosol can by the propellant(s) in the form of a fine mist spray or fog allowing a uniform film of the sunscreen composition to be applied to the skin of a person to provide a uniform form of protection so as to overcome the harmful effects of the suns rays on the skin.03-05-2009
20120207838Treatment of Psoriasis Using Oral Dosage Forms of Nitrone Spin Traps - Psoriasis is treated by oral administration of a pharmaceutical composition containing a nitrone spin trap such as α-phenyl t-butyl nitrone (PBN) and derivatives thereof. Preferred compositions and method of treatments further comprise at least one adjunct ingredient including fatty acid esters of ascorbic acid such as ascorbyl palmitate and ascorbyl stearate. The pharmaceutical composition can be prepared as an immediate release formulation or controlled released formulations.08-16-2012
20090311327Oral Therapeutic Compound Delivery System - The present, invention provides an oral delivery system for a therapeutic compound that is an acid, a salt of an acid or an unionized compound or a proactive form thereof with pharmacological, physiological or biochemical activity. The present invention particularly provides a swallow formulation comprising a therapeutic compound that is an acid, a salt of an acid or an unionized compound or a proactive form thereof which facilitates the rapid delivery of the therapeutic compound to the circulatory system.12-17-2009
20120058188LIPID ENCAPSULATED INTERFERING RNA - The present invention provides compositions and methods for silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell.03-08-2012
20120207840Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment Of Non-Melanoma Skin Cancer - This invention relates to a transdermal delivery system for treating skin related diseases employing protein nanoparticles to deliver drugs to the keratinocytes and basal membrane cells for the treatment of non-melanoma skin cancer. The current invention presents an effective method for delivering small molecule nucleic acids to the epidermal cells.08-16-2012
20090274763IMMUNOADJUVANT - An immunoadjuvant comprising one kind or two or more kinds of immunostimulating substances carried separately by two or more kinds of different microparticle immunostimulating substance carriers, and comprising at least a combination of (a) an inorganic substance such as microparticle calcium phosphate having a size phagocytizable by cells, and (b) precipitates of a soluble protein and a mucopolysaccharide formed by coacervation as the microparticle immunostimulating substance carriers, which is highly safe and can exhibit potent immunoadjuvant activity.11-05-2009
20120156300MICROBUBBLES AND METHODS FOR OXYGEN DELIVERY - Compositions containing a carrier and microbubbles encapsulating one or more gases, preferably oxygen, and methods for making and using the compositions are described herein. The microbubbles contain a lipid envelope. The compositions may be administered to a patient to quickly deliver large amounts of oxygen to the patient's blood supply or directly to a tissue in need of oxygen. The compositions may be administered via injection or as a continuous infusion. The compositions contain a concentrated microbubble suspension, where the suspension contains at least 40 mL oxygen/dL suspension. The microbubbles are preferably less than 20 microns in diameter, more preferably less than 15 microns in diameter. The microbubbles described herein may be administered to a patient in an effective amount to increase in oxygen concentration in the patient's blood, and/or one or more tissues or organs.06-21-2012
20110091561PERFLUORCARBON NANOEMULSIONS WITH ENDOCYTOSIS ENHANCING SURFACE FOR GENE-TRANSFER - The present invention provides stable perfluorcarbon nanoemulsions with endocytosis enhancing surfaces that are suitable for gene-transfer, its production and use.04-21-2011
20110091559COMPOSITIONS COMPRISING ADJUVANT, MACROLIDE AND PROTEINACEOUS ANTIGEN AND METHODS OF USE THEREOF - The invention is directed to compositions comprising an oil adjuvant, a macrocyclic lactone effective for the prevention or control of parasitic infection in a warm-blooded animal and an immunizing amount of at least one immunogenic polypeptide and methods of use thereof.04-21-2011
20110091557COMPOSITE MATERIAL - The invention relates to a composite material, a precursor for forming the composite material and a method of forming the composite material from the precursor. The invention also relates to the use of said composite material and in particular to its use as an antibacterial or antimicrobial agent.04-21-2011
20100196488Pharmaceutical Formulation - The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.08-05-2010
20100291223TREATMENT FOR DERMATOLOGICAL CONDITIONS - A composition and method of using a composition containing kunzea oil for treating dermatological conditions in humans and animals, particularly greasy heel occurring in horses, in which the kunzea oil is formulated into a composition for topical application at ambient temperatures to the skin of the animal or human to cover the area of the affected lesions. Improvement in certain dermatological conditions such as pastern dermatitis in horses was noted almost immediately with total resolution of the condition in about 7 days. The composition can be used to treat humans suffering from psoriasis and similar dermatological conditions. This invention offers persons and animals suffering from dermatological conditions a low cost effective treatment based on a natural product which shows significant improvement of the condition within days of applying an effective amount of the composition to the affected area as part of the treatment.11-18-2010
20100291218IMMUNOMODULATORY COMPOSITIONS, FORMULATIONS, AND METHODS FOR USE THEREOF - The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMO/MC) complexes comprising 3-6mer immunomodulatory oligonucleotides. The IMO/MC complexes may be covalently or non-covalently bound. Also provided are immunomodulatory compositions comprising a 3-6mer IMO encapsulated in an MC.11-18-2010
20110104290COMPOSITIONS FOR REDUCING BLOOD GLUCOSE LEVEL AND USES THEREOF - A composition, its preparation and use for reducing the blood glucose level in a subject, comprising Radix Ginseng, Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae, Ginger, and one or more components selected from the group consisting of Tartarian Buckwheat, Rhizoma Phragmitis (05-05-2011
20110104287FENOLDOPAM FORMULATIONS AND PRO-DRUG DERIVATIVES - Formulations of fenoldopam are disclosed for repeated administration or continued slow release administration, over prolonged periods of time or targeted slow and regulated delivery. The formulations include those formulations that increase the bioavailability of fenoldopam after oral intake, particularly lipid based nano dispersions and pronanodispersions and surfactant rich formulations. This may be accomplished by entrapment in nanoparticles or liposomal formulations or conjugation to a polymer or small molecule via a soft bond.05-05-2011
20110104285PROCESS FOR THE MANUFACTURE OF A PHARMACEUTICAL PRODUCT - A process for the preparation of a pharmaceutical composition comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulphate and, optionally, saccharin sodium and/or orange flavour; products, intermediate products, and uses thereof.05-05-2011
20110104288Microcrystalline Cellulose and Calcium Phosphate Compositions Useful as Pharmaceutical Excipients - Coprocessed compositions containing calcium phosphate and microcrystalline cellulose are useful as excipients in the preparation of solid dosage forms containing active pharmaceutical ingredients, particularly those prepared by processes involving multiple compaction steps. Such compositions may be obtained by preparing aqueous slurries of microcrystalline cellulose and calcium phosphate and drying such slurries to produce particulate products. The coprocessed products exhibit improved compactibility, as compared to dry physical blends of the same components.05-05-2011
20100092567IMMUNOSTIMULATORY NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS - Provided herein are immunostimulatory nanolipoprotein particles and related compositions methods and systems.04-15-2010
20100092566Highly concentrated drug particles, formulations, suspensions and uses thereof - Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and/or small molecules (such as steroid hormones). The particle formulation typically further includes one or more additional component, for example, one or more stabilizer (e.g., carbohydrates, antioxidants, amino acids, and buffers). Such concentrated particle formulations can be combined with a suspension vehicle to form suspension formulations. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a highly concentrated drug particle formulation. Devices for delivering the suspension formulations and methods of use are also described. The present invention provides needed improvements in drug formulation and delivery to improve patient compliance and expand drug availability.04-15-2010
20100092565PHARMACEUTICAL COMPOSITION COMPRISING MICROPARTICLE OILY SUSPENSION - A pharmaceutical composition comprising a suspension of medicinally-active ingredient microparticles having a mean particle diameter of 20 μm or smaller in a base oil which can achieve extremely high intestinal absorption and bioavailability especially when the medicinally-active ingredient is hardly water-soluble.04-15-2010
20100092563Methods for the Preparation of Biologically Active Compounds in Nanoparticulate Form - A method for producing a composition comprising nanoparticles of a biologically active compound.04-15-2010
20120121711MICROSPHERE DRUG CARRIER, PREPARATION METHOD, COMPOSITION AND USE THEREOF - A nanosphere or microsphere drug carrier, formulations comprising the drug carrier and the preparation method of the formulations and the use of the carrier are disclosed. The carrier comprises a biodegradable methoxy end-capped polyethylene glycol-polylactide block copolymersor a derivative thereof represented by formula (I) as the main carrier material: CH05-17-2012
20120121707Tolbutamide Particle And Preparing Method Thereof And Method Of Reducing A Blood Glucose - A method for preparing a tolbutamide particle is provided. The method comprises steps of mixing a bulk drug of tolbutamide with a supercritical fluid to form a supercritical mixture; and expanding the supercritical mixture to obtain the tolbutamide particle.05-17-2012
20120121709PHASE TRANSITION BIOPOLYMERS AND METHODS OF USE - The present disclosure describes environmentally responsive polypeptides capable of displaying stimuli-triggered conformational changes in a reversible or irreversible manner that may be accompanied by aggregation. Polypeptides include a number of repeated motifs and may be elastomeric or non-elastomeric. The polypeptides may be used to deliver therapeutics to a biological site and to develop bioactive polypeptides that are environmentally responsive.05-17-2012
20090246284O-desmethylvenlafaxine Cocrystals - Disclosed herein are co-crystals comprising O-desmethylvenlafaxine and succinic acid, process for the preparation, pharmaceutical compositions, and method of treating thereof.10-01-2009
20100247658ORGANIC COMPOUNDS - A process for reducing the tendency of a drug substance to aggregate and/or agglomerate during storage. The process involves micronising the drug substance to give a mean particle size of less than about 10 μm, and exposing the micronised drug substance to a dry environment at an elevated temperature between 40° C. and 120° C. for at least six hours.09-30-2010
20100247657TELOMERASE REVERSE TRANSCRIPTASE VARIANT - The present invention relates to nucleic and amino acid sequences of a novel variant of the telomerase reverse transcriptase. More particularly, the present invention is directed to a novel variant of human telomerase reverse transcriptase, which displays properties distinct from those of wildtype telomerase reverse transcriptase, and methods of use thereof.09-30-2010
20100247655Synthesis of Small Particles - The invention provides an apparatus for forming fine particles of a substance in a precipitation chamber, in which the apparatus has means to convey the fine particles from the precipitation chamber to at least one particle collection chamber, downstream of the precipitation chamber, the particle collection chamber having an inlet and an outlet separate from the inlet. The invention also provides a method of forming fine particles of a substance, the method comprising contacting a non-gaseous fluid containing the substance with a dense fluid to expand the non-gaseous fluid in a precipitation chamber, conveying a resulting mixture of fluid and the fine particles from the precipitation chamber to a collection chamber, the collection chamber having an inlet and an outlet separate from the inlet.09-30-2010
20100247654STABLE MICELLES FORMED WITH DIBLOCK COPOLYMERS OF CRITICAL MICELLE CONCENTRATION COPOLYMER AND TEMPERATURE-SENSITIVE COPOLYMER - A novel class of mixed micelles formed with critical micelle concentration (Cmc) character's diblock copolymer, and temperature-sensitive character's diblock copolymer were disclosed. The mixed micelles possess complementary effects in adjusting external temperature shift (storage vs. body temperature) and concentration change (dilution after intravenous injection). The mixed micelles of the present invention can serve as a potential injectable drug delivery system for anticancer drugs, such as doxorubicin and many others.09-30-2010
20100247656Method for in situ Generation of Molecular Iodine on Mucus Membranes Using Nanoparticles - Nano-particles created using a biodegradable chemical backbone structure suitably designed to permit creation of at least two populations of nano-particles that contain chemical compositions. A first population of particles can contain iodide (I09-30-2010
20100247653NANOPARTICLES CONTAINING NICOTINE AND/OR COTININE, DISPERSIONS, AND USE THEREOF - The present invention relates to nanoparticles containing nicotine and/or cotinine. The present invention further relates to dispersions containing these nanoparticles. The invention relates in particular to corresponding novel transdermal pharmaceuticals containing nicotine and cotinine in nanoparticulate form, and use thereof for smoking cessation.09-30-2010
20090130214Gemcitabine derivatives nanoparticles - The invention concerns a 2′,2′-difluoro-2′-deoxycytidine derivative of general formula (I), wherein: R05-21-2009
20090130216MULTIMODAL PARTICULATE FORMULATIONS - Multimodal particulate formulations of medicaments and methods for their use, e.g. by nasal or pulmonary administration for the treatment of various medical conditions, are provided.05-21-2009
20090130215GRANULAR PREPARATION CONTAINING BIGUANIDE COMPOUND - A granular preparation containing a biguanide compound and a solidification-preventive agent does not solidify during storage and can avoid the difficulty in dosing.05-21-2009
20100086603COMPOSITION FOR PHOTOPROTECTION - The present invention relates to a method for improving the lifetime of compounds that are prone to photo-degradation by containing the compounds in microcapsules, which have light protecting particles bonded chemically to the capsule walls. In particular, the present invention relates to a microcapsule comprising a biologically active compound inside the microcapsule and light protecting particles which are chemically bonded to the microcapsule wall material; to the use of such a microcapsule; to a process for preparing such a microcapsule; and to surface-modified light protecting particles and their use in such a microcapsule.04-08-2010
20120128775BIOCARRIER AND METHOD OF USING THE SAME - The present invention discloses a biocarrier for delivery of a bioactive substance near/into a target cell, comprising a bioactive substance-loaded core with a first electricity, and one or more block copolymer, each block copolymer comprising a zwitterionic block and an anchoring block with an initial electricity opposite to the first electricity, wherein the anchoring block binds to the core by electrostatic attraction, and the zwitterionic block extends outwardly to increase the biocarrier stability in mammalian blood. Additionally, the present invention also discloses a method of using the biocarrier.05-24-2012
20120128776METHOD FOR THE PREPARATION OF MICROPARTICLES WITH EFFICIENT BIOACTIVE MOLECULE INCORPORATION - The present invention relates to relates to a method for the preparation of drug filled polymer microparticles comprising a gas core and shell, which particles are suitable as part of a therapeutic composition, especially for drug delivery. By using this method, polymeric microparticles are obtained that combine high incorporation efficiency for hydrophilic and/or hydrophobic drugs with a large, preferably hollow, core.05-24-2012
20120164229DEPOT SYSTEMS COMPRISING GLATIRAMER OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF - The present invention provides long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer. In particular, the present invention provides a long acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.06-28-2012
20120164228NOVEL PHARMACEUTICAL FORMULATIONS TO PREVENT THE MISUSE OF MEDICINAL DRUGS - Granules having a solid core on which an active ingredient is supported, the core being chosen preferably from among insoluble supports, the granules also having, supported on said the core, the following compounds: one or more colouring agents, one or more metallic pigments, one or more gas-releasing compounds, and optionally one or more embittering agents.06-28-2012
20120164226Compositions and Methods for Improving Prognosis of a Human with Subarachnoid Hemorrhage - The described invention provides a pharmaceutical composition, delivery system and a method for treating a delayed complication associated with a brain injury in a mammal and improving its prognosis in a mammal by implanting a therapeutically effective amount of the pharmaceutical composition containing a voltage-gated calcium channel blocker and a pharmaceutically acceptable carrier into a predetermined location in the brain, which reduces signs or symptoms of at least one delayed complication associated with brain injury.06-28-2012
20120164227NEW GRANULATING PROCESS AND THUS PREPARED GRANULATE - The present invention relates to a process for manufacturing microcrystalline ezetimibe containing granulate, wherein a) ezetimibe is dissolved; b) the dissolved ezetimibe is precipitated with water, which if necessary contains pharmaceutical excipients, preferably lauryl-sulfate derivatives, and c) granulates are formed from the obtained suspension by spraying the suspension onto pharmaceutical excipients. A further aspect of the present invention is the granulate obtained by the present process and the pharmaceutical composition containing such granulate.06-28-2012
20110182995MEDICAL AND DENTAL BIOMATERIAL AND METHOD OF USE FOR THE SAME - The embodiments herein provide a dental and medical biomaterial and its use for sealing and/or filling the tooth and bone cavities. In the embodiments herein, the calcium salt, calcium oxide, calcium silicate, and calcium phosphate compounds are mixed with a water-base solution, and a bioactive phosphate and calcium enriched mixture is prepared. The mixture comprises high concentration of water-soluble calcium and phosphate, and consequently forms hydroxyapatite during and after setting. The dental/medical biomaterial is biocompatible, antibacterial and capable of forming an effective seal against reentrance of microorganisms into the filled cavity. The biomaterial is compatible to handle and set in an aqueous environment and to stimulate soft/hard tissue healing/generation/regeneration.07-28-2011
20110182993FILM-FORM PREPARATION - An object of the present invention is to provide a film-form preparation to be used in desensitization therapy and a method for producing the same. This film-form preparation enables the patient to self-administer an allergen and adjust the dose, has excellent portability, has no residual sensation, provides excellent protection against accidental swallowing, is easy for a caregiver to administer, and can greatly improve the QOL of both patients and caregivers. Additionally, this film-form preparation enables arbitrary control of the dissolution time in the mouth, particularly sublingually and has very little gummy sensation in the mouth and better feeling when touched by the fingers. A film-form preparation including: an allergen; an edible polymer that is soluble in both water and a polar organic solvent; and one or two or more types of particles selected from the group consisting of monosaccharide to hexasaccharide sugars and sugar alcohols thereof that have an average particle size of 0.1 to 100 μm.07-28-2011
20110182992PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES ASSOCIATED WITH EYE DISEASE - This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of eye disease and/or other pathologies characterized by an inflammatory response, hi certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route or via intraocular injection.07-28-2011
20100310665BACTERIOSTATIC OR BACTERIOCIDAL COMPOSITIONS AND METHODS - Particular aspects provide compositions and methods for treating bacterial infection or at least one symptom related to bacterial infection in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically-altered fluid (including gas-enriched electrokinetically altered fluids) which comprise an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. The electrokinetically-altered ionic fluid compositions are sufficient to provide for modulation of intracellular signal transduction, wherein treating bacterial infection or at least one symptom related to bacterial infection is thereby afforded. In particular embodiments, the fluids are gas-enriched fluids or therapeutic compositions and methods, and include oxygen-enriched ionic aqueous solutions optionally in combination with other therapeutic agents. Other embodiments include particular routes of administration or formulations for the gas-enriched therapeutic compositions.12-09-2010
20100172995Process For Preparing A Solid Pharmaceutical Composition - The invention relates to a process for preparing a solid pharmaceutical composition of perindopril or a salt thereof which avoids a wet granulation step and results in very stable pharmaceutical compositions, like tablets.07-08-2010
20100172996Chain-End Functionalized Methoxy Poly(Ethylene Glycol) and Metal Nano-Particles Using the Same - Disclosed is a chain-end functionalized methoxy poly(ethylene glycol) (mPEG), a process of preparing the same, a living methoxy poly(ethylene glycol) for preparing the functionalized methoxy poly(ethylene glycol), a nano-particles of transition metal or metal salt encapsulated in the micelle structure formed by the chain-end functionalized methoxy poly(ethylene glycol), and a method for preparing the nano-particles of transition metal or metal salt.07-08-2010
20120171290HPV PARTICLES AND USES THEREOF - The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors.07-05-2012
20120213854METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS - Described herein are methods for treating a subject with combinations of polymer-agent particles and cyclodextrin polymer agent conjugates. The methods herein may be used to treat subjects identified with cancer, cardiovascular disorders, autoimmune disorders, or inflammatory disorders. Also described herein are compositions, dosage forms, and kits comprising polymer-agent particles and cyclodextrin polymer agent conjugates.08-23-2012
20120219630Treatment of Urinary Incontinence Using Nitrone Spin Traps - Urinary incontinence is treated by administration of pharmaceutical compositions containing at least one nitrone spin trap such as α-phenyl t-butyl nitrone (PBN) and derivatives thereof. Preferred compositions and methods of treatment further comprise at least one adjunctive ingredient including fatty acid esters of ascorbic acid such as ascorbyl palmitate and ascorbyl stearate, and polyenylphosphatidylcholine.08-30-2012
20100239675PLASMON MEDIATED PHOTOINDUCED SYNTHESIS OF SILVER TRIANGULAR BIPYRAMIDS - A method of preparing silver triangular bipyramids having a high shape selectivity and low edge length variation is disclosed. Also disclosed are silver triangular bipyramids prepared by this method.09-23-2010
20120076860COMPOSITIONS, METHODS, AND SYSTEMS RELATING TO CONTROLLED CRYSTALLIZATION AND/OR NUCLEATION OF MOLECULAR SPECIES - The present invention generally relates to compositions, methods, and systems relating to controlled crystallization and/or nucleation of a molecular species. In some embodiments, the crystallization and/or nucleation of the molecular species may be controlled by tuning the surface chemistry and/or the morphology of a crystallization substrate. In some embodiments, the molecular species is a small organic molecule (e.g., pharmaceutically active agent).03-29-2012
20100047354COMBRETUM LAURIFOLIUM MART. EXTRACT AND METHODS OF EXTRACTING AND USING SUCH EXTRACT - A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of 02-25-2010
20100028440DRYING OF DRUG-CONTAINING PARTICLES - A secondary drying process is disclosed for removing residual solvent from drug-containing particles that have been formed by solvent-based processes.02-04-2010
20120177741POSITIVELY-CHARGED POLY (D,L-LACTIDE-CO-GLYCOLIDE) NANOPARTICLES AND FABRICATION METHODS OF THE SAME - The present technology provides compositions with positively-charged poly(d,l-lactide-co-glycolide) nanoparticles capable of releasing a bioactive substance in a body tissue for extended periods of time, as well as methods for manufacture of the same and methods for prophylactic and therapeutic treatment of a subject in need thereof.07-12-2012
20120177740DRUG DELIVERY FORMULATION FOR CONTROLLING OF INITIAL BURST AND MANUFACTURING METHOD THEREOF - Provided is a drug delivery system for control of initial burst of a drug. More particularly, there are provided a drug delivery formulation including: a granule containing a biodegradable polymer and a drug; and a temperature-sensitive hydrogel, and a method for preparing the same. The presently disclosed drug delivery formulation can be prepared via a relatively simple process and allows a drug to be released slowly at a constant rate without initial burst and thus maintains a constant blood level of the drug for a long period of time. Consequently, it is capable of preventing the initial burst of the existing injection-type drug delivery formulations and slow-release granules and providing a desired release profile, including sustained release with time.07-12-2012
20100272815AMORPHOUS FORM OF TAPENTADOL HYDROCHLORIDE - Disclosed herein is a novel and stable amorphous form of tapentadol hydrochloride, a process for the preparation, pharmaceutical compositions, and a method of treating thereof. Disclosed also herein is a stable amorphous co-precipitate of tapentadol hydrochloride with pharmaceutically acceptable excipients, a method for the preparation, pharmaceutical compositions, and a method of treating thereof. Advantageously, the amorphous co-precipitates of tapentadol hydrochloride have improved physiochemical characteristics that assist in the effective bioavailability.10-28-2010
20100272814METHOD AND MEANS FOR PRODUCING BRONCHORELAXATION - A method of producing bronchorelaxation in the lungs of a human or animal affected by airway obstruction comprises administration of a pharmacologically effective amount to the body or to the intestine of said human or animal of an agent capable of binding mercury in elemental, ionic and/or organic form present in the body or in the intestinal lumen to enhance its excretion via the feces and/or the urine. A corresponding use of the agent and its use for the manufacture of a medicament are also disclosed.10-28-2010
20100272813NANOPARTICLE-MEDIATED TREATMENT FOR INFLAMMATORY DISEASES - The present invention provides nanoparticles for treatment of inflammatory diseases. The nanoparticles preferably comprise chitosan and a siRNA targeting a mRNA encoding a pro-inflammatory cytokine, such as e.g. tnf-alfa. A preferred route of administration of the nanoparticles is by injection intraperitoneally.10-28-2010
20100272811COMPLEX OF TROSPIUM AND PHARMACEUTICAL COMPOSITIONS THEREOF - The invention is directed to a complex of trospium and saccharin. In one embodiment, the complex is a crystalline form. In another embodiment, the complex is a monohydrate form. The invention also encompasses methods of preparing the the saccharin complex of trospium and to pharmaceutical compositions thereof.10-28-2010
20120225125Nanoparticles for Extravascular Administration - Disclosed are drug delivery systems and methods for extravascular administration of drug, vaccine, and/or diagnostic agents, for use in research and medical applications.09-06-2012
20110097410FORMULATIONS OF PX COMPOUNDS - Nanoparticles of PX compounds in the size range of 10 to 1000 nanometers are incorporated into formulations that are safe for intravenous administration and used to treat disease conditions caused by phospholipase A04-28-2011
20100008998SUBMICRON NANOPARTICLE OF POORLY WATER SOLUBLE CAMPTOTHECIN DERIVATIVES AND PROCESS FOR PREPARATION THEREOF - The present invention relates to a nanoparticle composition comprising a camptothecin derivative, solid polyethyleneglycol and an anti-associative agent, and the process for preparing the same. Specifically, the present invention provides a composition comprising a nanoparticle of the camptothecin derivative, which is prepared by solid-dispersing the poorly water soluble camptothecin derivative in polyethyleneglycol and dissolving the solid dispersions in an aqueous solution containing an anti-associative agent. The composition of the present invention stabilizes the camptothecin derivative lactone form in body fluid for effective anticancer activity.01-14-2010
20100008999COMPOSITIONS FOR ORAL ADMINSTRATION OF ACTIVE PRINCIPLES REQUIRING MASKING OF TASTE - Composition intended for the oral administration of active principles with unacceptable taste, which comprises from about 15% to about 30% of organoleptically unpleasant active ingredient (principle) that is mixed with from about 60% to about 80% of an ester of glycerol or of a fatty acid, to which a wax is optionally added and to which a surfactant is added, and in that it is prepared by a spray-cooling process which can produce a particle size of less than 350 μm.01-14-2010
20080241261 PROCESS FOR PRODUCING SOLID ORAL DOSAGE FORMS WITH SUSTAINED RELEASE OF ACTIVE INGREDIENT - The present invention relates to a process for producing solid oral dosage forms with sustained release of active ingredient, comprising at least one active ingredient, a preformulated mixture of polyvinyl acetate and polyvinylpyrrolidone, where appropriate, water-soluble polymers or lipophilic additives and, where appropriate, other conventional excipients, wherein this mixture or parts of this mixture are granulated by heating to from 40° C. to 130° C., and the granules are, after admixture with conventional excipients, subsequently tabletted.10-02-2008
20090291144Therapeutic and Prophylactic Compositions Including Catalytic Biomimetic Solids and Methods to Prepare and Use Them - The invention discloses therapeutic and prophylactic compositions based on synthetic solid catalysts such as zeolites, clays, silicates, silicas and double hydroxides. These solids can be used to treat numerous disease conditions such as diabetes, arthritis and other autoimmune diseases, cancer, skin diseases, microbial infections etc. The invention also describes methods to produce such products and use them independently or in combination with other pharmaceutically and biologically active ingredients. Such catalysts are designed so to imitate biological catalytic systems (enzymes, antigen presenting cells, delayed active component release, cell organeles, etc.) and are, therefore, biomimetic.11-26-2009
20100285138COMPOSITIONS COMPRISING NANOPARTICLES AND APOPTOTIC AGENTS AND METHODS OF USE - Compositions comprising nanoparticles, such as silver or gold nanoparticles or carbon nanotubes (CNTs), and apoptotic agents are described. The nanoparticles can significantly enhance the cancer chemotherapeutic effects of the apoptotic agents. In particular, a highly increased anti-tumor activity has been demonstrated for the combination of etoposide and CNTs against HeLa cells compared to the administration of either etoposide alone or nanoparticles alone. Data provided by flow cytometry, Caspase 3 and other methods, suggest a strong interaction between the nanoparticles and the cellular structure, which can result in the improved effectiveness of chemotherapeutic agents. These findings provide potential new cancer therapies by carefully selecting the right combination of cytostatic drugs and nanostructural materials which synergistically provide significantly greater curative rates.11-11-2010
20100285137ANTIBIOTIC/BONE MORPHOGENIC PROTEIN FORMULATION AND METHOD OF TREATMENT - A formulation comprised of particles which may be in groups and are comprised of a biocompatible polymer and an antimicrobial drug for controlled release of the drug is disclosed. The particles may be in an aqueous solution comprising thrombin and be dispersed in a gel. The formulation is administered to an area such as an open wound having an orthopedic implant therein and provides a therapeutically effective level of drug to the patient over therapeutically effective period of time.11-11-2010
20090061004Leave-In Hair Styling Product with Particles for Improving Hair Volume - The present invention relates to a leave-in hair styling product that improves the volume of a hair-do. More specifically, it relates to a leave-in composition in the form of aerosol mousse, pump mousse, gel, spray-gel, aerosol hairspray, pump spray, hair wax, hair styling cream or hair setting lotion. The leave-in compositions according to the present invention comprise solid particles of spherical, ellipsoid or oval shape and at least one film-forming ingredient.03-05-2009
20090061002CALCIUM PHOSPATE BASED DELIVERY OF GROWTH AND DIFFERENTIATION FACTORS TO COMPROMISED BONE - Resorbable calciumphosphate (CaP) based compositions comprising growth and differentiation factors (GDF) and their uses in bone regeneration and preventive treatment, in particular of osteoporotic bone, are disclosed.03-05-2009
20090061003CARRIERS FOR DRUG DELIVERY - The present invention relates to chemically bonded ceramic precursor material of aluminates and silicates exhibiting a controlled release rate and properties that make the material suitable as a carrier material used in drug delivery. According to the invention, this is accomplished by selecting a microstructure based on pre-reacted phases and/or reacting phases, which contains the drugs. The present invention also relates to a cured ceramic material and a method of manufacturing said cured material. The precursor and the cured ceramic material according to the present invention can suitably be used for different types of drug intake and delivery.03-05-2009
201002972401- [2- (2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT - 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT11-25-2010
20120082726SURFACE-TREATED MODAFINIL PARTICLES - The present invention is directed to solid oral dosage forms comprising surface-treated particles comprising modafinil particles and a hydrophilic treating agent, methods of making the same, and uses thereof.04-05-2012
20120082725Composition Comprising Immunogenic Microparticles - The invention provides an immunogenic composition comprising at least one antigen in association with microparticles, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting immune responses in a subject.04-05-2012
20120189700Nanoparticle Based Immunological Stimulation - A nanoparticle-based delivery system and methods for its use are disclosed. In one aspect, a nanoparticle-based delivery system comprising at least one molecule such as proteins, DNA/RNA or fragments thereof, carbohydrates, enzymes, chemicals, virus cells, bacteria, parts of a virus, parts of a bacteria, parts of a cell, part of a tissue, or a combination of one or more of these, which shall be referred to as immunogens, are chemically or physically combined with water soluble nanoparticles which, when administered to a living system, is capable of eliciting a desired immunological response. More particularly, the invention relates to nanoparticle-based delivery systems that are specifically engineered to enhance humoral or cellular immune response without the use of adjuvants.07-26-2012
20090017124Nucleic Acid Microparticles for Pulmonary Delivery - The present disclosure is related to microparticle compositions, in which the microparticles are made of nucleic acids and non-polymeric cations, which are suitable for administration to moist or aqueous target locations (e.g., the lung tissue), where the substantially spherical nucleic acid microparticles release the nucleic acids through dissolution, allowing the released nucleic acids to freely interact with the target cells.01-15-2009
20110123626PULMONARY DELIVERY OF A FLUOROQUINOLONE - A composition for pulmonary administration comprises a fluoroquinolone betaine, such as ciprofloxacin betaine, and an excipient. In one version, the particles have a mass median aerodynamic diameter from about 1 μm to about 5 μm, and the fluoroquinolone has a half life in the lungs of at least 1.5 hours. The composition is useful in treating an endobronchial infection, such as 05-26-2011
20080299207METHODS AND COMPOSITIONS FOR ADMINISTRATION OF OXYBUTYNIN - Administration of Oxybutynin in nebulized dry powder form directly to a patient's lungs for treating urinary incontinence or respiratory disease.12-04-2008
20080299205Particulate Constructs For Release of Active Agents - Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments.12-04-2008
20080299204Dosage forms for movement disorder treatment - The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug compositions and dosage forms comprising said drug composition. Another aspect of the invention relates to methods of manufacturing the drug compositions and dosage forms. Another aspect of the invention relates to methods of treatment, comprising administering the drug composition and dosage form to an individual.12-04-2008
20110003001BISMUTH-THIOLS AS ANTISEPTICS FOR EPITHELIAL TISSUES, ACUTE AND CHRONIC WOUNDS, BACTERIAL BIOFILMS AND OTHER INDICATIONS - Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.01-06-2011
20090317477COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A GLUCOCORTICOSTEROID FOR TREATMENT OF ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE OR ALLERGIC RHINITIS - A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a glucocorticosteroid for the treatment of asthma, chronic obstructive pulmonary disease, allergic rhinitis, or any other respiratory disease. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease.12-24-2009
20110038937Methods for delivering siRNA via Ionthophoresis - Disclosed herein are formulations of siRNA suitable for delivery by ocular iontophoresis, devices for iontophoretic delivery of siRNA and methods of use thereof.02-17-2011
20110038938Compositions for tissue augmentation - The embodiments set forth herein provide biocompatible self-setting compositions suitable for use in tissue augmentation applications. The biocompatible self-setting compositions described herein exhibit advantageous theological properties and may be applied to a site in the body of a patient by injecting the composition through a 20-30 gauge needle. Once applied to a site in the body, the composition sets to a slow resorbing or substantially non-resorbing matrix. Advantageously, exposure of the composition material to body heat at its site of use enhances setting of the composition. Composition materials prepared in accordance with the present disclosure may find use in applications involving, for example, soft tissue augmentation such as for dermal fold augmentation, prevention of adhesions, soft tissue void filling, soft tissue bleb creation, urethral sphincter augmentation for treatment of urinary incontinence, treatment of unilateral vocal fold paralysis, and lower esophageal sphincter augmentation for treatment of gastroesophageal reflux disease. In some embodiments, the presently described biocompatible compositions may serve as bone void fillers.02-17-2011
20110045086Steroid Nebuliser Formulation - A nebulizer formulation comprises particles of size 0.5-3 microns obtained by crystallization of beclomethasone diproprionate monohydrate in the presence of ultrasound.02-24-2011
20110045085PROCESS FOR OBTAINING POWDER COMPOSITIONS OF ORLISTAT - The invention relates to a novel process for the manufacture of stable, meeting relevant quality requirements pharmaceutical compositions in the form of encapsulated powder comprising Orlistat and pharmaceutically acceptable additives. The invention further relates to pharmaceutical compositions of Orlistat in the form of encapsulated powder obtained in accordance with the process of the present invention.02-24-2011
20100098768Method of neuroprotection from oxidant injury using metal oxide nanoparticles - A metal oxide nanoparticle composition including a cerium oxide nanoparticle and a metal adapted to enhance the neuroprotective activity of the cerium oxide nanoparticle. The metal can include noble metals such as platinum, and rare earth metals such as gadolinium, samarium, titanium, yttrium, zirconium, and a combination thereof Another metal oxide nanoparticle composition including a cerium oxide nanoparticle and a surface modifier, such as polyethylene oxide, polyethylene imine, dextran, polylactic acid, chitosan, alginate, and a combination thereof is provided. A method of using the metal oxide nanoparticle compositions as neuroprotective agents for the inactivation of reactive oxygen species in nervous tissues is also provided. More specifically, a neuroprotective method using the metal oxides such as ceria, yttria, or mixed ceria and yttria (or any of the other referenced metal oxide nanoparticle compositions) before, during, or after an ischemic event.04-22-2010
20100172992PATHOGENIC ATTENUATION VIA THE ADMINISTRATION OF AN EQUILIBIOTIC COMPOUND - A pharmaceutical preparation comprising as an active ingredient micron-sized sulphur particles [−(300 microns]. The pharmaceutical preparation further comprises an excipient, i.e. a sodium lignin sulphate or other suitable agents. The preparation is used for the prevention and treatment of pathogenic disorders in humans and animals, in a nutritional and/or supplemental regime, as well as, to improve feed and reproductive performance. A variety of conditions were treated including: pneumonia, arthritis, ulcers, diabetes mellitus, GI cancer, lupus, herpes, psoriasis and early menopause.07-08-2010
20110236490TREATMENT OR PREVENTION OF VIRAL INFECTION BY CHLORINATION - The invention provides methods and systems for treating or preventing viral infection. In one embodiment, the invention provides a method of treating or preventing viral infection in an individual, the method comprising: administering to the individual, via at least one nasal cavity, nebulized ECAW containing a quantity of hypochlorous acid (HOCI) and a quantity of hypochlorite ion (OCI).09-29-2011
20110236489VACCINE ADJUVANT COMBINATIONS - An immunological adjuvant comprises an oil-in-water emulsion, an immunostimulatory oligonucleotide and a polycationic polymer, wherein the oligonucleotide and the polymer ideally associate with each other to form a complex. The adjuvant can be combined with immunogens for preparing vaccines.09-29-2011
20110236488HERBAL FORMULATION FOR PREVENTION AND TREATMENT OF DIABETES AND ASSOCIATED COMPLICATIONS - An herbal formulation for prevention and treatment of Diabetes and associated complications comprising extracts from selected Indian medicinal herbs 09-29-2011
20110236487SOLID GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF - In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.09-29-2011
20110159102Apparatus and Method for Continuous Production of Spherical Powder Agglomerates - The disclosure relates to a process for continuously producing spherical powder agglomerates, in which morphologically irregular starting agglomerates of micronized pulverulent particles are rounded off continuously by application to a surface induced to vibrate.06-30-2011
20100233273POLYMER COMPOSITIONS WITH BIOACTIVE AGENT, MEDICAL ARTICLES, AND METHODS - A polymer composition that includes a hydrophilic polymer, an optional secondary organic polymer, and a bioactive agent distributed therein, wherein the bioactive agent is selected from the group consisting of a silver compound, a copper compound, a zinc compound, and combinations thereof.09-16-2010
20100233272DOSAGE FORMS COMPRISING CELECOXIB PROVIDING BOTH RAPID AND SUSTAINED PAIN RELIEF - A pharmaceutical dosage form comprising celecoxib and a pharmaceutically acceptable carrier, the dosage form when initially administered to at least 12 human patients in the fasted state in a crossover study providing: (a) a mean blood plasma concentration of celecoxib within 0.5 hour after administration (C09-16-2010
20100233270Delivery of Oligonucleotide-Functionalized Nanoparticles - The present invention relates to compositions and methods for delivering an oligonucleotide-functionalized nanoparticle.09-16-2010
20100233269MINERALIZED POLYMER PARTICLES AND THE METHOD FOR THEIR PRODUCTION - A process for mineralizing a particulate organic material includes providing particles of a non-porous, swellable organic material, and contacting the particles with a solution containing at least one cation and a solution containing at least one anion, thereby obtaining the mineralized particulate organic material.09-16-2010
20110250275PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS - Compositions and methods involving administration of agents useful for the treatment, prevention, inhibition, etc., of inflammatory disease or fibrous adhesions using low sulphate fucans and, if desired, one or more other anti-inflammatory disease or anti-fibrous adhesion agent.10-13-2011
20120321715MICELLES FOR THE SOLUBILIZATION OF GOSSYPOL - The invention provides biocompatible micelles loaded with one or more active agents. The micelles can encapsulate anticancer drugs such as gossypol, and combinations of drugs, such as gossypol and paclitaxel, gossypol and 17-AAG, gossypol and cyclopamine, gossypol, paclitaxel, and 17-AAG, and gossypol, paclitaxel, and cyclopamine. The micelle compositions provide effective solubilization of difficult to solubilize drug combinations without the need for additional surfactants that can be toxic to patients. Thus, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity.12-20-2012
20120321714SOLID PHARMACEUTICAL COMPOSITION CONTAINING 6-OXO-6,7,8,9,10,11-HEXAHYDROCYCLOHEPTA (C)CHROMEN-3-YL SULFAMATE AND POLYMORPHS THEREOF - The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound.12-20-2012
20080311206Anti-Chafing Compositions Comprising Boron Nitride - The invention in one aspect relates to an anti-chafing composition with improved efficacy, in one embodiment, comprising an effective amount of boron nitride suspended in a dermatologically acceptable carrier vehicle. Another embodiment relates to an anti-chafing composition in the form of a powder or a stick containing boron nitride. The present invention also relates to a method of inhibiting or reducing chafing to the skin by topically applying an effective amount of such anti-chafing composition to the skin or to a surface to be in contact with the skin.12-18-2008
20090208582Templated Open Flocs of Anisotropic Particles for Enhanced Pulmonary Delivery - The present invention includes compositions and methods for treating and delivering medicinal formulations using an inhaler. The composition includes a space filled flocculated suspension having one or more flocculated particles of one or more active agents and a hydrofluoroalkane propellant. A portion of the one or more flocculated particles is templated by the formation of hydrofluoroalkane droplets upon atomization and the templated floc compacts upon the evaporation of the hydrofluoroalkane propellant to form a porous particle for deep lung delivery.08-20-2009
20110280943Sunscreen Compositions Comprising Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same - Aspects of the invention include sunscreen formulations that include uniform, rigid, spherical nanoporous calcium phosphate particles. Also provided are methods of making the sunscreen formulations. The sunscreen formulations find use in sunblocking applications.11-17-2011
20100215750ORAL PREPARATION COMPRISING SPECIFIC ORGANIC ACID, AND METHOD FOR IMPROVEMENT IN ELUTION PROPERTY AND CHEMICAL STABILITY OF ORAL PREPARATION - A chemically stable oral preparation with an excellent dissolution property comprising as an effective ingredient a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof is disclosed. The oral preparation according to the present invention comprises a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof as an effective ingredient and an organic acid, wherein 1 g of said organic acid requires not less than 30 mL of water to dissolve in at 20° C. The method for improving dissolution property and chemical stability of an oral preparation according to the present invention comprises incorporating an organic acid in the oral preparation comprising as an effective ingredient a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof, wherein 1 g of said organic acid requires not less than 30 mL of water to dissolve in at 20° C.08-26-2010
20100215755Resveratrol Ferulate Compounds, Compositions Containing The Compounds, And Methods Of Using The Same - The present invention relates to methods of using topical or cosmetic compositions containing resveratrol ferulates for skin lightening and anti-aging applications and method of synthesizing resveratrol ferulates.08-26-2010
20090053314SUBMICRONIZATION OF PROTEINS USING SUPERCRITICAL FLUIDS - An apparatus and a method for the submicronization of proteins using supercritical fluids is provided for feeding the supercritical fluid and feeding a protein solution using a precipitation vessel with a taper shape at its lower part, in which the precipitation vessel accommodates the supercritical fluid and the protein solution to generate submicroparticles of the protein, and a spray nozzle with coaxial arrangement having an outer nozzle for spraying the supercritical fluid and an inner nozzle for spraying the protein solution.02-26-2009
20120100219COMPOSITION FOR THE PRODUCTION OF TABLETS, AND METHOD FOR THE PRODUCTION OF SAID COMPOSITION - The present invention relates to a process for the preparation of a composition for the production of tablets and to a composition obtained thereby. This composition is a directly compressible composition which results both in improved tabletting properties and in improved tablet properties.04-26-2012
20120100218Intralymphatic Chemotherapy Drug Carriers - A chemotherapeutic composition can be configured for subcutaneous administration for preferential intralymphatic accumulation while also providing a therapeutic systemic concentration that is not toxic. The composition can include a pharmaceutically acceptable carrier, and a nanoconjugate configured for preferential intralymphatic accumulation after subcutaneous administration. The nanoconjugate can include a nanocarrier configured for preferential intralymphatic accumulation after subcutaneous or interstitial administration, and a plurality of chemotherapeutic agents coupled to the nanocarrier. The nanoconjugate can have a dimension of about 10 nm to about 5 nm. Also, the nanoconjugate can be loaded with the chemotherapeutic agents from about 10% to about 50% w/w. The nanocarrier can be a hyaluronan polymer of about 3 kDa to about 50 kDa. Alternatively, the nanocarrier can be a dendrimer.04-26-2012
20100203146INTERMITTENT DOSING STRATEGY FOR TREATING RHEUMATOID ARTHRITIS - The present invention provides methods of treating rheumatoid arthritis. The methods generally involve an intermittent dosing strategy for administering Atiprimod alone or in combination with a second therapeutic agent wherein the second therapeutic agent is selected from the group consisting of Methotrexate, gold compounds, antimalarials, cyclosporine A, leflunomide, azathioprine, sulfasalazine d-penicillamine, aurothioglucose, auranofin, or a TNF inhibitor.08-12-2010
20100203145CONTINUOUS PROCESS FOR MICROSPHERES PRODUCTION BY USING EXPANDED FLUIDS - The invention concerns a process for the continuous treatment of an emulsion and/or a micro-emulsion assisted by an “expanded liquid” for the production of micro- and/or nano-particles or micro- and/or nano-spheres containing one or more active ingredients. In particular, a liquid solvent expanded by compressed or supercritical CO08-12-2010
20110135738SINGLE DOSAGE PHARMACEUTICAL FORMULATION COMPRISING EPROSARTAN MESYLATE - A dry formulation or granulation of eprosartan mesylate is described which comprises eprosartan mesylate in particulate form with a particle size, wherein at least 65 v/v % eprosartan mesylate particles fall in a particle size range of from 2 to 27 μm. In another aspect, a dry formulation or granulation of eprosartan mesylate comprises eprosartan mesylate combined with an excipient which at least comprises a PEG having molecular weight in the range of 400 to 20000 and mannitol. Further described is a single dosage pharmaceutical formulation such as tablet obtained from such a dry formulation or granulation of eprosartan mesylate by direct compression or dry granulation. A dry formulation or granulation of eprosartan mesylate, or a process for the preparation thereof is also described, which comprising eprosartan mesylate in particulate form mixed with one or more excipients or additives in a way that a limited water activity is obtained. The dry formulation or granulation of eprosartan mesylate can be directly compressed or processed by dry granulation, while maintaining the eprosartan mesylate in only one stable form. Suitable prophylactic and/or therapeutic uses are also described.06-09-2011
20080254128Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same - The present invention provides a method of continuous precipitation and isolation of an amorphous solid particulate form of 3-[2-(3-tert-Butyl-ureido)-3,3-dimethyl-butyryl]-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid (2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide having controlled physical properties. The present invention provides also pharmaceutical formulations comprising the precipitated compound.10-16-2008
20080254127Inhalation particles incorporating a combination of two or more active ingredients - Crystalline spherical inhalation particles incorporating a combination of two or more different active ingredients and a process for the preparation thereof. The particles have a narrow particle size distribution, rough surfaces and improved stability. The inhalation particles of the invention are particularly useful in the administration of a combination medicament, e.g. a combination of an anti-inflammatory agent and a bronchodilator, by inhalation in the treatment of asthma and other respiratory disorders.10-16-2008
20080254126Composition comprising nanoparticle ginkgo biloba extract with the effect of brain function activation - To supply the 10-16-2008
20080241260Compositions for Enhanced Absorption of Biologically Active Agents - The present invention relates to a novel pharmaceutical composition comprising polymeric nanoparticles with one or more biologically active agent/s for mucosal and or oral administration. Said polymeric nanoparticles further comprise of an agent that enhances absorption of said biologically active agent/s. The compositions are formulated as powders, sprays, suspension, freeze dried powders for reconstitution, tablets, capsules, pellets, wafers, patches, films, rods, pessaries, suppositories, aerosols, bioadhesive gels, creams.10-02-2008
20080241258TREATMENT OF DISEASES WITH NANOPARTICLES HAVING A SIZE-DEPENDENT CYTOTOXICITY - The present invention relates to the use of at least one gold nanocluster compound in the manufacture of a pharmaceutical composition or medicament for the prophylactic and/or therapeutic (curative) treatment of a disease, especially a tumor and/or cancer disease. The gold nanocluster compound having a defined particle size, especially a defined size of the core of said gold nanocluster compound, the size ranging from 0.5 nm to 10 nm, the outer limits of this range being included. Especially, the gold nanocluster compounds used possess size-dependent cytotoxic properties, stimulating or inducing cellular death when treating and/or contacting respective cells, especially tumor and/or cancer cells, with the gold nanocluster compounds either via apoptosis or via necrosis, depending on the respective gold cluster size or core size.10-02-2008
20080241257Biodegradable Nanoparticles Incorporating Highly Hydrophilic Positively Charged Drugs - Nanoparticles of a biodegradable polymer containing a hydrophilic, cationic drug, like streptomycin, and preparations containing the same, are disclosed. Pharmaceutical preparations containing the nanoparticles are administered, preferably orally, to individuals suffering from a disease or condition, and the nanoparticles release the drug, in vivo, to treat the disease or condition.10-02-2008
20100015234Pharmaceutical preparations and their manufacture - A method for making a composition comprising active particles comprising an active substance comprises the steps of a) providing an emulsion having a dispersed phase comprising a solution of the active substance in a solvent and b) inducing the formation, in the emulsion, of solid particles comprising the active substance. The particles may be isolated from the emulsion. Active particles having a normalized kurtosis of at least 5 and a mean diameter of less than 100 μm are provided.01-21-2010
20100008996INHALATIVE AND INSTILLATIVE USE OF SEMIFLUORINATED ALKANES AS AN ACTIVE SUBSTANCE CARRIER IN THE INTRAPULMONARY AREA - A medical aid for the direct transport of at least one drug into lung regions of a patient, wherein provided as the carrier for at least one active substance is at least one semifluorinated alkane in which the at least one active substance is purely physically dissolved in a homogeneous phase.01-14-2010
20080233196INJECTABLE STERILE PHARMACEUTICAL COMPOSITION WITH PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM AS ACTIVE PRINCIPLES - A sterile pharmaceutical composition having as its active principles piperacillin sodium and tazobactam sodium of substantially the same density, mixed with sodium bicarbonate. The mixture is soluble in water to give injectable reconstituted solutions having high stability with time.09-25-2008
20080226737Use of Calcitonin For the Treatment of Ra - The present invention relates to a novel use of calcitonin in rheumatoid arthritis, and to methods of treating and/or preventing rheumatoid arthritis and conditions associated therewith in mammals, particularly humans. In particular, a method is provided of preventing or/and treating rheumatoid arthritis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of calcitonin, e.g. salmon calcitonin in free form or salt form, in a pharmaceutically acceptable oral delivery form, wherein the therapeutically effective amount of a calcitonin is delivered orally in a composition comprising the calcitonin and a delivery agent for calcitonin.09-18-2008
20080226736Inhalatory Pharmaceutical Compositions in Form of Dry Powders, Solutions or Suspensions Obtained From the Same and Process for their Preparation - Inhalatory pharmaceutical composition comprising a drug, a soluble excipient and a surfactant, characterized by: said soluble excipient is present in an amount between 10% and less than 100% by weight; —the weight ratio between said surfactant and said drug is between 0.01 and 10; —the particle size of at least 50% of the particles of said powder is below 5 μm; —the bulk density d09-18-2008
20080226735RARE EARTH METAL COMPOSITIONS FOR TREATING HYPERPHOSPHATEMIA AND RELATED METHODS - Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.09-18-2008
20080226734COMBINATION OF A NARCOTIC AND NON-NARCOTIC ANALGESIC - The present invention is directed to a formulation comprising a narcotic analgesic and a non-narcotic analgesic, methods of use and methods of preparing thereof.09-18-2008
20080226733SPATIAL ARRANGEMENT OF PARTICLES IN A DRINKING DEVICE FOR ORAL DELIVERY OF PHARMACEUTICALS - The present invention relates to spatially arranging a plurality of particles in a device for the oral delivery of a pharmaceutical. In particular, the plurality of particles is utilized for the oral delivery of a pharmaceutical to a subject via the drinking device.09-18-2008
20080226732NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS - Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.09-18-2008
20080226731Pharmaceutical Compositions Comprising I Matinib and a Release Retardant - Sustained release pharmaceutical compositions that contain imatinib or a pharmaceutically acceptable salt thereof. The pharmaceutical compositions further contain a release retardant, for example a water soluble, a water swellable and/or a water insoluble polymer. The present invention also features a particularly useful process of making such sustained release pharmaceutical compositions by using an extruder.09-18-2008
20080226730PARTICLES FOR INHALATION HAVING RAPID RELEASE PROPERTIES - The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Improved formulations comprising DPPC, insulin and sodium citrate which are useful in the treatment of diabetes are disclosed. Also, the invention relates to a method of for the pulmonary delivery of a bioactive agent comprising administering to the respiratory tract of a patient in need of treatment, or diagnosis an effective amount of particles comprising a bioactive agent or any combination thereof in association, wherein release of the agent from the administered particles occurs in a rapid fashion.09-18-2008
20080226729STABLE POWDER FORMULATIONS OF ALUM-ADSORBED VACCINES - The present invention is directed to methods for preparing a stable powder formulation of an alum-adsorbed vaccine. The methods comprise atomizing a liquid formulation comprising an immunogen adsorbed onto an aluminum adjuvant to produce an atomized formulation, freezing the atomized formulation to produce frozen particles, and drying the frozen particles to produce dried powder particles. Pharmaceutical compositions comprising a stable powder formulation of an alum-adsorbed vaccine are also disclosed herein. The pharmaceutical compositions are stable at high temperatures and can be reconstituted in a pharmaceutically acceptable carrier to produce a reconstituted liquid vaccine that exhibits little or no particle agglomeration and retains immunogenicity. Methods of using the alum-adsorbed vaccine compositions for preventing and treating a disease in a subject, wherein the disease is associated with the particular immunogen, are further provided.09-18-2008
20080226728Antimicrobial Nanoparticulate Additives Forming Non-Leachable Sustained Antimicrobial Polymeric Compositions - The present invention provides a particle comprising at least one aliphatic polymer having anti-microbially active quaternary ammonium groups chemically bound thereto. The particle of the invention may be used to inhibit populations of microorganisms and biofilms. Also provided are methods for the preparation of such particles and uses thereof for the inhibition of microorganisms.09-18-2008
20080226727Water-In-Silicone Oil Emulsion for Use as a Sunscreen Product - A water-in-silicone oil emulsion contains (i) in the range from 0.1 to 25% by weight of particles of metal oxide having a median particle volume diameter in dispersion in the range from 18 to 32 nm, (ii) 5 to 60% by weight of silicone oil, and (iii) greater than 20% by weight of water. The metal oxide particles are preferably incorporated into the emulsion in the form of an aqueous dispersion. The emulsion exhibits good skin feel, effective UV protection, stability and improved transparency.09-18-2008
20090104272INHALED HYPERTONIC SALINE DELIVERED BY A HEATED NASAL CANNULA - The invention described herein is directed to method of treating chronic obstructive pulmonary disease, comprising administering an effective amount of an osmolyte by at least one nasal cannula to a subject in need thereof. Also provided is a nasal cannula system for delivering an osmolyte, comprising a nebulizer and tubing having two ends, where the first end of the tubing is connected to the nebulizer and the second end of the tubing is tapered to fit in the nostril of a subject.04-23-2009
20080220074GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHODS OF MAKING SAME - Nanoparticulate compositions comprising docetaxel or a salt, derivative, conjugate or analogue thereof, wherein the compositions are terminally sterilized via gamma radiation, are described, as well as methods of making and using such compositions.09-11-2008
20080220073The Treatment of Respiratory Diseases - A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.09-11-2008
20080220072BIOLOGIC MODULATIONS WITH NANOPARTICLES - Certain aspects of the invention relate to the use of small particles in biological systems, including the delivery of biologically active agents to cells or tissues using nanoparticles of less than about 200 nm in approximate diameter. Embodiments include collection of particles having a bioactive component, a surfactant molecule, a biocompatible polymer, and a cell recognition component, wherein the cell recognition component has a binding affinity for a cell recognition target. Compositions and methods of use are also set forth, including the use of antisense directed against Protein Kinase CK2, CK2alpha, CK2 alpha′, and CK2 beta.09-11-2008
20080220071Aqueous Suspensions of Poorly Water-Soluble and Water-Insoluble Active Ingredients and Drying Powder Produced Therefrom - Aqueous suspensions comprising: (a) at least one sparingly water-soluble or water-insoluble active agent in the form of nanoparticulate particles; (b) at least one whey component selected from the group consisting of whey proteins, whey protein hydrolysates, and mixtures thereof; and (c) at least one sucrose fatty acid ester having an HLB value of 10 to 18; processes for preparing such aqueous suspensions; powders and oil-miscible compositions prepared therefrom and uses therefore.09-11-2008
20080213376Medicament that is Intended for Oral Administration, Comprising a Cyclooxygenase-2 Inhibitor, and Preparation Method Thereof - The invention relates to a medicament which is intended for oral administration, which comprises a cyclooxygenase-2 inhibitor and which has improved bioavailability, and to a method of preparing said medicament. The inventive medicament comprises an agglomerate based on inert solid particles based on at least one excipient, said agglomerate comprising a cyclooxygenase-2 inhibitor and at least one hydrophilic polymer. According to the invention, the agglomerate comprises a spray which is applied to the aforementioned particles, consisting of a solution or suspension of micronized grains of the inhibitor in said polymer(s), in order to agglomerate said particles. The inventive method essentially comprises the following steps, namely: (i) the preparation of a sprayable liquid that is based on the micronized grains of said inhibitor in solution or in suspension in at least one hydrophilic polymer; and (ii) the spraying of the liquid onto the solid particles, in order to obtain the agglomerate by means of wet granulation, said agglomerate comprising the grain solution or suspension spray.09-04-2008
20110268803LUNG TARGETING DUAL DRUG DELIVERY SYSTEM - The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases.11-03-2011
20130171258Pharmaceutical composition for elevating radio-sensitivity of cancer cells, pharmaceutical composition for detecting cancer cells with radio-sensitivity, and detection method thereof - The present invention relates to a pharmaceutical composition for elevating radiation-sensitivity of cancer cells, which comprises: a nanoparticle containing with a first element, which is iron, copper, or the combination thereof; and a pharmaceutically acceptable carrier, wherein the nanoparticle is a metal nanoparticle, an alloy nanoparticle, or a metal nanoparticle with core-shell structure, and the size of the nanoparticle is under a controllable range of 3 nm to 150 nm. In addition, the present invention provides a detection method to detect radiation-sensitivity of the cancer cells through different modalities such as CT or MRI due to its native high CT number and magnetic property. Furthermore, the present invention provides a pharmaceutical composition for elevating radiation-sensitivity of the cancer cells through preferential uptake of the nanoparticle, in order to enhance the radiation-sensitivity of the cancer cells and improve the efficiency of radiation therapy to the cancer cells.07-04-2013
20090035379Fenofibrate compositions - The invention provides fenofibrate compositions comprising granulates, where the granulates comprise micronized fenofibrate.02-05-2009
20080292709KITS FOR DHEA AND DHEA-SULFATE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE - Kits for treating or preventing chronic obstructive pulmonary disease (COPD) by using as active agent a non-glucorticoid steroid, analogue thereof, such as dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S), or their salts, in an amount effective for preventing or treating COPD.11-27-2008
20100278920Polyacrylate Nanoparticle Drug Delivery - Drug delivery of resistance reversal agents by polyacrylate nanoparticles for treatment of drug (e.g. chloroquine) resistant malaria. Also provided are drug delivery by polyacrylate nanoparticles of ciprofloxacin for treatment of anthrax.11-04-2010
20090104273Novel nifedipine compositions - The present invention is directed to nanoparticulate compositions comprising nifedipine. The nifedipine particles of the composition have an effective average particle size of less than about 2 microns.04-23-2009
20080206346PREPARATION OF POWDER AGGLOMERATES - The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. Agglomerates capable of conversion as well as the finished agglomerates and oral and nasal dosing systems including same are also contemplated. The process produces agglomerates which are rugged but which will produce an acceptable fine particle fraction during dosing.08-28-2008
20080199525Micronized wood preservative formulations - The present invention provides wood preservative compositions comprising micronized particles. In one embodiment, the composition comprises dispersions of micronized metal or metal compounds. In another embodiment, the wood preservative composition comprises an inorganic component comprising a metal or metal compound and organic biocide. When the composition comprises an inorganic component and an organic biocide, the inorganic component or the organic biocide or both are present as micronized particles. When compositions of the present invention are used for preservation of wood, there is minimal leaching of the metal and biocide from the wood.08-21-2008
20080199524Eyedrops containing particulate agar - It is intended to prepare a composition which contains polysaccharide at a high concentration and yet remains in the state of a liquid having low viscosity to thereby provide drugs, eyedrops, foods, cosmetics, toiletry products having a novel texture or function. The composition in the state of a liquid having low viscosity is obtained by heating polysaccharide at a high concentration in a water-containing liquid and then cooling under applying a shear force, which enables the provision of the above-described drugs. The composition is usable as an aqueous drug vehicle which is free from gelling due to temperature changes during storage and easily applied without pouring and/or streaming down. Eyedrops containing agar have an effect of enhancing ocular drug penetration. Eyedrops containing particulate agar maintain a low viscosity and, achieve easy instillation and impart a favorable feel in instillation.08-21-2008
20090110736ALLOPLASTIC INJECTABLE DERMAL FILLER AND METHODS OF USE THEREOF - A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided. In an embodiment of the method of augmenting soft tissue, the stimulation of collagen production is effected by injecting into the deep reticular dermis an a dermal filler, said dermal filler being an alloplastic injectable suspension and comprising a biocompatible and pliable material and a physiologically acceptable suspending agent.04-30-2009
20110250276Cosmetic Composition Containing Acetylated Oligoglucuronans - The present invention relates to the field of cosmetic and dermopharmaceutical compositions. It concerns oligomer compounds of D-glucuronic acid or D-glucuronate with a β (1-4) sequence (or oligoglucuronans) containing a degree of acetylation specifically between 8.7±0.5 and 9.2±0.5% by weight of O—CO—CH10-13-2011
20130149381ABSORPTION METHOD FOR ENTRAPMENT OF DRUGS IN POLYMERIC NANOPARTICLES - A method for preparing polymeric nanoparticles having entrapped active ingredients or drugs, the method includes the step of preparing a reaction by mixturing water, a surfactant, and a water-soluble radical initiator; polymerizing a polymerizable monomer in the reaction to obtain a dispersion of polymeric nanoparticles having a controlled size with average diameters smaller than 50 nm; dissolving one or more active ingredients in a suitable solvent; adding the solution of active ingredients to the dispersion of polymeric nanoparticles and allowing that the active ingredients to become entrapped within polymeric nanoparticles; and evaporating the dispersion of polymeric nanoparticles having entrapped active ingredients to evaporate the residual monomer and the solvent used as a vehicle for loading the active ingredient.06-13-2013
20120276205SILVER OXIDE FORMULATIONS - A formulation including at least one silver oxide including a silver(II) oxide, the silver(II) oxide having an irregular macrocrystal structure, the silver oxide having an average particle size (D11-01-2012
20100297244NANODISPERSION - The present invention provides a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more taxane derivative, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or its derivatives or its salts.11-25-2010
20100303917COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS - Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating cystic fibrosis or a symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered fluids optionally in combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). Particular embodiments comprise use and/or synergy with tobramycin for treating bacterial infection, and use and/or synergy with a bronchiodilator. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (like, membrane receptors, including but not limited to G protein coupled receptors, and intercellular junctions).12-02-2010
20100310660DRY POWDER MICROPARTICLES FOR PULMONARY DELIVERY - The invention provides a dry powder microparticle for pulmonary delivery, which comprises at least one nanoparticle in the form of liposome or micelle wherein the nanopaparticle encapsulates one or more therapeutic agent therein, and a diluent layer surrounding the nanaparticles.12-09-2010
20100316726TOOTH SEALANT - The invention provides a method of treating sensitive teeth comprising attaching a sealant composition comprising a basic amino acid to a person's tooth and allowing the basic amino acid to be slowly released over time in order to reduce chrome and/or acute tooth sensitivity together with compositions and methods of use.12-16-2010
20100316725REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS - This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.12-16-2010
20100316724COMPOSITION - The invention provides microparticles comprising an immunosuppressant, such as tacrolimus, sirolimus, pimecrolimus, ciclosporin, everolimus or a derivative thereof, and optionally a pharmaceutically acceptable excipient or carrier, such as a saccharide, amino acid, a sugar alcohol or a mixture thereof, and having a median geometric diameter of less than, or equal to, about 10 μm and which have a tap density of less than or equal to about 0.3 g/cm12-16-2010
20100316723COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION - Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating inflammation or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (electrokinetically-generated gas-enriched fluids and solutions) and therapeutic compositions.12-16-2010
20110274760USE OF SYNTHETIC INORGANIC NANOPARTICLES AS CARRIERS FOR OPHTHALMIC AND OTIC DRUGS - The use of nanoparticles of inorganic materials (e.g., synthetic smectite clays) in ophthalmic and otic pharmaceutical compositions is described. The nanoparticles are utilized as biologically inert carriers or depots for ophthalmic and otic drugs. The nanoparticles may also be utilized to modify the rheological properties of the compositions, so as to enhance the viscosity or flow characteristics of the compositions and/or increase the retention time of the compositions in the eye or ear.11-10-2011
20110274759Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic)acid-poly(ethylene)glycol.11-10-2011
20110274758MICROSPHERE-BASED COMPOSITION FOR PREVENTING AND/OR REVERSING NEW-ONSET AUTOIMMUNE DIABETES - AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.11-10-2011
20110274757NUCLEIC ACID DELIVERY VEHICLE AND USES THEREOF - A nucleic acid-delivery vehicle for delivering nucleic acids to target cells is provided. The nucleic acid-delivery vehicle comprises a plurality of nanoparticles; and a plurality of nucleic acids. The nanoparticles and the nucleic acids are agglomerated to form a nucleic acid-granulation particle having a dimension of at least 5 nm. Methods of making the nucleic acid-delivery vehicle and kits comprising nucleic acid-delivery vehicle are also provided.11-10-2011
20120282341Lipid Formulated Compositions And Methods For Inhibiting Expression Of Eg5 And VEGF Genes - This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, methods of using the compositions to inhibit the expression of the Eg5/KSP and VEGF, and methods of using the compositions to treat pathological processes mediated by Eg5/KSP and VEGF expression, such as cancer.11-08-2012
20130156856ANTICOAGULANT-CONJUGATED CARBON NANOCAPSULE, ANTITHROMBOTIC AGENT CONTAINING THEREOF - The embodiments provide a carbon nanocapsule conjugated with at least one of the anticoagulants on the surface and an antithrombotic drug containing the anticoagulant-conjugated carbon nanocapsule as an active ingredient. The anticoagulant-conjugated carbon nanocapsule has less cytotoxicity and good biocompatibility. A method for preparing the anticoagulant-conjugated carbon nanocapsule is also provided.06-20-2013
20120021055NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS - The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.01-26-2012
20120027860ENCAPSULATED ADIPOSE-DERIVED STEM CELLS, METHODS FOR PREPARATION AND THERAPUTIC USE - A therapeutic composition comprising a purified fraction of adipose-derived mesenchymal stem cells encapsulated in a three-dimensional biocompatible gel matrix, and methods, and systems for preparing and using encapsulated adipose-derived mesenchymal stem cells. Hydrogel microbeads encapsulating stem cells maintain the viability and location of the stem cells for an extended period as compared to stem cells in suspension. The gel matrix allows the release of cellular factors from the encapsulated stem cells to surrounding tissues to achieve desired therapeutic results.02-02-2012
20120027859Biodegradable Proline-Based Polymers - The invention provides sequential poly(ester amide)s derived from Proline and that are synthesized by a two-step method, involving a final thermal polyesterification reaction. Molecular weights of polymers prepared by this method are from 14,000 Da to about 77,000 Da.1 When invention proline-based PEAs were thermally characterized, their glass transition temperatures were lower than other alpha-amino acid based poly(ester amides) due to lack of internal hydrogen bonding. These Proline-based PEAs assemble as nano-particles in aqueous solutions and form complexes with various cations and biologies, including hydrophobic small molecule drugs and biologies. Therefore the invention Proline-based PEAs are useful for drug delivery applications requiring a polymer with a molecular weight in the range from 14,000 Da to about 77,000 Da and for fabrication of nanoparticles for delivery of hydrophobic drugs.02-02-2012
20130202706NANOSTRUCTURED ATORVASTATIN, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS OF THEM, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured Atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Atorvastain, its pharmaceutically acceptable salts and compositions of them according to the invention have an average particle size of less than about 600 nm. The stable amorphous nanostructured particles of the present invention are characterized by increased solubility and bioequivalent biological performance compared to the marketed crystalline drug. Atorvastatin is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms.08-08-2013
20130202707Controlled Delivery of TLR Agonists in Structural Polymeric Devices - The present invention comprises compositions, methods, and devices for creating an stimulating an antigen-specific dendritic cell immune response. Devices and methods provide prophylactic and therapeutic immunity to subjects against cancer and infectious agents.08-08-2013
20120076859Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases - A method of treatment of cystic fibrosis and other pulmonary diseases identified by nitric oxide deficiency, comprising administration of a nebulized solution of citrulline and/or another nitric oxide precursor as an inhalable aerosol or an inhalable dry powder for targeted delivery into conducting and central airways. Citrulline or another nitric oxide precursor is formulated as a composition having predetermined limited volume, salinity, pH and osmolality. The composition is nebulized into an aerosol having a mass median aerodynamic diameter (MMAD) between 2 μm and 6 μm.03-29-2012
20120087983ORTHOPEDIC APPLICATION OF ENCAPSULATED STEM CELLS - Described herein are orthopedic applications of mesenchymal stem cell encapsulated and delivered for treatment of cartilage damage in joints. A therapeutic composition is prepared comprising a purified fraction of adipose-derived mesenchymal stem cells encapsulated in microbeads of a three-dimensional biocompatible gel matrix. The hydrogel microbeads encapsulating stem cells maintain the viability and location of the stem cells for an extended period as compared to stem cells in suspension. The microbeads are implanted adjacent a target orthopedic treatment site where the microbeads allow the release of cellular factors from the encapsulated stem cells to surrounding orthopedic tissues to achieve desired therapeutic results such as healing of cartilage damage in joints.04-12-2012
20120093933DENATURED LACTOGLOBULIN AND POLYPHENOL COASSEMBLIES - The present invention is directed to co-assembled nanoparticle composition comprising denatured β-lactoglobulin and at least one nutraceutical compound, specifically polyphenols, such as EGCG, compositions comprising same and methods of preparing thereof.04-19-2012
20120093932TARGETED SUSTAINED-RELEASE MICROSPHERE OF VASCULAR OCCLUSIVE AGENT CONTAINING SODIUM ALGINATE AND SORAFENIB, PRODUCTION METHOD AND USE THEREOF - A targeted sustained-release microsphere vascular embolizing agent, the production method and the use thereof are disclosed. The microsphere comprises sodium alginate as the carrier and sorafenib as the targeted anti-tumor medicine and sorafenib is encapsulated by sodium alginate. The weight ratio of sorafenib to sodium alginate is 1:1˜1:30. The microspheres are used for manufacturing medicament for the treatment of solid tumors with advantages including high medicine concentration in the target regions with reduced systemic dosage and toxic and side effects.04-19-2012
20120093931Inhibition of Neovascularization by Cerium Oxide Nanoparticles - The present invention provides methods for reducing, reversing or inhibiting neovascularization in a tissue of a mammalian subject having a pathological condition involving neovascularization by administration in vivo of nanoceria particles (cerium oxide nanoparticles) to the subject. The method of the invention is useful, for example, for reducing, treating, reversing or inhibiting neovascularization in ocular tissue such as the retina, macula or cornea; in skin; in synovial tissue; in intestinal tissue; or in bone. In addition, the method of the invention is useful for reducing or inhibiting neovascularization in a neoplasm (tumors), which can be benign or malignant and, where malignant, can be a metastatic neoplasm. As such, the invention provides compositions, which contain nanoceria particles and are useful for reducing, treating, reversing or inhibiting angiogenesis in a mammalian subject.04-19-2012